BioMedLib Search Engine
[ goto HOMEPAGE ]
Find more relevant answers, faster!
Skip to content
Advanced Search
Search History
MeSH Query
Page Format
Query is expanded
Login
Skip to content
Export Citations
Search Results
RSS
Email
Articles' Details
Start new query
Reset All
Refine your query
(more in Advanced-Search):
Search all of MEDLINE
Focus on the recent 5 years
Focus on the current year
Focus on the last 30 days
More choices ...
Focus on articles with free fulltexts
More choices ...
Do simple 'keyword' search (no query expansion)
[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click
here to
RESET
all values
Click
here to
GO BACK
without resetting any value
Advanced Search
Submit one or more of the following items, and they will be searched along with your query in the search box above.
Any submit button will submit all of the items you have changed.
+
Publication-Date
Published in the last:
30 days
60 days
90 days
6 months
12 months
this year
2 years
3 years
5 years
10 years
Or published in the following date range: From (yyyy/mm/dd - month and day are optional)
to ('to' is optional)
+
Full Text
Retrieve articles with hyperlinks to:
full text (either free or subscription)
free full text
subscription full text
no full text link
+
Sort-Order
Sort the retrieved articles by:
relevance
publication date
+
Language
And with languages:
English
French
German
Italian
Japanese
Russian
Spanish
More languages:
Afrikaans
Albanian
Amharic
Arabic
Armenian
Azerbaijani
Bengali
Bosnian
Bulgarian
Catalan
Chinese
Czech
Danish
Dutch
Esperanto
Estonian
Finnish
Georgian
Scottish Gaelic
Greek, Modern
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Kinyarwanda
Korean
Latin
Latvian
Lithuanian
Macedonian
Malayalam
Maori
Malay
Multiple languages
Norwegian
Persian
Polish
Portuguese
Pushto
Romanian
Sanskrit
Serbian
Croatian
Slovak
Slovenian
Swedish
Thai
Turkish
Ukrainian
Undetermined
Urdu
Vietnamese
Welsh
+
Publication-Type
And with publication types:
Clinical Trial
Editorial
Letter
Meta-Analysis
Practice Guideline
Randomized Controlled Trial
Review
More publication types:
Addresses
Bibliography
Biography
Case Reports
Classical Article
Clinical Conference
Clinical Trial, Phase I
Clinical Trial, Phase II
Clinical Trial, Phase III
Clinical Trial, Phase IV
Comment
Comparative Study
Congresses
Consensus Development Conference
Consensus Development Conference, NIH
Controlled Clinical Trial
Corrected and Republished Article
Dictionary
Directory
Duplicate Publication
English Abstract
Evaluation Studies
Festschrift
Government Publications
Guideline
Historical Article
Interactive Tutorial
Interview
Introductory Journal Article
In Vitro
Journal Article
Lectures
Legal Cases
Legislation
Multicenter Study
News
Newspaper Article
Overall
Patient Education Handout
Periodical Index
Portraits
Published Erratum
Retracted Publication
Research Support, N.I.H., Extramural
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Retraction of Publication
Scientific Integrity Review
Technical Report
Twin Study
Validation Studies
+
Species
And for:
Humans
Animals
+
Gender
And for:
Male
Female
+
Age
And for these age groups:
Newborn: birth to 1 month
Infant: 1 to 23 months
Preschool child: 2 to 5 years
Child: 6 to 12 years
Adolescent: 13 to 18 years
Adult: 19 to 44 years
Middle aged: 45 to 64 years
Aged: 65+ years
80 and over: 80+ years
+
Title
And for this query matching the titles:
+
Transliterated-Title
And for this query matching the title in original language:
+
Abstract
And for this query matching the abstratcs:
+
Major-Mesh
And for this query matching the MeSH-Major terms:
+
Mesh
And for this query matching any MeSH terms:
+
Journal
And for one or more of these journal abbreviated names:
OR
OR
(see
title abbreviations
)
+
Volume
And with journal volume number:
+
Issue
And with journal issue number:
+
Page
And with page number:
+
ISSN
And with ISSN:
+
Publication-Place
And with journal's country of publication:
+
Author
And for...
all these author names:
AND
AND
(see
help
)
one or more of these author names:
OR
OR
but not having any of these unwanted author names:
NOT
NOT
+
Affiliation
And with affiliation to:
+
Has-Abstract
Find MEDLINE records with the abstract status:
has abstract
does not have abstract
include both record types
include both record types but rank higher the records having abstract (the default BML behavior)
+
PMID
Show me only articles for these PMIDs (PubMed IDs):
+
Semantic-Type
And with semantic types:
A. Entity
A1. Physical Object
A1.1. Organism
A1.1.1. Archaeon
A1.1.2. Bacterium
A1.1.3. Eukaryote
A1.1.3.1. Animal
A1.1.3.1.1. Vertebrate
A1.1.3.1.1.1. Amphibian
A1.1.3.1.1.2. Bird
A1.1.3.1.1.3. Fish
A1.1.3.1.1.4. Mammal
A1.1.3.1.1.4.1. Human
A1.1.3.1.1.5. Reptile
A1.1.3.2. Fungus
A1.1.3.3. Plant
A1.1.4. Virus
A1.2. Anatomical Structure
A1.2.1. Embryonic Structure
A1.2.2. Anatomical Abnormality
A1.2.2.1. Congenital Abnormality
A1.2.2.2. Acquired Abnormality
A1.2.3. Fully Formed Anatomical Structure
A1.2.3.1. Body Part, Organ, or Organ Component
A1.2.3.2. Tissue
A1.2.3.3. Cell
A1.2.3.4. Cell Component
A1.2.3.5. Gene or Genome
A1.3. Manufactured Object
A1.3.1. Medical Device
A1.3.1.1. Drug Delivery Device
A1.3.2. Research Device
A1.3.3. Clinical Drug
A1.4. Substance
A1.4.1. Chemical
A1.4.1.1. Chemical Viewed Functionally
A1.4.1.1.1. Pharmacologic Substance
A1.4.1.1.1.1. Antibiotic
A1.4.1.1.2. Biomedical or Dental Material
A1.4.1.1.3. Biologically Active Substance
A1.4.1.1.3.1. Neuroreactive Substance or Biogenic Amine
A1.4.1.1.3.2. Hormone
A1.4.1.1.3.3. Enzyme
A1.4.1.1.3.4. Vitamin
A1.4.1.1.3.5. Immunologic Factor
A1.4.1.1.3.6. Receptor
A1.4.1.1.4. Indicator, Reagent, or Diagnostic Aid
A1.4.1.1.5. Hazardous or Poisonous Substance
A1.4.1.2. Chemical Viewed Structurally
A1.4.1.2.1. Organic Chemical
A1.4.1.2.1.5. Nucleic Acid, Nucleoside, or Nucleotide
A1.4.1.2.1.6. Organophosphorus Compound
A1.4.1.2.1.7. Amino Acid, Peptide, or Protein
A1.4.1.2.1.8. Carbohydrate
A1.4.1.2.1.9. Lipid
A1.4.1.2.1.9.1. Steroid
A1.4.1.2.1.9.2. Eicosanoid
A1.4.1.2.2. Inorganic Chemical
A1.4.1.2.3. Element, Ion, or Isotope
A1.4.2. Body Substance
A1.4.3. Food
A2. Conceptual Entity
A2.1. Idea or Concept
A2.1.1. Temporal Concept
A2.1.2. Qualitative Concept
A2.1.3. Quantitative Concept
A2.1.4. Functional Concept
A2.1.4.1. Body System
A2.1.5. Spatial Concept
A2.1.5.1. Body Space or Junction
A2.1.5.2. Body Location or Region
A2.1.5.3. Molecular Sequence
A2.1.5.3.1. Nucleotide Sequence
A2.1.5.3.2. Amino Acid Sequence
A2.1.5.3.3. Carbohydrate Sequence
A2.1.5.4. Geographic Area
A2.2. Finding
A2.2.1. Laboratory or Test Result
A2.2.2. Sign or Symptom
A2.3. Organism Attribute
A2.3.1. Clinical Attribute
A2.4. Intellectual Product
A2.4.1. Classification
A2.4.2. Regulation or Law
A2.5. Language
A2.6. Occupation or Discipline
A2.6.1. Biomedical Occupation or Discipline
A2.7. Organization
A2.7.1. Health Care Related Organization
A2.7.2. Professional Society
A2.7.3. Self-help or Relief Organization
A2.8. Group Attribute
A2.9. Group
A2.9.1. Professional or Occupational Group
A2.9.2. Population Group
A2.9.3. Family Group
A2.9.4. Age Group
A2.9.5. Patient or Disabled Group
B. Event
B1. Activity
B1.1. Behavior
B1.1.1. Social Behavior
B1.1.2. Individual Behavior
B1.2. Daily or Recreational Activity
B1.3. Occupational Activity
B1.3.1. Health Care Activity
B1.3.1.1. Laboratory Procedure
B1.3.1.2. Diagnostic Procedure
B1.3.1.3. Therapeutic or Preventive Procedure
B1.3.2. Research Activity
B1.3.2.1. Molecular Biology Research Technique
B1.3.3. Governmental or Regulatory Activity
B1.3.4. Educational Activity
B1.4. Machine Activity
B2. Phenomenon or Process
B2.1. Human-caused Phenomenon or Process
B2.1.1. Environmental Effect of Humans
B2.2. Natural Phenomenon or Process
B2.2.1. Biologic Function
B2.2.1.1. Physiologic Function
B2.2.1.1.1. Organism Function
B2.2.1.1.1.1. Mental Process
B2.2.1.1.2. Organ or Tissue Function
B2.2.1.1.3. Cell Function
B2.2.1.1.4. Molecular Function
B2.2.1.1.4.1. Genetic Function
B2.2.1.2. Pathologic Function
B2.2.1.2.1. Disease or Syndrome
B2.2.1.2.1.1. Mental or Behavioral Dysfunction
B2.2.1.2.1.2. Neoplastic Process
B2.2.1.2.2. Cell or Molecular Dysfunction
B2.2.1.2.3. Experimental Model of Disease
B2.3. Injury or Poisoning
Page Format
Any submit button will submit all of the items you have changed.
[theme]
Use this page design theme:
original
twenty ten
[shown]
Results per page:
5
10
20
50
100
200
500
[expand/collapse]
show these sections expanded by default:
Advanced search
MeSH query
Search history
Page format
Query expansion
Articles details
Export citations
Email
[text size]
use this font size for text:
25%
50%
75%
100%
125%
150%
200%
or enter your choice of font size:
[page width]
use this page width (relative to the default initial value):
25%
50%
75%
100%
125%
150%
200%
or enter your choice of page width:
[highlight color]
use this color to highlight query words in the articles:
red
green
blue
black
purple
yellow
orange
navy
olive
maroon
none
[query history]
maximum number of queries shown in the history section:
[annotate]
Annotate these parts of each article:
title
abstract
both
none
Reset all values
Find best MeSH terms for
Search History
1
bcc metatypical basal cell carcinoma of skin 2005:2010[pubdate] *count=100
225 results
Searchbox
Export
PDF
RSS
Email
Delete
Email this search result to the following email address:
[X] Close
Expand the query
'
bcc metatypical basal cell carcinoma of skin
' expanded to all its synonyms;
details
Email the results to the following email address:
Export the checked citations in RIS format (RIS format is used by RefWorks, Endnote, among others).
Items 1 to 100 of about 225
1.
Saetta AA, Aroni K, Stamatelli A, Lazaris AC, Patsouris E:
Expression of mismatch repair enzymes, hMLH1 and hMSH2 is not associated with microsatellite instability and P53 protein accumulation in basal cell carcinoma.
Arch Dermatol Res
; 2005 Sep;297(3):99-107
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of mismatch repair enzymes, hMLH1 and hMSH2 is not associated with microsatellite instability and P53 protein accumulation in
basal cell carcinoma
.
The role of MSI in
basal cell carcinoma
(
BCC
) has not been clearly delineated yet. p53 gene as a target for ultraviolet radiation-induced mutations may enhance genomic instability in
BCC
, with loss of its function.
Our aim was to investigate the involvement of MSI and expression of hMLH1 and hMSH2 in parallel with P53 protein accumulation in the pathogenesis
of BCC
and its possible correlation to the clinicopathological features of the patients.
Alterations of the BAT-26 marker were observed in one fibroepithelioma of Pincus, one nodular and one multifocal superficial
BCC
.
A keratotic
BCC
showed an altered BAT-25 locus.
Two samples, a multifocal superficial
and a
nodular
BCC
, displayed MSI at two markers (BAT-25 and BAT-26; and BAT-25 and TGF-beta-RII, respectively).
Three more cases, a
metatypical
, a multifocal superficial
and a
signet ring
BCC
exhibited frameshift mutations in the TGF-beta-RII.
[MeSH-major]
Carcinoma
,
Basal Cell
/ genetics.
Carcinoma
,
Basal Cell
/ metabolism. Carrier Proteins / metabolism. MutS Homolog 2 Protein / metabolism. Nuclear Proteins / metabolism.
Tumor
Suppressor Protein p53 / metabolism
[MeSH-minor]
Adaptor Proteins, Signal Transducing. Female. Gene Expression Regulation, Neoplastic. Genomic Instability / genetics. Humans. Male. Microsatellite Repeats / genetics. Protein Transport.
Skin
Neoplasms / genetics.
Skin
Neoplasms / metabolism.
Skin
Neoplasms / pathology
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16012876.001).
[ISSN]
0340-3696
[Journal-full-title]
Archives of dermatological research
[ISO-abbreviation]
Arch. Dermatol. Res.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Protein p53; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
2.
de Haas ER, de Vijlder HC, van Reesema WS, van Everdingen JJ, Neumann HA:
Quality of clinical practice guidelines in dermatological oncology.
J Eur Acad Dermatol Venereol
; 2007 Oct;21(9):1193-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: We searched MEDLINE, PubMed, EMBASE and Cochrane literature and relevant websites of guidelines development programmes and the national dermatological society to identify evidence-based dermatological guidelines especially in the treatment of to
basal cell carcinoma
,
squamous
cell carcinoma
and melanoma.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17894704.001).
[ISSN]
0926-9959
[Journal-full-title]
Journal of the European Academy of Dermatology and Venereology : JEADV
[ISO-abbreviation]
J Eur Acad Dermatol Venereol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
3.
Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, Nelson HH:
Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire.
Environ Health Perspect
; 2007 Aug;115(8):1231-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma
skin
cancer in New Hampshire.
UV damage is specifically repaired by nucleotide excision repair (NER), and common genetic variants in NER may increase risk for non-melanoma
skin
cancer (NMSC).
METHODS: Incident cases
of basal
and squamous
cell carcinoma
(
BCC
and SCC, respectively) were identified through a network of dermatologists and pathology laboratories across New Hampshire.
The analysis included 880 cases
of BCC
, 666 cases of SCC, and 780 controls.
RESULTS: There was an increased
BCC
risk associated with high arsenic exposure among those homozygous variant for XPA [odds ratio (OR) = 1.8; 95% confidence interval (CI), 0.9-3.7].
For XPD, having variation at both loci (312Asn and 751Gln) occurred less frequently among
BCC
and SCC cases compared with controls (OR = 0.8; 95% CI, 0.6-1.0) for both case groups.
MedlinePlus Health Information.
consumer health - Arsenic
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
ARSENIC, ELEMENTAL
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50
[
9703491.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81
[
9950243.001
]
[Cites]
Toxicol Lett. 1998 Dec 28;102-103:235-9
[
10022259.001
]
[Cites]
Oncol Res. 1998;10(9):475-82
[
10223623.001
]
[Cites]
Int J Cancer. 1999 May 17;81(4):555-9
[
10225444.001
]
[Cites]
Toxicol Appl Pharmacol. 1999 Aug 15;159(1):65-75
[
10448126.001
]
[Cites]
Carcinogenesis. 2002 Feb;23(2):295-9
[
11872635.001
]
[Cites]
Environ Health Perspect. 1999 Sep;107(9):727-9
[
10464073.001
]
[Cites]
Prensa Med Argent. 1964 Oct 23;51:994-8
[
14231402.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1788-93
[
15533908.001
]
[Cites]
Carcinogenesis. 2004 Dec;25(12):2433-41
[
15333465.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2242-6
[
15598786.001
]
[Cites]
Hum Mutat. 2005 Apr;25(4):353-9
[
15776433.001
]
[Cites]
Cancer Lett. 2005 May 26;222(2):205-9
[
15863269.001
]
[Cites]
Carcinogenesis. 2000 Apr;21(4):551-5
[
10753184.001
]
[Cites]
Carcinogenesis. 2000 May;21(5):965-71
[
10783319.001
]
[Cites]
J Natl Cancer Inst. 2000 Jun 7;92(11):874-97
[
10841823.001
]
[Cites]
Pharmacology. 2000 Sep;61(3):212-27
[
10971208.001
]
[Cites]
Cancer Res. 2001 Feb 15;61(4):1354-7
[
11245433.001
]
[Cites]
Am J Epidemiol. 2001 Mar 15;153(6):559-65
[
11257063.001
]
[Cites]
Carcinogenesis. 2001 Apr;22(4):593-7
[
11285194.001
]
[Cites]
Cancer Res. 2001 Apr 15;61(8):3321-5
[
11309287.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60
[
11319176.001
]
[Cites]
Carcinogenesis. 2001 Jun;22(6):899-904
[
11375896.001
]
[Cites]
Mutat Res. 2001 Jul 1;478(1-2):159-68
[
11406180.001
]
[Cites]
Carcinogenesis. 2001 Aug;22(8):1185-8
[
11470747.001
]
[Cites]
Toxicol Appl Pharmacol. 2001 Dec 1;177(2):132-48
[
11740912.001
]
[Cites]
Cancer Res. 2002 Jan 1;62(1):152-5
[
11782372.001
]
[Cites]
Carcinogenesis. 2002 Apr;23(4):599-603
[
11960912.001
]
[Cites]
Int J Hyg Environ Health. 2002 Mar;205(1-2):85-94
[
12018020.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):993-7
[
12376498.001
]
[Cites]
Mutat Res. 2002 Nov 30;509(1-2):165-74
[
12427537.001
]
[Cites]
J Invest Dermatol. 2003 Jan;120(1):48-55
[
12535197.001
]
[Cites]
Int J Cancer. 2003 Apr 10;104(3):263-8
[
12569548.001
]
[Cites]
Carcinogenesis. 2003 Mar;24(3):505-9
[
12663511.001
]
[Cites]
Toxicol Lett. 2003 Jul 20;143(2):123-31
[
12749816.001
]
[Cites]
Mutat Res. 2003 Dec 10;533(1-2):37-65
[
14643412.001
]
[Cites]
Mutagenesis. 2004 Mar;19(2):143-8
[
14981161.001
]
[Cites]
Carcinogenesis. 2004 May;25(5):729-34
[
14688016.001
]
[Cites]
Br J Cancer. 2004 Oct 18;91(8):1604-9
[
15381933.001
]
[Cites]
J Natl Cancer Inst. 1968 Mar;40(3):453-63
[
5644201.001
]
[Cites]
Beitr Pathol. 1974 Apr;151(4):384-400
[
4838015.001
]
[Cites]
Can Med Assoc J. 1975 Sep 6;113(5):396-401
[
125622.001
]
[Cites]
Am J Epidemiol. 1976 Dec;104(6):609-20
[
998608.001
]
[Cites]
Hum Toxicol. 1983 Jan;2(1):121-33
[
6840787.001
]
[Cites]
Cancer Res. 1985 Nov;45(11 Pt 2):5895-9
[
4053060.001
]
[Cites]
J Mol Biol. 1987 Aug 20;196(4):947-50
[
3681984.001
]
[Cites]
J Clin Epidemiol. 1989;42(4):317-24
[
2723692.001
]
[Cites]
Mol Toxicol. 1989 Winter;2(1):1-9
[
2615768.001
]
[Cites]
Biol Trace Elem Res. 1989 Jul-Sep;21:373-81
[
2484616.001
]
[Cites]
Biol Met. 1991;4(4):197-200
[
1777354.001
]
[Cites]
Mutagenesis. 1992 Jan;7(1):51-5
[
1635456.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7
[
8220096.001
]
[Cites]
Mutat Res. 2005 Jul 1;574(1-2):105-11
[
15914210.001
]
[Cites]
Cancer Detect Prev. 2005;29(3):209-14
[
15936590.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1539-44
[
15941969.001
]
[Cites]
Mutat Res. 2006 Jun;612(3):215-46
[
16574468.001
]
[Cites]
Environ Health Perspect. 2006 Aug;114(8):1193-8
[
16882524.001
]
[Cites]
Carcinogenesis. 2006 Aug;27(8):1670-5
[
16513681.001
]
[Cites]
Carcinogenesis. 2007 Mar;28(3):672-6
[
17050553.001
]
[Cites]
IARC Monogr Eval Carcinog Risks Hum. 2004;84:1-477
[
15645577.001
]
[Cites]
Am J Epidemiol. 1994 Oct 1;140(7):598-607
[
7942760.001
]
[Cites]
Br J Cancer. 1995 Jan;71(1):109-14
[
7819025.001
]
[Cites]
Mamm Genome. 1996 Aug;7(8):563-74
[
8679005.001
]
[Cites]
Carcinogenesis. 1997 Feb;18(2):399-405
[
9054635.001
]
[Cites]
Mutat Res. 1997 Jun;386(3):345-51
[
9219571.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):589-96
[
9264271.001
]
[Cites]
Epidemiology. 1997 Sep;8(5):545-50
[
9270957.001
]
[Cites]
Trends Biochem Sci. 1998 Jan;23(1):1-4
[
9478126.001
]
[Cites]
Cancer Res. 1998 Feb 15;58(4):604-8
[
9485007.001
]
[Cites]
Mutat Res. 1998 Feb;407(1):25-34
[
9539978.001
]
(PMID = 17687452.001).
[ISSN]
0091-6765
[Journal-full-title]
Environmental health perspectives
[ISO-abbreviation]
Environ. Health Perspect.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / R01CA082354; United States / NIEHS NIH HHS / ES / P42 ES007373; United States / NIEHS NIH HHS / ES / T32 ES07155; United States / NIEHS NIH HHS / ES / P42 ES07373; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155; United States / NCI NIH HHS / CA / R01 CA082354
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Carcinogens; 0 / Environmental Pollutants; 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; N712M78A8G / Arsenic
[Other-IDs]
NLM/ PMC1940098
Advertisement
4.
Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF:
Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
Dermatol Ther
; 2010 Nov-Dec;23(6):651-61
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Electrochemotherapy for cutaneous and subcutaneous
tumor
lesions: a novel therapeutic approach.
Electroporation uses pulsed, high-intensity electric fields to temporarily increase
cell
membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal.
ECT has already been proven to be effective in diverse
tumor
histotypes, including melanoma and
basal
and squamous
cell carcinoma
, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile.
ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous
tumor
lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.
[MeSH-major]
Antineoplastic Agents / administration & dosage. Electrochemotherapy.
Skin
Neoplasms / drug therapy
[MeSH-minor]
Animals. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Humans.
Skin
/ pathology. Treatment Outcome
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
BLEOMYCIN
.
Hazardous Substances Data Bank.
CIS-DIAMINEDICHLOROPLATINUM
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© 2010 Wiley Periodicals, Inc.
(PMID = 21054709.001).
[ISSN]
1529-8019
[Journal-full-title]
Dermatologic therapy
[ISO-abbreviation]
Dermatol Ther
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
5.
Petrella LI, Valle HA, Issa PR, Martins CJ, Pereira WC, Machado JC:
Study of cutaneous cell carcinomas ex vivo using ultrasound biomicroscopic images.
Skin Res Technol
; 2010 Nov;16(4):422-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Study of cutaneous
cell
carcinomas
ex vivo using ultrasound biomicroscopic images.
In this sense, several studies are being conducted for the measurement of cutaneous
tumor
sizes and for the evaluation of their response to therapeutic procedures.
The present work was conducted to analyze the ability of UBM to identify diverse histological structures associated with cutaneous
carcinomas
ex vivo regarding the evaluation of the technique as a diagnostic tool that could, eventually, improve the patient's healthcare protocol.
METHODS: Ex vivo human tissue samples, corresponding to
basal cell carcinoma
and squamous
cell carcinoma
cases, were studied.
RESULTS: The histological components present in the tumors were identified by variations in the echogenicity level for several of the studied cases and particular characteristics were observed for the different
tumor
types.
CONCLUSION: The possibility of differentiating the histological components associated with cutaneous
carcinomas
indicates the potential use of UBM for diagnostic applications.
[MeSH-major]
Bowen's
Disease
/ ultrasonography.
Carcinoma
,
Basal Cell
/ ultrasonography.
Carcinoma
,
Squamous
Cell
/ ultrasonography. Dermoscopy / methods.
Skin
Neoplasms / ultrasonography. Ultrasonography / methods
MedlinePlus Health Information.
consumer health - Skin Cancer
.
MedlinePlus Health Information.
consumer health - Ultrasound
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
© 2010 John Wiley & Sons A/S.
(PMID = 21039907.001).
[ISSN]
1600-0846
[Journal-full-title]
Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
[ISO-abbreviation]
Skin Res Technol
[Language]
eng
[Publication-type]
Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
6.
Thomas L, Dalle S:
[Pathology of the eyelid in elderly patients].
J Fr Ophtalmol
; 2006 Jun;29(6):672-86
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
METHODS: Illustrated review centered on
diagnosis
of the usual aspects and pitfalls of eyelid pathology divided into semiological chapters (tumors, blisters, erythema, etc.).
It is mainly centered on
skin
cancers (
basal cell carcinoma
,
squamous
cell carcinoma
, adnexal
carcinomas
, and melanoma).
A number of rare diseases deserve mention since their presence could lead to the
diagnosis
of internal or systemic diseases (dermatomyositis, necrobiotic xanthogranuloma, Erdheim-Chester, etc.).
In such conditions, early
diagnosis
is often based on the observation of isolated periocular symptoms.
CONCLUSIONS: Even though topographic dermatology is a somewhat reductive vision
of skin
diseases, pathology of the eyelids deserves special mention because of its polymorphism as well as its diagnostic and/or therapeutic significance.
[MeSH-major]
Eyelid Diseases /
diagnosis
[MeSH-minor]
Aged. Eyelid Neoplasms /
diagnosis
. Humans
MedlinePlus Health Information.
consumer health - Eyelid Disorders
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16885900.001).
[ISSN]
1773-0597
[Journal-full-title]
Journal français d'ophtalmologie
[ISO-abbreviation]
J Fr Ophtalmol
[Language]
fre
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
France
[Number-of-references]
123
7.
McGuire JF, Ge NN, Dyson S:
Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior.
Am J Otolaryngol
; 2009 Mar-Apr;30(2):121-33
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nonmelanoma
skin
cancer of the head and neck I: histopathology and clinical behavior.
Non-Melanoma
skin
cancer (NMSC) is the most commonly encountered malignancy in almost every area of practice, but the cases that present to an Otolaryngology practice will be advanced in nature.
The major subtypes of NMSC include
basal cell carcinoma
,
squamous
cell carcinoma
, dermatofibrosarcoma protuberans, merkel
cell carcinoma
, and adnexal malignancies.
[MeSH-major]
Carcinoma
/ pathology. Dermatofibrosarcoma / pathology. Head and Neck Neoplasms / pathology.
Skin
Neoplasms / pathology
[MeSH-minor]
Humans.
Neoplasm
Metastasis. Organ Transplantation / adverse effects
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19239954.001).
[ISSN]
1532-818X
[Journal-full-title]
American journal of otolaryngology
[ISO-abbreviation]
Am J Otolaryngol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
123
8.
Caccialanza M, Piccinno R, Kolesnikova L, Gnecchi L:
Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients.
Int J Dermatol
; 2005 Jun;44(6):513-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Radiotherapy
of skin
carcinomas
of the pinna: a study of 115 lesions in 108 patients.
BACKGROUND: The possibility of treating
skin
carcinomas
of the pinna with radiotherapy is somewhat under discussion and scarcely known.
Therefore the aim of the study was to evaluate the effectiveness and safety of dermatologic radiotherapy in a series of patients affected by
basal
or
squamous
cell carcinoma
of the pinna.
METHODS: A retrospective study was performed on 108 patients affected by 115
carcinomas
of the pinna (99
basal cell
carcinomas
, 16
squamous
cell
carcinomas
) without involvement of the external auditory canal.
During follow up a relapse was observed in 12 lesions (all
basal cell
carcinomas
): nine central and three marginal to the irradiation field.
CONCLUSIONS: The results obtained confirm the possibility of treating epithelial
skin
neoplasms of the pinna with dermatologic radiotherapy, which can afford high-remission percentages without damaging cartilaginous tissue.
[MeSH-major]
Carcinoma
,
Basal Cell
/ radiotherapy.
Carcinoma
,
Squamous
Cell
/ radiotherapy. Ear Neoplasms / radiotherapy. Ear, External.
Skin
Neoplasms / radiotherapy
[MeSH-minor]
Aged. Aged, 80 and over. Esthetics. Female. Humans. Male. Middle Aged.
Neoplasm
Recurrence, Local / therapy. Retrospective Studies. Treatment Outcome
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15941445.001).
[ISSN]
0011-9059
[Journal-full-title]
International journal of dermatology
[ISO-abbreviation]
Int. J. Dermatol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
9.
Aboutalebi S, Strickland FM:
Immune protection, natural products, and skin cancer: is there anything new under the sun?
J Drugs Dermatol
; 2006 Jun;5(6):512-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Immune protection, natural products, and
skin
cancer: is there anything new under the sun?
Non-melanoma
skin
cancers such as
squamous
cell carcinoma
and
basal cell carcinoma
are the most common types of human neoplasms, representing one third of all new malignancies diagnosed in the US.
Ultraviolet (UV) radiation from the sun is a major cause of non-melanoma
skin
cancer in humans.
Aside from the mutagenic effects of UV radiation, there are suggestions from clinical studies and evidence in animal models that the immune system plays an important role in preventing
skin
cancer development and progression, and is suppressed by cutaneous exposure to UV radiation.
In this article, we review the research on new and existing agents that are being developed to protect the
skin
immune response from suppression by UV radiation.
[MeSH-major]
Aloe. Antioxidants / therapeutic use.
Carcinoma
,
Basal Cell
. Phytotherapy.
Skin
Neoplasms. Ultraviolet Rays / adverse effects
MedlinePlus Health Information.
consumer health - Antioxidants
.
MedlinePlus Health Information.
consumer health - Herbal Medicine
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
Sodium ascorbate
.
Hazardous Substances Data Bank.
L-Ascorbic Acid
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16774102.001).
[ISSN]
1545-9616
[Journal-full-title]
Journal of drugs in dermatology : JDD
[ISO-abbreviation]
J Drugs Dermatol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 1406-18-4 / Vitamin E; PQ6CK8PD0R / Ascorbic Acid
[Number-of-references]
67
10.
Thosani MK, Marghoob A, Chen CS:
Current progress of immunostains in Mohs micrographic surgery: a review.
Dermatol Surg
; 2008 Dec;34(12):1621-36
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Mohs micrographic surgery is often considered the treatment of choice for a variety
of skin
malignancies.
In recent years, the application of immunostaining techniques has facilitated the successful removal of a number of common and less common cutaneous malignancies, including
basal cell carcinoma
,
squamous
cell carcinoma
,
malignant
melanoma, dermatofibrosarcoma protuberans, microcystic adnexal
carcinoma
, sebaceous
carcinoma
, atypical fibroxanthoma, extramammary Paget's
disease
, and even sarcomas.
Immunostains highlight the
tumor
cells and allow the Mohs surgeons to pinpoint and eliminate the residual
tumor
at the surgical margin.
It is especially helpful when
a tumor
presents with subtle or nonspecific histologic features or when
a tumor
is masked in a pocket of dense inflammation.
[MeSH-major]
Mohs Surgery / methods.
Skin
Neoplasms / pathology.
Skin
Neoplasms / surgery. Staining and Labeling / methods
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19018832.001).
[ISSN]
1524-4725
[Journal-full-title]
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
[ISO-abbreviation]
Dermatol Surg
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
127
11.
Basile J, Thiers B, Maize J Sr, Lathers DM:
Chemokine receptor expression in non-melanoma skin cancer.
J Cutan Pathol
; 2008 Jul;35(7):623-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Chemokine receptor expression in non-melanoma
skin
cancer.
Prior studies have shown that in metastatic melanoma
and squamous
cell carcinoma
of the head and neck upregulation of CXC (alpha) chemokine receptor (CXCR)4 and CC (beta) chemokine receptor (CCR)7 expression is accompanied by downregulation of the chemokine receptor CCR6.
However, the expression patterns of CCR6, CCR7 and CXCR4 in non-melanoma
skin
cancer have yet to be elucidated.
METHODS: The expression patterns of CCR6, CCR7 and CXCR4 were determined using an immunohistochemical approach on formalin-fixed, paraffin-embedded normal, pre-cancerous actinic (solar) keratosis,
squamous
cell carcinoma
and
basal cell carcinoma
tissues.
RESULTS: Analysis of chemokine receptor expression showed downregulation of CCR6 and upregulation of CCR7 and CXCR4 in potentially metastatic non-melanoma
skin
cancer, invasive
squamous
cell carcinoma
, but this pattern did not exist in non-melanoma
skin
cancer with no metastatic potential,
basal cell carcinoma
; or actinic keratosis, when compared with normal
skin
.
CONCLUSIONS: Chemokine receptor expression may influence the biological behavior of non-melanoma
skin
cancer.
[MeSH-major]
Carcinoma
,
Basal Cell
/ metabolism.
Carcinoma
,
Squamous
Cell
/ metabolism. Keratosis / metabolism. Receptors, CCR6 / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR4 / metabolism.
Skin
Neoplasms / metabolism
[MeSH-minor]
Analysis of Variance. Biomarkers / metabolism. Down-Regulation. Humans. Immunohistochemistry.
Neoplasm
Metastasis / physiopathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology.
Skin
/ metabolism.
Skin
/ pathology. Staining and Labeling. Ultraviolet Rays / adverse effects. Up-Regulation
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18312436.001).
[ISSN]
1600-0560
[Journal-full-title]
Journal of cutaneous pathology
[ISO-abbreviation]
J. Cutan. Pathol.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Denmark
[Chemical-registry-number]
0 / Biomarkers; 0 / CCR6 protein, human; 0 / CCR7 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR6; 0 / Receptors, CCR7; 0 / Receptors, CXCR4
12.
Chovanec M, Smetana K Jr, Plzák J, Betka J, Plzáková Z, Stork J, Hrdlicková E, Kuwabara I, Dvoránková B, Liu FT, Kaltner H, André S, Gabius HJ:
Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia.
Prague Med Rep
; 2005;106(2):209-16
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in
squamous
epithelia.
Lectins represent one of pivotal regulators of the
cell
proliferation The potential of galectin-7 as a new prognostic marker was studied in normal and transformed
squamous
epithelia of both ectodermal (epidermis, cornea vs. trichoepithelioma,
basal
and squamous
cell carcinoma
) and endodermal (vocal fold epithelium vs.
carcinoma
) origin.
Its expression is significantly reduced in
malignant
cells, thus galectin-7 might be a differentiation marker of epithelial malignancies.
[MeSH-major]
Carcinoma
,
Squamous
Cell
/
diagnosis
. Epithelium / chemistry. Galectins / analysis
[MeSH-minor]
Biomarkers,
Tumor
/ analysis.
Cell
Division / physiology. Cells, Cultured. Humans.
Tumor
Cells, Cultured
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16315769.001).
[ISSN]
1214-6994
[Journal-full-title]
Prague medical report
[ISO-abbreviation]
Prague Med Rep
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Czech Republic
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Galectins; 0 / LGALS7 protein, human
13.
Krathen MS, Gottlieb AB, Mease PJ:
Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis.
J Rheumatol
; 2010 Nov;37(11):2205-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
OBJECTIVE: It is unclear if
skin
cancer risk is affected by the use of immunomodulatory medications in rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA).
METHODS: The English language literature on PubMed was searched with a combination of phrases, including "malignancy," "
skin
cancer," "
squamous
cell carcinoma
," "
basal cell carcinoma
," "melanoma," "psoriasis," "psoriatic arthritis," and "rheumatoid arthritis" in addition to the generic names of a variety of common immunomodulatory drugs.
Treatment with
tumor
necrosis factor inhibitors increases the rates of non-melanoma
skin
cancer (NMSC) in RA and psoriasis.
Methotrexate may increase the risk of
malignant
melanoma in patients with RA and the risk of NMSC in psoriasis.
More careful recording
of skin
cancer development during clinical trials and cohort studies is necessary to further delineate the risks of immunomodulatory therapy.
[MeSH-major]
Arthritis, Psoriatic / therapy. Arthritis, Rheumatoid / therapy. Immunosuppression / adverse effects. Psoriasis / therapy.
Skin
Neoplasms / etiology
Genetic Alliance.
consumer health - Arthritis
.
Genetic Alliance.
consumer health - Psoriasis
.
Genetic Alliance.
consumer health - Psoriatic Arthritis
.
Genetic Alliance.
consumer health - Rheumatoid arthritis
.
MedlinePlus Health Information.
consumer health - Psoriasis
.
MedlinePlus Health Information.
consumer health - Psoriatic Arthritis
.
MedlinePlus Health Information.
consumer health - Rheumatoid Arthritis
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20810498.001).
[ISSN]
0315-162X
[Journal-full-title]
The Journal of rheumatology
[ISO-abbreviation]
J. Rheumatol.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Canada
[Chemical-registry-number]
0 / Immunologic Factors
14.
Mancuso M, Gallo D, Leonardi S, Pierdomenico M, Pasquali E, De Stefano I, Rebessi S, Tanori M, Scambia G, Di Majo V, Covelli V, Pazzaglia S, Saran A:
Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
Carcinogenesis
; 2009 Feb;30(2):340-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Modulation
of basal
and squamous
cell carcinoma
by endogenous estrogen in mouse models
of skin
cancer.
Patched1 heterozygous mice (Ptch1(+/-)) are useful for
basal cell carcinoma
(
BCC
) studies, being remarkably susceptible to
BCC
induction by ultraviolet or ionizing radiation.
Analogously,
skin
carcinogenesis-susceptible (Car-S) mice are elective for studies of papilloma
and squamous
cell carcinoma
(SCC) induction.
We previously reported a striking effect of gender on
BCC
induction in Ptch1(+/-) mice, with total resistance of females; likewise, Car-S females show increased
skin
tumor
resistance relative to males.
Here, we investigated the protective role of endogenous estrogen in
skin
keratinocyte tumorigenesis.
Control (CN) and ovariectomized Ptch1(+/-) or Car-S females were irradiated for
BCC
induction or topically treated with chemical carcinogens for SCC induction.
Susceptibility to
BCC
or SCC was dramatically increased in ovariectomized Ptch1(+/-) and Car-S females and restored to levels observed in males.
Remarkably, progression of initially benign papillomas to
malignant
SCC occurred only in ovariectomized Car-S females.
We explored the mechanisms underlying
tumor
progression and report overexpression of estrogen receptor (ER)-alpha, downregulation of ERbeta and upregulation of cyclin D1 in papillomas from ovariectomized Car-S relative to papillomas from CN females.
Thus, an imbalanced ERalpha/ERbeta expression may be associated with estrogen-mediated modulation of non-melanoma
skin
carcinogenesis, with a key role played by cyclin D1.
Our findings underscore a highly protective role of endogenous estrogen against
skin
tumorigenesis by diverse agents in two independent mouse models
of skin
cancer.
[MeSH-major]
Carcinoma
,
Basal Cell
/ metabolism.
Carcinoma
,
Squamous
Cell
/ metabolism. Estrogens / physiology.
Skin
Neoplasms / metabolism
[MeSH-minor]
Animals.
Cell
Transformation, Neoplastic / metabolism.
Cell
Transformation, Neoplastic / pathology. Cyclin D1 / metabolism.
Disease
Models, Animal. Estrogen Receptor alpha / metabolism. Estrogen Receptor beta / metabolism. Female. Male. Mice. Neoplasms, Radiation-Induced / metabolism. Neoplasms, Radiation-Induced / pathology. Ovariectomy. Papilloma / metabolism. Papilloma / pathology. Receptors,
Cell
Surface / genetics. Receptors,
Cell
Surface / metabolism. Ultraviolet Rays
MedlinePlus Health Information.
consumer health - Skin Cancer
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Carcinogenesis. 2009 Apr;30(4):720
[
19168587.001
]
(PMID = 18952596.001).
[ISSN]
1460-2180
[Journal-full-title]
Carcinogenesis
[ISO-abbreviation]
Carcinogenesis
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / Estrogens; 0 / Receptors, Cell Surface; 0 / patched receptors; 136601-57-5 / Cyclin D1
15.
Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST:
Mast cells and cutaneous malignancies.
Mod Pathol
; 2006 Jan;19(1):149-59
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
This paper reviews the role of mast cells in the development and progression
of basal cell carcinoma
,
squamous
cell carcinoma
and malignant
melanoma.
Upon irradiation of the
skin
, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers.
These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in
basal cell carcinoma
and malignant
melanoma.
Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial
cell
wall into the matrix.
Mast
cell
proteases reorganize the stroma to facilitate endothelial
cell
migration.
As well, heparin, the dominant mast
cell
proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for
tumor
spread. (4) Mitogenesis: Mast
cell
mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.
Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in
tumor
biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.
[MeSH-major]
Mast Cells / physiology.
Skin
Neoplasms / pathology
[MeSH-minor]
Carcinoma
,
Basal Cell
/ blood.
Carcinoma
,
Basal Cell
/ blood supply.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Squamous
Cell
/ blood.
Carcinoma
,
Squamous
Cell
/ blood supply.
Carcinoma
,
Squamous
Cell
/ pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood
MedlinePlus Health Information.
consumer health - Skin Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16258517.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Vascular Endothelial Growth Factor A
[Number-of-references]
71
16.
Eide MJ, Weinstock MA, Dufresne RG Jr, Neelagaru S, Risica P, Burkholder GJ, Upegui D, Phillips KA, Armstrong BK, Robinson-Bostom L:
Relationship of treatment delay with surgical defect size from keratinocyte carcinoma (basal cell carcinoma and squamous cell carcinoma of the skin).
J Invest Dermatol
; 2005 Feb;124(2):308-14
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Relationship of treatment delay with surgical defect size from keratinocyte
carcinoma
(
basal cell carcinoma
and squamous
cell carcinoma
of the
skin
).
Larger keratinocyte
carcinoma
(KC) lesions are associated with higher morbidity.
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Eur J Cancer. 2001 May;37(7):843-8
[
11313171.001
]
[Cites]
Br J Dermatol. 2001 Mar;144(3):476-83
[
11260002.001
]
[Cites]
Dermatol Surg. 2001 Nov;27(11):955-9
[
11737130.001
]
[Cites]
Br J Dermatol. 2002 Jul;147(1):48-54
[
12100184.001
]
[Cites]
Arch Dermatol. 2002 Aug;138(8):1043-51
[
12164742.001
]
[Cites]
Melanoma Res. 2002 Aug;12(4):389-94
[
12170189.001
]
[Cites]
Ann Plast Surg. 2002 Oct;49(4):439-42
[
12370654.001
]
[Cites]
CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26
[
12568441.001
]
[Cites]
Br J Dermatol. 2004 Jul;151(1):141-7
[
15270883.001
]
[Cites]
Br J Psychiatry. 1967 Jan;113(494):89-93
[
6029373.001
]
[Cites]
J Dermatol Surg Oncol. 1981 Apr;7(4):311-6
[
7240532.001
]
[Cites]
Prog Clin Biol Res. 1984;156:169-79
[
6473424.001
]
[Cites]
J Psychosom Res. 1985;29(2):139-53
[
4009515.001
]
[Cites]
J Am Acad Dermatol. 1988 Mar;18(3):591-8
[
3351022.001
]
[Cites]
J Dermatol Surg Oncol. 1989 Mar;15(3):315-28
[
2646336.001
]
[Cites]
Eur J Surg Oncol. 1989 Apr;15(2):143-8
[
2703058.001
]
[Cites]
Arch Dermatol. 1991 Mar;127(3):356-61
[
1998366.001
]
[Cites]
J Am Acad Dermatol. 1991 Jan;24(1):1-13
[
1999506.001
]
[Cites]
Postgrad Med. 1991 Mar;89(4):151-2, 155-8
[
2000349.001
]
[Cites]
Ann R Coll Surg Engl. 1991 Jul;73(4):248-52
[
1863047.001
]
[Cites]
J Dermatol Surg Oncol. 1991 Sep;17(9):713-8
[
1890243.001
]
[Cites]
Cancer. 1991 Nov 1;68(9):2064-8
[
1913555.001
]
[Cites]
Dermatol Surg. 1996 Mar;22(3):255-61
[
8599737.001
]
[Cites]
J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):422-9
[
9308558.001
]
[Cites]
Arch Dermatol. 1999 Mar;135(3):269-74
[
10086447.001
]
[Cites]
Arch Dermatol. 1999 Mar;135(3):339-40
[
10086457.001
]
[Cites]
J Clin Epidemiol. 1999 Nov;52(11):1111-6
[
10527006.001
]
[Cites]
Br J Dermatol. 1999 Nov;141(5):783-7
[
10583157.001
]
[Cites]
Br J Dermatol. 1999 Nov;141(5):876-9
[
10583170.001
]
[Cites]
Int J Cancer. 2000 May 20;89(3):271-9
[
10861504.001
]
[Cites]
Int J Cancer. 2000 May 20;89(3):280-5
[
10861505.001
]
[Cites]
Arch Dermatol. 2001 Aug;137(8):1055-8
[
11493098.001
]
(PMID = 15675948.001).
[ISSN]
0022-202X
[Journal-full-title]
The Journal of investigative dermatology
[ISO-abbreviation]
J. Invest. Dermatol.
[Language]
ENG
[Grant]
United States / NIMH NIH HHS / MH / K24 MH063975; United States / NCI NIH HHS / CA / R01 CA078800; United States / AHRQ HHS / HS / T32 HS000011; United States / NCI NIH HHS / CA / CA 78800
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
[Publication-country]
United States
[Other-IDs]
NLM/ NIHMS12744; NLM/ PMC1613794
17.
Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R:
Basosquamous carcinoma: treatment with Mohs micrographic surgery.
Cancer
; 2005 Jul 1;104(1):170-5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Basosquamous
carcinoma
: treatment with Mohs micrographic surgery.
BACKGROUND:
Basosquamous
carcinoma
(BSC) is a rare
tumor
defined as a
basal cell carcinoma
(
BCC
) differentiating into
squamous
cell carcinoma
(SCC).
METHODS: The prospective, multicenter case series included all patients in Australia treated with MMS for BSC, who were monitored by the
Skin
and Cancer Foundation Australia between 1993 and 2002.
The tumors were diagnosed initially as
BCC
in 87.4% and as SCC in 12.0% of patients.
Of 98 patients who completed a 5-year follow-up period after MMS, 4 (4.1%) had
disease
recurrence.
CONCLUSIONS: The low 5-year
disease
recurrence rate of BSC with MMS emphasized the importance of margin-controlled excision using MMS.
[MeSH-major]
Carcinoma
,
Basosquamous
/ surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods
[MeSH-minor]
Adult. Aged. Arm. Female. Follow-Up Studies. Humans. Leg. Male. Middle Aged.
Neoplasm
Recurrence, Local
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15929123.001).
[ISSN]
0008-543X
[Journal-full-title]
Cancer
[ISO-abbreviation]
Cancer
[Language]
eng
[Publication-type]
Clinical Trial; Journal Article; Multicenter Study
[Publication-country]
United States
18.
Kang SY, Lee KG, Lee W, Shim JY, Ji SI, Chung KW, Chung YK, Kim NK:
Polymorphisms in the DNA repair gene XRCC1 associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population.
Cancer Sci
; 2007 May;98(5):716-20
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Polymorphisms in the DNA repair gene XRCC1 associated with
basal cell carcinoma
and squamous
cell carcinoma
of the
skin
in a Korean population.
Unrepaired damage can result in apoptosis or may lead to unregulated
cell
growth and cancer.
This hospital-based case-control study examined whether polymorphisms in the DNA repair gene X-ray repair cross-complementing groups 1 (XRCC1) (Arg194Trp[C > T], Arg280His[G > A] and Arg399Gln[G > A]) play a role in susceptibility to
skin
cancer.
We genotyped these polymorphisms for 212 histopathologically confirmed
skin
cancer cases (n = 114
basal cell carcinoma
, n = 98
squamous
cell carcinoma
) and 207 age- and sex-matched healthy control cases in Korea.
We found that individuals with the Arg/Gln and Arg/Gln + Gln/Gln genotypes at XRCC1 Arg399Gln(G > A) had an approximately 2-fold increased risk
of basal cell carcinoma
compared to individuals with the Arg/Arg genotype (adjusted odds ratio [AOR] = 2.812, 95% confidence interval [CI] 1.32-5.98, and AOR = 2.324, 95% CI 1.11-4.86).
However, we observed that the 194Trp allele of the Arg194Trp(C > T) polymorphism was inversely associated with
squamous
cell carcinoma
risk (Trp/Trp, AOR = 0.06, 95% CI 0.006-0.63).
Our data suggest that the Arg194Trp and Arg399Gln polymorphisms may be differentially associated with
skin
cancer risk.
[MeSH-major]
Carcinoma
,
Basal Cell
/ genetics.
Carcinoma
,
Squamous
Cell
/ genetics. DNA-Binding Proteins / genetics. Polymorphism, Genetic.
Skin
Neoplasms / genetics
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Asian Continental Ancestry Group / genetics. Case-Control Studies. Gene Frequency. Genetic Predisposition to
Disease
/ ethnology. Genotype. Haplotypes. Humans. Korea. Middle Aged. Odds Ratio
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17355263.001).
[ISSN]
1347-9032
[Journal-full-title]
Cancer science
[ISO-abbreviation]
Cancer Sci.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1
19.
Wimmer E, Kraehn-Senftleben G, Issing WJ:
HER3 expression in cutaneous tumors.
Anticancer Res
; 2008 Mar-Apr;28(2A):973-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: In order to elucidate the role of the receptor tyrosine kinase HER3, the expression characteristics in different tissues of cutaneous malignancies and in normal
skin
were compared.
MATERIALS AND METHODS: In this study HER3 expression was evaluated by RT-PCR analysis and immunohistochemistry from different tissue specimens of cutaneous tumors like nevi, primary
malignant
melanomas,
basal cell carcinoma
,
squamous
cell carcinoma
and malignant
melanoma metastases and normal
skin
samples and graded into weak, moderate and strong expression.
Associations of
tumor
thickness in these specimens with HER3 expressions were also analyzed.
RESULTS: HER3 expression was found in 63% (10/16) of the
basal cell
carcinomas
, in 4/5 of
squamous
cell
carcinomas and
in one Merkel
cell carcinoma
.
Within the group of different
malignant
melanomas, HER3 expression was detected in 35% of the nodular
malignant
melanomas (6/17) and in 9/19 of the superficial spreading melanomas, including 2 lentigo
malignant
melanomas.
The majority of melanomas with a higher
tumor
thickness expressed HER3, and 85% of melanoma metastasis were HER3-positive.
CONCLUSION: HER3 expression was associated with hyperproliferate
tumor
stages and suggested that HER3 expression could reflect an increased
malignant
potential in cutaneous lesions.
[MeSH-major]
Skin
Neoplasms / metabolism
[MeSH-minor]
Carcinoma
,
Basal Cell
/ genetics.
Carcinoma
,
Basal Cell
/ metabolism.
Carcinoma
,
Squamous
Cell
/ genetics.
Carcinoma
,
Squamous
Cell
/ metabolism. Humans. Immunohistochemistry. Melanoma / genetics. Melanoma / metabolism.
Neoplasm
Metastasis. Nevus. Receptor, ErbB-3 / genetics. Receptor, ErbB-3 / metabolism. Reverse Transcriptase Polymerase Chain Reaction.
Skin
/ metabolism
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18507044.001).
[ISSN]
0250-7005
[Journal-full-title]
Anticancer research
[ISO-abbreviation]
Anticancer Res.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
Greece
[Chemical-registry-number]
EC 2.7.10.1 / Receptor, ErbB-3
20.
Zhang H, Yan J, Li Y, Zhang P:
Mucoepidermoid carcinoma of the eyelid: a case report and review of the literature.
Yan Ke Xue Bao
; 2005 Sep;21(3):152-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Mucoepidermoid
carcinoma of
the eyelid: a case report and review of the literature.
PURPOSE: To report the clinical features, therapeutic method, and histopathological findings of a case of mucoepidermoid
carcinoma
in the lower eyelid and review the literature about the mucoepidermoid
carcinoma
arising from the eye.
RESULTS: An 88-year-old man developed a painless, indurated nodule in the left lower eyelid for two years and ulceration of the
skin
existed for a year.
He underwent
tumor
resection and reconstruction of the eyelid.
By histopathology,
tumor
cells showed an admixture of epidermoid and mucus-secreting cells, which was consistent with mucoepidermoid
carcinoma
.
Mucoepidermoid
carcinoma
is a common
malignant tumor
of the salivary glands, but rare in the eye tissues among which conjunctiva and lacrimal gland are most commonly involved.
It has a higher degree of malignancy than
basal cell carcinoma
and squamous
cell carcinoma
.
CONCLUSIONS: Mucoepidermoid
carcinoma
arising from the eye is rare and has a high degree of malignancy.
It should be differentiated from other neoplasms such as
basal cell carcinoma
and squamous
cell carcinoma
.
Genetic Alliance.
consumer health - Mucoepidermoid carcinoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17162853.001).
[ISSN]
1000-4432
[Journal-full-title]
Yan ke xue bao = Eye science
[ISO-abbreviation]
Yan Ke Xue Bao
[Language]
ENG
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
China
[Number-of-references]
23
21.
Reisinger DM, Shiffer JD, Cognetta AB Jr, Chang Y, Moore PS:
Lack of evidence for basal or squamous cell carcinoma infection with Merkel cell polyomavirus in immunocompetent patients with Merkel cell carcinoma.
J Am Acad Dermatol
; 2010 Sep;63(3):400-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Lack of evidence for
basal
or
squamous
cell carcinoma
infection with Merkel
cell
polyomavirus in immunocompetent patients with Merkel
cell carcinoma
.
BACKGROUND: Merkel
cell
polyomavirus (MCV) was discovered by digital transcriptome subtraction as a monoclonal infection of Merkel
cell carcinoma
(MCC) tumors.
Polymerase chain reaction-based detection of the virus in other nonmelanoma
skin
cancers, however, has been inconsistent and controversial.
OBJECTIVE: We sought to directly assay for MCV infection in
squamous
cell carcinoma
(SCC) or
basal cell carcinoma
(
BCC
)
tumor
cells by immunostaining for viral antigen.
METHODS: CM2B4, a monoclonal antibody to exon 2 peptides of MCV T antigen, was used to examine tumors from 20 patients with MCC with and without secondary SCC or
BCC
tumors.
RESULTS: MCV T antigen was readily detected in 15 (75%) of 20 MCC tumors including 11 MCC tumors from patients with secondary SCC or
BCC
.
In contrast to MCC, none of these secondary
BCC
or SCC was MCV T-antigen positive.
CONCLUSIONS: MCV T antigen is generally not expressed in
BCC
or SCC tumors from a population favored to have MCV infection, ie, those persons already given the
diagnosis
of MCV-positive MCC.
This suggests that episodic polymerase chain reaction detection of MCV genome in
BCC
or SCC tumors may represent coincidental rather than causal infection, and that these tumors share other noninfectious risk factors.
[MeSH-major]
Carcinoma
,
Basal Cell
/ virology.
Carcinoma
, Merkel
Cell
/ virology.
Carcinoma
,
Squamous
Cell
/ virology. Immunocompetence.
Skin
Neoplasms / virology
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
(PMID = 20584559.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / CA120726; United States / NCI NIH HHS / CA / CA136363
[Publication-type]
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral
22.
Leibeling D, Laspe P, Emmert S:
Nucleotide excision repair and cancer.
J Mol Histol
; 2006 Sep;37(5-7):225-38
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
XP patients show severe sun sensitivity, freckling in sun exposed
skin
, and develop
skin
cancers already during childhood.
Clinical symptoms of TTD patients include sun sensitivity, freckling in sun exposed
skin
areas, and brittle sulfur-deficient hair.
In contrast to XP patients, CS and TTD patients are not
skin
cancer prone.
Studying these syndromes can increase the knowledge
of skin
cancer development including cutaneous melanoma as well as
basal
and squamous
cell carcinoma
in general that may lead to new preventional and therapeutic anticancer strategies in the normal population.
MedlinePlus Health Information.
consumer health - Hair Problems
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cells Tissues Organs. 2004;177(3):189-98
[
15388993.001
]
[Cites]
Arch Dermatol. 1980 Dec;116(12):1375-84
[
7458366.001
]
[Cites]
Skin Pharmacol. 1994;7(5):257-61
[
8054207.001
]
[Cites]
EMBO J. 1999 Jun 15;18(12 ):3491-501
[
10369688.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7260-4
[
8346243.001
]
[Cites]
Photochem Photobiol. 1993 Sep;58(3):450-4
[
8234481.001
]
[Cites]
Basic Life Sci. 1990;53:149-60
[
2282032.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 May 25;96(11):6090-5
[
10339546.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81
[
9950243.001
]
[Cites]
Mol Gen Genet. 1991 Aug;228(1-2):153-9
[
1679524.001
]
[Cites]
Biochemistry. 1992 Jul 28;31(29):6794-800
[
1637815.001
]
[Cites]
Exp Dermatol. 2003 Oct;12(5):529-36
[
14705792.001
]
[Cites]
J Dtsch Dermatol Ges. 2006 Sep;4(9):721-31
[
16928240.001
]
[Cites]
Carcinogenesis. 2005 Jun;26(6):1085-90
[
15731165.001
]
[Cites]
Mol Cell Biol. 1995 Jan;15(1):290-7
[
7799936.001
]
[Cites]
Cold Spring Harb Symp Quant Biol. 1994;59:317-29
[
7587084.001
]
[Cites]
Biochimie. 1999 Jan-Feb;81(1-2):15-25
[
10214906.001
]
[Cites]
Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1614-8
[
8434025.001
]
[Cites]
J Invest Dermatol. 1996 Oct;107(4):647-53
[
8823375.001
]
[Cites]
EMBO J. 1996 Apr 1;15(7):1666-77
[
8612591.001
]
[Cites]
Hautarzt. 2002 Mar;53(3):167-73
[
11974587.001
]
[Cites]
Exp Dermatol. 1996 Jun;5(3):173-80
[
8840158.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8658-63
[
9238033.001
]
[Cites]
Proc Natl Acad Sci U S A. 1975 Oct;72(10):4071-5
[
172893.001
]
[Cites]
Br J Dermatol. 1993 Apr;128(4):384-7
[
8494750.001
]
[Cites]
Am J Med Genet. 1992 Jan 1;42(1):68-84
[
1308368.001
]
[Cites]
Am J Hum Genet. 2001 Aug;69(2):291-300
[
11443545.001
]
[Cites]
J Invest Dermatol. 1994 Nov;103(5 Suppl):96S-101S
[
7963692.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):465-8
[
9641488.001
]
[Cites]
Science. 1999 Dec 3;286(5446):1897-905
[
10583946.001
]
[Cites]
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):815-20
[
11773631.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3116-21
[
9096355.001
]
[Cites]
Am J Hum Genet. 1998 Jan;62(1):77-85
[
9443879.001
]
[Cites]
Eur J Hum Genet. 2005 Feb;13(2):253-5
[
15494739.001
]
[Cites]
Mol Cell. 1999 Jan;3(1):33-42
[
10024877.001
]
[Cites]
J Biol Chem. 1993 Oct 5;268(28):21293-300
[
8407967.001
]
[Cites]
Biochimie. 1999 Jan-Feb;81(1-2):39-44
[
10214908.001
]
[Cites]
J Cell Physiol. 2002 Apr;191(1):28-41
[
11920679.001
]
[Cites]
Nature. 1993 May 13;363(6425):114-5
[
8483493.001
]
[Cites]
J Invest Dermatol. 1998 Nov;111(5):791-6
[
9804340.001
]
[Cites]
J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):329-35
[
8294592.001
]
[Cites]
Science. 1997 Feb 14;275(5302):990-3
[
9020084.001
]
[Cites]
Am J Med Genet A. 2004 Jul 30;128A(3):235-45
[
15216543.001
]
[Cites]
Hum Mol Genet. 2001 Oct 15;10(22):2539-47
[
11709541.001
]
[Cites]
Carcinogenesis. 2003 Mar;24(3):505-9
[
12663511.001
]
[Cites]
Nat Genet. 2004 Jul;36(7):714-9
[
15220921.001
]
[Cites]
J Biol Chem. 1997 Mar 21;272(12):7570-3
[
9065408.001
]
[Cites]
Clin Dermatol. 1985 Jan-Mar;3(1):33-69
[
3833325.001
]
[Cites]
Neurology. 2000 Nov 28;55(10):1442-9
[
11185579.001
]
[Cites]
J Biol Chem. 2001 Mar 30;276(13):10103-9
[
11124949.001
]
[Cites]
Carcinogenesis. 2001 Mar;22(3):403-8
[
11238179.001
]
[Cites]
Hum Genet. 1996 Apr;97(4):418-23
[
8834235.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2151-6
[
10681431.001
]
[Cites]
Nucleic Acids Res. 1992 Sep 25;20(18):4761-4
[
1357629.001
]
[Cites]
Science. 1996 Jul 5;273(5271):63-7
[
8658197.001
]
[Cites]
Carcinogenesis. 2002 Feb;23(2):295-9
[
11872635.001
]
[Cites]
Arch Dermatol. 1987 Feb;123(2):241-50
[
3545087.001
]
[Cites]
J Invest Dermatol. 1972 Mar;58(3):124-8
[
5013606.001
]
[Cites]
Cancer Surv. 1985;4(3):601-24
[
3916657.001
]
[Cites]
Photodermatol Photoimmunol Photomed. 2002 Jun;18(3):109-16
[
12207672.001
]
[Cites]
JAMA. 1988 Jul 15;260(3):384-8
[
3379749.001
]
[Cites]
Am J Hum Genet. 1993 Oct;53(4):817-21
[
8213812.001
]
[Cites]
J Invest Dermatol. 1995 Jun;104(6):933-6
[
7769261.001
]
[Cites]
Jpn J Cancer Res. 1987 Nov;78(11):1135-43
[
3121549.001
]
[Cites]
Mol Med Today. 1999 Feb;5(2):86-94
[
10200950.001
]
[Cites]
Nucleic Acids Res. 1993 Mar 11;21(5):1055-9
[
8464692.001
]
[Cites]
Photodermatol Photoimmunol Photomed. 2001 Oct;17(5):203-12
[
11555329.001
]
[Cites]
Hum Mol Genet. 1994 Jun;3(6):963-7
[
7951246.001
]
[Cites]
Photochem Photobiol. 1998 Sep;68(3):243-56
[
9747581.001
]
[Cites]
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9463-8
[
9256505.001
]
[Cites]
Mutat Res. 1991 Jul;255(1):1-9
[
2067547.001
]
[Cites]
Photochem Photobiol. 1991 Nov;54(5):753-60
[
1665912.001
]
[Cites]
Mutat Res. 1982 Dec;106(2):347-56
[
6185841.001
]
[Cites]
Ann Intern Med. 1974 Feb;80(2):221-48
[
4811796.001
]
[Cites]
Hum Genet. 1986 Oct;74(2):107-12
[
3770739.001
]
[Cites]
Nat Genet. 1994 Jun;7(2):189-94
[
7920640.001
]
[Cites]
Cell. 2000 Apr 14;101(2):159-71
[
10786832.001
]
[Cites]
Science. 2001 Feb 16;291(5507):1284-9
[
11181991.001
]
[Cites]
Photochem Photobiol. 1989 Jun;49(6):805-19
[
2672059.001
]
[Cites]
Cancer Res. 1992 Aug 1;52(15):4227-31
[
1638536.001
]
[Cites]
Science. 1992 Apr 24;256(5056):523-6
[
1575827.001
]
[Cites]
Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1790-5
[
10660687.001
]
[Cites]
J Invest Dermatol. 1994 Apr;102(4):485-9
[
8151125.001
]
[Cites]
Mol Cell Biol. 2005 Nov;25(22):9784-92
[
16260596.001
]
[Cites]
J Natl Cancer Inst. 2003 Feb 19;95(4):308-15
[
12591987.001
]
[Cites]
Nucleic Acids Res. 2001 Apr 1;29(7):1443-52
[
11266544.001
]
[Cites]
J Invest Dermatol. 2002 Jun;118(6):972-82
[
12060391.001
]
[Cites]
Science. 1999 Jul 9;285(5425):263-5
[
10398605.001
]
[Cites]
Am J Hum Genet. 1997 Feb;60(2):320-9
[
9012405.001
]
[Cites]
Nucleic Acids Res. 2002 Aug 15;30(16):3624-31
[
12177305.001
]
[Cites]
J Invest Dermatol. 2000 Jan;114(1):34-9
[
10620112.001
]
[Cites]
Brain. 1991 Jun;114 ( Pt 3):1335-61
[
2065254.001
]
[Cites]
Cancer Res. 1996 Sep 15;56(18):4103-7
[
8797573.001
]
[Cites]
Oncogene. 2000 Sep 28;19(41):4721-8
[
11032022.001
]
[Cites]
J Natl Cancer Inst. 1979 Jun;62(6):1415-21
[
286113.001
]
[Cites]
Carcinogenesis. 2006 Jan;27(1):84-94
[
16081512.001
]
[Cites]
Mol Cell Biol. 1991 Aug;11(8):4128-34
[
1649389.001
]
[Cites]
Genes Dev. 2001 Jan 1;15(1):15-23
[
11156600.001
]
[Cites]
Methods Mol Biol. 1999;113:133-46
[
10443416.001
]
[Cites]
Photodermatol Photoimmunol Photomed. 1996 Jun;12(3):122-30
[
8956362.001
]
[Cites]
J Invest Dermatol. 1994 Oct;103(4):461-8
[
7930668.001
]
[Cites]
Am J Hum Genet. 2003 Dec;73(6):1217-39
[
14639525.001
]
[Cites]
Cutis. 2004 Nov;74(5 Suppl):10-3
[
15603216.001
]
[Cites]
Nature. 1999 Jun 17;399(6737):700-4
[
10385124.001
]
[Cites]
J Virol. 1984 Dec;52(3):846-56
[
6092716.001
]
[Cites]
J Am Acad Dermatol. 2001 Jun;44(6):891-920; quiz 921-4
[
11369901.001
]
[Cites]
J Biol Chem. 1994 Dec 30;269(52):32709-12
[
7806489.001
]
[Cites]
Ann Neurol. 1986 Jul;20(1):70-5
[
3740815.001
]
[Cites]
Lancet. 2001 Mar 24;357(9260):926-9
[
11289350.001
]
[Cites]
J Invest Dermatol. 2002 Feb;118(2):344-51
[
11841555.001
]
[Cites]
Hum Genet. 1997 Dec;101(3):317-22
[
9439661.001
]
[Cites]
Carcinogenesis. 2000 Mar;21(3):453-60
[
10688865.001
]
[Cites]
Nat Med. 2001 Aug;7(8):961-6
[
11479630.001
]
[Cites]
Mutat Res. 1996 Feb 15;362(2):209-11
[
8596540.001
]
[Cites]
Am J Hum Genet. 2000 Apr;66(4):1221-8
[
10739753.001
]
[Cites]
Photochem Photobiol. 1996 Apr;63(4):356-7
[
8934734.001
]
[Cites]
Nature. 2001 May 17;411(6835):366-74
[
11357144.001
]
[Cites]
Curr Biol. 1999 Mar 11;9(5):273-6
[
10074455.001
]
[Cites]
J Biol Chem. 1991 Nov 5;266(31):20940-5
[
1939143.001
]
(PMID = 16855787.001).
[ISSN]
1567-2379
[Journal-full-title]
Journal of molecular histology
[ISO-abbreviation]
J. Mol. Histol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Netherlands
[Number-of-references]
150
23.
Sedda AF, Rossi G, Cipriani C, Carrozzo AM, Donati P:
Dermatological high-dose-rate brachytherapy for the treatment of basal and squamous cell carcinoma.
Clin Exp Dermatol
; 2008 Nov;33(6):745-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Dermatological high-dose-rate brachytherapy for the treatment
of basal
and squamous
cell carcinoma
.
BACKGROUND:
Basal cell carcinoma
(
BCC
)
and squamous
cell carcinoma
(SCC) are among the most common cancers in humans.
We describe a new treatment for
BCC
and SCC.
METHODS: In total, 53 patients with histologically confirmed
diagnosis
of BCC
and of SCC were enrolled for the treatment.
CONCLUSION: The results indicated that brachytherapy is an effective treatment for
BCC
and SCC.
[MeSH-major]
Brachytherapy / methods.
Carcinoma
,
Basal Cell
/ radiotherapy.
Carcinoma
,
Squamous
Cell
/ radiotherapy. Facial Neoplasms / radiotherapy.
Neoplasm
Recurrence, Local / radiotherapy.
Skin
Neoplasms / radiotherapy
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18681873.001).
[ISSN]
1365-2230
[Journal-full-title]
Clinical and experimental dermatology
[ISO-abbreviation]
Clin. Exp. Dermatol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Ointments; 7440-15-5 / Rhenium
24.
Wells MJ, Taylor RS:
Mohs micrographic surgery for penoscrotal malignancy.
Urol Clin North Am
; 2010 Aug;37(3):403-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Specific penoscrotal neoplasias discussed in this article include invasive and in situ
squamous
cell carcinoma
,
basal cell carcinoma
, extramammary Paget
disease
, and granular
cell
tumor
.
[MeSH-minor]
Carcinoma
,
Squamous
Cell
/ surgery. Humans. Male. Paget
Disease
, Extramammary / surgery. Penile Neoplasms / surgery
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Inc. All rights reserved.
(PMID = 20674695.001).
[ISSN]
1558-318X
[Journal-full-title]
The Urologic clinics of North America
[ISO-abbreviation]
Urol. Clin. North Am.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
25.
Chew YK, Noorizan Y, Khir A, Brito-Mutunayagam S, Prepagaran N:
The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose.
Med J Malaysia
; 2008 Oct;63(4):339-40
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The use of paramedian forehead flap reconstruction after wide excision
of basal cell carcinoma
of the nose.
Basal cell carcinoma
(
BCC
) is an indolent, slow-growing
malignant
skin
tumour.
The nose is a common site for
malignant
skin
tumours, such as
basal cell carcinoma
and squamous
cell carcinoma
because it is exposed to the sun.
Excision of the
BCC
will leave the nose with a soft tissue defect which requires reconstruction.
This report illustrates a case
of BCC
of nose whereby a wide excision and reconstruction was performed with a paramedian forehead flap.
[MeSH-major]
Carcinoma
,
Basal Cell
/ surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Surgical Flaps
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19385500.001).
[ISSN]
0300-5283
[Journal-full-title]
The Medical journal of Malaysia
[ISO-abbreviation]
Med. J. Malaysia
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Malaysia
26.
Chen T, Bertenthal D, Sahay A, Sen S, Chren MM:
Predictors of skin-related quality of life after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma.
Arch Dermatol
; 2007 Nov;143(11):1386-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Predictors
of skin
-related quality of life after treatment of cutaneous
basal cell carcinoma
and squamous
cell carcinoma
.
OBJECTIVE: To identify predictors
of skin
-related quality of life (QOL) after treatment of nonmelanoma
skin
cancer (NMSC).
SETTING: University-affiliated private practice
and a
Veterans Affairs clinic.
MAIN OUTCOME MEASURE:
Skin
-related QOL, measured with the 16-item version of Skindex-16, a validated measure.
RESULTS: Controlling for treatment group, the strongest independent predictor
of skin
-related QOL after treatment of NMSC was pretreatment
skin
-related QOL.
No
tumor
or care characteristic (including location of
tumor
, size of
tumor
, site of therapy, or training level of treating clinician [attending physician, resident, or nurse practitioner]) was found to predict better
skin
-related QOL after treatment of NMSC.
CONCLUSIONS: Patients with better pretreatment
skin
-related QOL, less comorbidity, and better mental health status had better
skin
-related QOL after treatment of NMSC.
[MeSH-major]
Carcinoma
,
Basal Cell
/ therapy.
Carcinoma
,
Squamous
Cell
/ therapy. Quality of Life.
Skin
/ physiopathology.
Skin
Neoplasms / therapy
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Arch Dermatol. 2007 Nov;143(11):1429-32
[
18025368.001
]
[ErratumIn]
Arch Dermatol. 2008 Feb;144(2):230
(PMID = 18025362.001).
[ISSN]
1538-3652
[Journal-full-title]
Archives of dermatology
[ISO-abbreviation]
Arch Dermatol
[Language]
eng
[Grant]
United States / NIAMS NIH HHS / AR / K02 AR02203; United States / NIAMS NIH HHS / AR / K24-AR052667
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
[Publication-country]
United States
27.
Ouyang YH:
Skin cancer of the head and neck.
Semin Plast Surg
; 2010 May;24(2):117-26
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Skin
cancer of the head and neck.
The majority
of skin
cancers of the head and neck are nonmelanoma
skin
cancers (NMSC).
Basal cell carcinoma
and squamous
cell carcinoma
are the most frequent types of NMSC.
Malignant
melanoma is an aggressive
neoplasm
of skin
, and the ideal adjuvant therapy has not yet been found, although various options for treatment
of skin
cancer are available to the patient and physician, allowing high cure rate and excellent functional and cosmetic outcomes.
Sunscreen protection and early evaluation of suspicious areas remain the first line of defense against
skin
cancers.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 22550432.001).
[ISSN]
1535-2188
[Journal-full-title]
Seminars in plastic surgery
[ISO-abbreviation]
Semin Plast Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC3324239
[Keywords]
NOTNLM ; Basal cell carcinoma / Mohs' micrographic surgery / melanoma / nonmelanoma skin cancer / squamous cell carcinoma
28.
Babilas P, Landthaler M, Szeimies RM:
Photodynamic therapy in dermatology.
Eur J Dermatol
; 2006 Jul-Aug;16(4):340-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Currently, topical photodynamic therapy (PDT) has received approval for the treatment of dermato-oncologic conditions like actinic keratoses, Bowen's
disease
, in-situ
squamous
cell carcinoma
and
basal cell carcinoma
in many countries all over the world.
Due to the easy accessibility
of skin
to light activation, incoherent lamps or LED arrays are suitable for PDT.
Either cytotoxic effects resulting in
tumor
destruction or immunomodulatory effects improving inflammatory
skin
conditions are induced.
Treating superficial non-melanoma
skin
cancer, PDT has been shown to be highly efficient despite the low level of invasiveness.
[MeSH-major]
Photochemotherapy.
Skin
Diseases / drug therapy.
Skin
Neoplasms / drug therapy
[MeSH-minor]
Carcinoma
,
Basal Cell
/ drug therapy. Humans
MedlinePlus Health Information.
consumer health - Skin Cancer
.
MedlinePlus Health Information.
consumer health - Skin Conditions
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16935788.001).
[ISSN]
1167-1122
[Journal-full-title]
European journal of dermatology : EJD
[ISO-abbreviation]
Eur J Dermatol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
France
[Number-of-references]
80
29.
Vaid M, Katiyar SK:
Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review).
Int J Oncol
; 2010 May;36(5):1053-60
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Changes in life style over the past several decades including much of the time spent outdoors and the use of tanning devices for cosmetic purposes by individuals have led to an increase in the incidence of solar ultraviolet (UV) radiation-induced
skin
diseases including the risk
of skin
cancers.
Solar UV radiations are considered as the most prevalent environmental carcinogens, and chronic exposure of the
skin
to UV leads to
squamous and
basal cell carcinoma
and melanoma in human population.
Silymarin is one of them and extensively studied for its
skin
photoprotective capabilities.
), and has been shown to have chemopreventive effects against photocarcinogenesis in mouse
tumor
models.
Topical treatment of silymarin inhibited photocarcinogenesis in mice in terms of
tumor
incidence,
tumor
multiplicity and growth of the tumors.
It is suggested that silymarin may favorably supplement sunscreen protection, and may be useful for
skin
diseases associated with solar UV radiation-induced inflammation, oxidative stress and immunomodulatory effects.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Science. 1993 Apr 23;260(5107):496-7
[
8097337.001
]
[Cites]
Science. 1993 Apr 23;260(5107):547-9
[
8097338.001
]
[Cites]
J Natl Cancer Inst. 1993 Jun 2;85(11):846-8
[
8388060.001
]
[Cites]
Immunol Today. 1993 Jul;14(7):335-8
[
8103338.001
]
[Cites]
N Engl J Med. 1993 Oct 14;329(16):1147-51
[
8377777.001
]
[Cites]
Photochem Photobiol. 1993 Dec;58(6):813-7
[
8310001.001
]
[Cites]
J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8
[
8176018.001
]
[Cites]
Carcinogenesis. 1994 Jun;15(6):1099-103
[
8020140.001
]
[Cites]
J Invest Dermatol. 1994 Aug;103(2):211-6
[
8040612.001
]
[Cites]
J Leukoc Biol. 1994 Dec;56(6):769-75
[
7996051.001
]
[Cites]
Arch Dermatol. 1995 Feb;131(2):170-5
[
7857113.001
]
[Cites]
J Immunol. 1995 May 15;154(10):5114-20
[
7730617.001
]
[Cites]
J Immunol. 1995 Nov 15;155(10):4661-8
[
7594465.001
]
[Cites]
Photochem Photobiol. 1995 Nov;62(5):855-61
[
8570723.001
]
[Cites]
J Cell Biol. 1996 Apr;133(1):211-20
[
8601609.001
]
[Cites]
J Biol Chem. 1996 Apr 5;271(14):8285-94
[
8626523.001
]
[Cites]
Cancer Res. 1996 Mar 1;56(5):1023-30
[
8640756.001
]
[Cites]
J Invest Dermatol. 1996 Jun;106(6):1187-91
[
8752655.001
]
[Cites]
Photochem Photobiol. 1996 Apr;63(4):356-7
[
8934734.001
]
[Cites]
Photochem Photobiol. 1996 Apr;63(4):380-3
[
8934743.001
]
[Cites]
J Immunol. 1996 Dec 15;157(12):5254-61
[
8955170.001
]
[Cites]
J Natl Cancer Inst. 1997 Apr 16;89(8):556-66
[
9106644.001
]
[Cites]
Int J Oncol. 2002 Dec;21(6):1213-22
[
12429970.001
]
[Cites]
Carcinogenesis. 2003 May;24(5):927-36
[
12771038.001
]
[Cites]
Carcinogenesis. 2003 Aug;24(8):1379-88
[
12807737.001
]
[Cites]
J Invest Dermatol. 2003 Oct;121(4):862-8
[
14632206.001
]
[Cites]
J Invest Dermatol. 2004 Feb;122(2):510-7
[
15009738.001
]
[Cites]
J Am Acad Dermatol. 1998 May;38(5 Pt 1):681-6
[
9591810.001
]
[Cites]
J Cell Biochem Suppl. 1997;27:59-67
[
9591194.001
]
[Cites]
J Invest Dermatol. 1998 Jun;110(6):966-71
[
9620307.001
]
[Cites]
Br J Dermatol. 1998 Jul;139(1):3-10
[
9764141.001
]
[Cites]
J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):611-25
[
9777769.001
]
[Cites]
Cancer Res. 1999 Feb 1;59(3):622-32
[
9973210.001
]
[Cites]
Nat Med. 1999 Apr;5(4):418-22
[
10202931.001
]
[Cites]
Br J Dermatol. 1999 Feb;140(2):255-8
[
10233218.001
]
[Cites]
J Invest Dermatol. 1999 May;112(5):751-6
[
10233767.001
]
[Cites]
J Am Acad Dermatol. 1999 May;40(5 Pt 1):697-701
[
10321596.001
]
[Cites]
Am J Health Syst Pharm. 1999 Jun 15;56(12):1195-7
[
10484652.001
]
[Cites]
Lancet. 1999 Aug 28;354(9180):723-9
[
10475183.001
]
[Cites]
Carcinogenesis. 2005 Aug;26(8):1404-13
[
15831527.001
]
[Cites]
Mol Cancer Ther. 2006 Jul;5(7):1660-8
[
16891451.001
]
[Cites]
J Dermatol Sci. 2007 Apr;46(1):21-30
[
17289350.001
]
[Cites]
J Dermatol Sci. 2007 Dec;48(3):213-24
[
17689055.001
]
[Cites]
Photochem Photobiol. 2008 Mar-Apr;84(2):266-71
[
18221354.001
]
[Cites]
J Invest Dermatol. 2009 May;129(5):1258-70
[
19020550.001
]
[Cites]
Cancer Prev Res (Phila). 2010 Feb;3(2):179-89
[
20103727.001
]
[Cites]
J Exp Med. 1998 Apr 6;187(7):1133-8
[
9529329.001
]
[Cites]
J Investig Dermatol Symp Proc. 1999 Sep;4(1):97-100
[
10537017.001
]
[Cites]
Carcinogenesis. 1999 Nov;20(11):2117-24
[
10545414.001
]
[Cites]
Cancer Lett. 1999 Dec 1;147(1-2):77-84
[
10660092.001
]
[Cites]
Int Urol Nephrol. 1999;31(4):417-22
[
10668934.001
]
[Cites]
J Heart Lung Transplant. 2000 Mar;19(3):249-55
[
10713249.001
]
[Cites]
Liver Transpl. 2000 May;6(3):253-62
[
10827224.001
]
[Cites]
Carcinogenesis. 2001 Feb;22(2):287-94
[
11181450.001
]
[Cites]
Int J Oncol. 2001 Jun;18(6):1307-13
[
11351267.001
]
[Cites]
J Leukoc Biol. 2001 May;69(5):719-26
[
11358979.001
]
[Cites]
Photochem Photobiol. 2001 Jun;73(6):600-4
[
11421064.001
]
[Cites]
Photochem Photobiol. 2001 Jun;73(6):621-9
[
11421067.001
]
[Cites]
J Invest Dermatol. 2001 Jul;117(1):147-50
[
11442762.001
]
[Cites]
Toxicol Appl Pharmacol. 2001 Oct 15;176(2):110-7
[
11601887.001
]
[Cites]
Drugs. 2001;61(14):2035-63
[
11735632.001
]
[Cites]
Photochem Photobiol. 2001 Dec;74(6):787-93
[
11783934.001
]
[Cites]
Clin Cancer Res. 2002 Feb;8(2):314-46
[
11839647.001
]
[Cites]
Carcinogenesis. 2002 Mar;23(3):499-510
[
11895866.001
]
[Cites]
Sci STKE. 2003 Jan 28;2003(167):RE2
[
12554854.001
]
[Cites]
Cancer Res. 2004 Sep 1;64(17):6349-56
[
15342425.001
]
[Cites]
Arzneimittelforschung. 1968 Jun;18(6):688-96
[
5755805.001
]
[Cites]
Arzneimittelforschung. 1974 Apr;24(4):466-71
[
4408125.001
]
[Cites]
J Natl Cancer Inst. 1974 Nov;53(5):1333-6
[
4139281.001
]
[Cites]
Proc Natl Acad Sci U S A. 1977 Dec;74(12):5574-8
[
271984.001
]
[Cites]
Br J Clin Pharmacol. 1978 May;5(5):431-6
[
656282.001
]
[Cites]
J Immunol. 1980 Jan;124(1):445-53
[
6153101.001
]
[Cites]
Br Med J. 1979 Dec 8;2(6203):1461-6
[
393355.001
]
[Cites]
Scand J Gastroenterol. 1982 Jun;17(4):517-21
[
6753109.001
]
[Cites]
Science. 1983 Sep 23;221(4617):1256-64
[
6351251.001
]
[Cites]
Immunol Rev. 1984 Aug;80:87-102
[
6237978.001
]
[Cites]
Cancer Res. 1986 May;46(5):2203-7
[
3516380.001
]
[Cites]
J Hepatol. 1989 Jul;9(1):105-13
[
2671116.001
]
[Cites]
J Exp Med. 1989 Oct 1;170(4):1117-31
[
2529340.001
]
[Cites]
Semin Dermatol. 1990 Mar;9(1):25-31
[
2203440.001
]
[Cites]
J Invest Dermatol. 1990 Oct;95(4):436-40
[
2120354.001
]
[Cites]
J Invest Dermatol. 1990 Nov;95(5):530-6
[
2230216.001
]
[Cites]
Pharm Res. 1991 Feb;8(2):273-7
[
1902564.001
]
[Cites]
Dermatol Clin. 1991 Oct;9(4):751-5
[
1934649.001
]
[Cites]
Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8
[
1946433.001
]
[Cites]
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7516-20
[
1502162.001
]
[Cites]
J Exp Med. 1993 Apr 1;177(4):1199-204
[
8096238.001
]
(PMID = 20372777.001).
[ISSN]
1791-2423
[Journal-full-title]
International journal of oncology
[ISO-abbreviation]
Int. J. Oncol.
[Language]
ENG
[Grant]
United States / NCI NIH HHS / CA / R03 CA105368-01; United States / NCI NIH HHS / CA / R03 CA105368; United States / NCI NIH HHS / CA / R03 CA105368-02; United States / NCI NIH HHS / CA / CA105368-02; United States / NCI NIH HHS / CA / CA105368-01; United States / NCI NIH HHS / CA / CA105368
[Publication-type]
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review
[Publication-country]
Greece
[Chemical-registry-number]
0 / Anti-Inflammatory Agents; 0 / Antioxidants; 0 / Carcinogens; 0 / Plant Extracts; 0 / Silymarin
[Other-IDs]
NLM/ NIHMS184206; NLM/ PMC2852174
30.
Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS:
Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.
Dermatol Surg
; 2008 Dec;34(12):1642-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Perineural invasion of cutaneous
squamous
cell carcinoma
and
basal cell carcinoma
: raising awareness and optimizing management.
BACKGROUND: Perineural invasion (PNI) by cutaneous
squamous
cell carcinoma
(CSCC) and
basal cell carcinoma
(
BCC
) is an infrequent but not rare complication of traditionally low-morbidity
skin
cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3%
of BCC
exhibit PNI.
MATERIALS AND METHODS: Cases of PNI treated with MMS and radiotherapy were reviewed for recurrence,
disease
-free follow-up, and adverse events.
When managing superficial
skin
tumors with PNI, a multidisciplinary team including a cutaneous surgeon
and a
radiation oncologist familiar with PNI is recommended.
[MeSH-major]
Bell Palsy / etiology.
Carcinoma
,
Basal Cell
/ complications.
Carcinoma
,
Basal Cell
/ therapy.
Carcinoma
,
Squamous
Cell
/ complications.
Carcinoma
,
Squamous
Cell
/ therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy.
Skin
Neoplasms / complications.
Skin
Neoplasms / therapy
[MeSH-minor]
Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery.
Neoplasm
Invasiveness. Peripheral Nerves
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Bell's Palsy
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19018830.001).
[ISSN]
1524-4725
[Journal-full-title]
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
[ISO-abbreviation]
Dermatol Surg
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
31.
Nemet AY, Deckel Y, Martin PA, Kourt G, Chilov M, Sharma V, Benger R:
Management of periocular basal and squamous cell carcinoma: a series of 485 cases.
Am J Ophthalmol
; 2006 Aug;142(2):293-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Management of periocular
basal
and squamous
cell carcinoma
: a series of 485 cases.
PURPOSE: To analyze the outcome of management of patients with
basal cell
carcinomas
(BCCs)
and squamous
cell
carcinomas
(SCCs) in a tertiary referral eye center in Sydney, Australia.
MAIN OUTCOME MEASURES: Survival period free of
tumor
, incomplete excision, recurrences, type of closure, and complications.
Morpheaform type
of BCC
(chi(2)P < .001), and medial canthus location BCCs (chi(2)P < .05) were associated with a higher incomplete resection rate.
Twenty-seven patients (5.6%) had a recurrent
tumor
.
CONCLUSIONS: In the setting of a tertiary referral center, incomplete primary resection of an eyelid
skin
cancer is the main risk factor for recurrence.
Incomplete resection is significantly associated with medial canthus location and morpheaform type
of BCC
and with moderately differentiated SCC.
MMS is the safer technique after incomplete
tumor
excision.
[MeSH-major]
Carcinoma
,
Basal Cell
/ surgery.
Carcinoma
,
Squamous
Cell
/ surgery. Eyelid Neoplasms / surgery.
Neoplasm
Recurrence, Local.
Skin
Neoplasms / surgery
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16876511.001).
[ISSN]
0002-9394
[Journal-full-title]
American journal of ophthalmology
[ISO-abbreviation]
Am. J. Ophthalmol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
32.
Varga E, Kiss M, Szabó K, Kemény L:
Detection of Merkel cell polyomavirus DNA in Merkel cell carcinomas.
Br J Dermatol
; 2009 Oct;161(4):930-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Detection of Merkel
cell
polyomavirus DNA in Merkel
cell
carcinomas
.
BACKGROUND: Merkel
cell carcinoma
(MCC) is a rare, aggressive tumour for which an increasing incidence has been reported.
A new human polyomavirus, Merkel
cell
polyomavirus (MCV), was recently isolated from these tumours by applying digital transcriptome subtraction methodology.
METHODS: Nine primary or recurrent MCCs from seven patients were examined; 29 other tumours (
squamous
cell
,
basal cell
and basosquamous carcinomas and malignant
melanomas) were examined for comparative purposes.
[MeSH-major]
Antigens, Viral,
Tumor
/ genetics. Capsid Proteins / genetics.
Carcinoma
, Merkel
Cell
/ virology. Polyomaviridae / genetics. Polyomavirus Infections / virology.
Skin
Neoplasms / virology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19438857.001).
[ISSN]
1365-2133
[Journal-full-title]
The British journal of dermatology
[ISO-abbreviation]
Br. J. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
[Chemical-registry-number]
0 / Antigens, Viral, Tumor; 0 / Capsid Proteins
33.
Hatina J, Ruzicka T:
[Relevance of cell culture models in cutaneous tumour biology. Part I: tumour cell lines].
Hautarzt
; 2008 Jan;59(1):36-45
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Relevance
of cell
culture models in cutaneous tumour biology. Part I: tumour
cell
lines].
[Transliterated title]
Stellenwert
der
Zellkulturmodelle in kutaner Tumorbiologie. Teil I: Zelllinien tumorigen transformierter Zellen.
Cutaneous
squamous
cell carcinoma
,
basal cell carcinoma
and melanoma, much like all other human solid tumors, result from a multi-step process in which genetic and epigenetic changes accumulate in the affected cells.
Cell
culture models are a very valuable experimental system.
Tumor
cell
lines display similar functional hierarchy as tumors or tissues in vivo and can, consequently, provide a crucial source of minor
cell
subsets, like
tumor
stem cells.
Progression series of clonally related
cell
lines offer the opportunity to follow the process of sequential acquisition of transformation-related traits up to the development of properties with direct clinical equivalents, like tumorigenicity and metastatic competence.
While for most studies, human transformed
cell
lines are the model of choice, there are questions for which animal
cell
lines are strongly preferred, such as interactions between the
tumor and
the immune system.
To properly interpret the results of all experiments with classical two-dimensional
cell
culture, a possible danger of artifacts due to grossly unnatural environment must be constantly taken into account.
[MeSH-major]
Cell
Line,
Tumor
/ pathology.
Cell
Line,
Tumor
/ physiology.
Disease
Models, Animal.
Skin
Neoplasms / pathology.
Skin
Neoplasms / physiopathology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Oncogene. 2004 Jan 8;23(1):30-8
[
14712208.001
]
[Cites]
Annu Rev Pathol. 2007;2:175-89
[
18039097.001
]
[Cites]
Am J Pathol. 1999 Aug;155(2):441-52
[
10433937.001
]
[Cites]
Am J Pathol. 2000 Jan;156(1):159-67
[
10623663.001
]
[Cites]
Ann N Y Acad Sci. 2003 May;995:151-61
[
12814947.001
]
[Cites]
Cancer Genet Cytogenet. 2003 Apr 15;142(2):87-91
[
12699882.001
]
[Cites]
Cancer Res. 2003 Nov 1;63(21):7147-57
[
14612508.001
]
[Cites]
Nature. 2000 Aug 3;406(6795):532-5
[
10952316.001
]
[Cites]
Anticancer Res. 1997 Nov-Dec;17(6D):4359-70
[
9494534.001
]
[Cites]
Mol Carcinog. 1998 Nov;23(3):144-58
[
9833775.001
]
[Cites]
J Surg Res. 1995 Feb;58(2):165-74
[
7861768.001
]
[Cites]
Cancer Res. 1996 Jul 1;56(13):3075-86
[
8674065.001
]
[Cites]
Cancer Res. 1990 Apr 15;50(8):2296-302
[
2156614.001
]
[Cites]
J Cell Biochem. 1994 Feb;54(2):161-73
[
8175891.001
]
[Cites]
Nat Rev Cancer. 2005 Apr;5(4):275-84
[
15803154.001
]
[Cites]
Exp Dermatol. 2007 Apr;16(4):297-301
[
17359335.001
]
[Cites]
J Mammary Gland Biol Neoplasia. 2000 Oct;5(4):365-78
[
14973382.001
]
[Cites]
Exp Dermatol. 2000 Apr;9(2):104-17
[
10772384.001
]
[Cites]
Am J Pathol. 2001 Oct;159(4):1567-79
[
11583982.001
]
[Cites]
Annu Rev Cell Dev Biol. 2006;22:339-73
[
16824012.001
]
[Cites]
Arch Dermatol. 1996 Oct;132(10):1185-93
[
8859029.001
]
[Cites]
J Invest Dermatol. 2006 Jun;126(6):1372-7
[
16470173.001
]
[Cites]
Cancer Res. 2005 May 15;65(10 ):4320-33
[
15899824.001
]
[Cites]
Nat Med. 1999 Nov;5(11):1285-91
[
10545995.001
]
[Cites]
Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36
[
12821146.001
]
[Cites]
Cancer Res. 1985 Nov;45(11 Pt 2):5670-6
[
4053039.001
]
[Cites]
J Invest Dermatol. 2005 Feb;124(2):401-4
[
15675960.001
]
[Cites]
Exp Cell Res. 2000 Aug 1;258(2):352-60
[
10896786.001
]
[Cites]
Eur J Cancer. 2007 Mar;43(5):935-46
[
17320377.001
]
[Cites]
J Dtsch Dermatol Ges. 2005 Jul;3(7):493-503
[
15967008.001
]
[Cites]
Cancer Res. 1991 Apr 15;51(8):2205-11
[
2009539.001
]
[Cites]
Cancer Res. 1990 May 1;50(9):2840-7
[
2183932.001
]
[Cites]
Cancer Res. 1996 Feb 15;56(4):875-9
[
8631027.001
]
[Cites]
Dtsch Med Wochenschr. 2007 Aug;132(31-32):1629-32
[
17654417.001
]
[Cites]
J Invest Dermatol. 2006 Jun;126(6):1214-6
[
16702970.001
]
[Cites]
Cancer Res. 2002 Jul 1;62(13):3759-65
[
12097286.001
]
[Cites]
Cancer Res. 1980 May;40(5):1636-44
[
7370995.001
]
[Cites]
Histol Histopathol. 2002;17 (3):951-9
[
12168807.001
]
[Cites]
J Invest Dermatol. 2000 Dec;115(6):1095-103
[
11121147.001
]
[Cites]
Melanoma Res. 1997 Aug;7 Suppl 2:S35-42
[
9578415.001
]
[Cites]
Blood. 2003 Nov 15;102(10):3837-44
[
12881305.001
]
[Cites]
Nat Genet. 2000 Mar;24(3):227-35
[
10700174.001
]
[Cites]
Genes Dev. 2005 Jan 15;19(2):214-23
[
15625189.001
]
[Cites]
J Invest Dermatol. 2005 Feb;124(2):457-65
[
15675968.001
]
[Cites]
Cancer Res. 1996 Jul 1;56(13):3112-7
[
8674069.001
]
[Cites]
Prostate. 1986;9(3):261-81
[
3774632.001
]
[Cites]
Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1050-5
[
9448283.001
]
[Cites]
Cancer Res. 2004 Aug 1;64(15):5270-82
[
15289333.001
]
[Cites]
Schweiz Med Wochenschr. 2000 Apr 29;130(17):617-24
[
10829299.001
]
[Cites]
Hautarzt. 2004 Oct;55(10):942-51
[
15349693.001
]
[Cites]
Pathologe. 1994 Jun;15(3):141-9
[
8072948.001
]
[Cites]
Cancer Res. 2005 Oct 15;65(20):9328-37
[
16230395.001
]
[Cites]
J Invest Dermatol. 2006 Jan;126(1):142-53
[
16417230.001
]
[Cites]
World J Gastroenterol. 2002 Dec;8(6):976-81
[
12439909.001
]
[Cites]
Int J Cancer. 1995 Mar 3;60(5):668-75
[
7532159.001
]
[Cites]
Nat Med. 1997 Jul;3(7):788-92
[
9212109.001
]
[Cites]
J Cell Biol. 1988 Mar;106(3):761-71
[
2450098.001
]
(PMID = 18058078.001).
[ISSN]
1432-1173
[Journal-full-title]
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
[ISO-abbreviation]
Hautarzt
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Germany
[Number-of-references]
64
34.
Love WE, Bernhard JD, Bordeaux JS:
Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
Arch Dermatol
; 2009 Dec;145(12):1431-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Topical imiquimod or fluorouracil therapy for
basal
and squamous
cell carcinoma
: a systematic review.
OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma
skin
cancers such as
basal
(
BCC
)
and squamous
cell carcinoma
(SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat
BCC
and SCC.
STUDY SELECTION: Prospective, retrospective, and case studies in English containing a minimum of 4 subjects
and a
6-month follow-up or posttreatment histologic evaluation.
DATA EXTRACTION: We calculated the rate of clearance and adverse effects for
BCC
subtypes and invasive and in situ SCC treated with topical imiquimod or fluorouracil.
Imiquimod use produced the following clearance rates: 43% to 100% for superficial
BCC
, 42% to 100% for nodular
BCC
, 56% to 63% for infiltrative
BCC
, 73% to 88% for SCC in situ, and 71% for invasive SCC.
Fluorouracil use produced the following clearance rates: 90% for superficial
BCC
and 27% to 85% for SCC in situ.
CONCLUSIONS: Evidence supports the use of topical imiquimod as monotherapy for superficial
BCC
and topical fluorouracil as monotherapy for superficial
BCC
and SCC in situ.
[MeSH-major]
Aminoquinolines / pharmacokinetics. Antineoplastic Agents / pharmacokinetics.
Carcinoma
,
Basal Cell
/ drug therapy.
Carcinoma
,
Squamous
Cell
/ drug therapy. Fluorouracil / pharmacokinetics.
Skin
Neoplasms / drug therapy
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
FLUOROURACIL
.
Hazardous Substances Data Bank.
Imiquimod
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
PubMed Health.
DARE review
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20026854.001).
[ISSN]
1538-3652
[Journal-full-title]
Archives of dermatology
[ISO-abbreviation]
Arch Dermatol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Chemical-registry-number]
0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
[Number-of-references]
47
35.
Ishihara K:
[Reasons for the increased incidence of skin cancer].
Gan To Kagaku Ryoho
; 2006 Oct;33(10):1380-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Reasons for the increased incidence
of skin
cancer].
The cutaneous malignancies with an increasing incidence in Japan are
squamous
cell carcinoma
,
basal cell carcinoma
,
and malignant
melanoma.
According to a nationwide questionnaire survey (responses from 94 centers),
basal cell carcinoma
has the highest incidence and accounts for nearly 50% of all
skin
malignancies, followed by
squamous
cell carcinoma
(31%)
and malignant
melanoma (21%).
The number of cases of each
tumor
has grown annually, and comparison of the percent increases between 1987 and 2001 shows an increase of about 1.5-fold for
basal cell carcinoma
or 1.7-fold for
squamous
cell carcinoma
or
malignant
melanoma.
Supported by a Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, the
Malignant
Skin
Tumor
Research Group has been investigating the factors behind these increases by detailed statistical analysis of data obtained from 1987 onwards from designated centers (19-22 centers).
[MeSH-major]
Carcinoma
,
Basal Cell
/ epidemiology.
Carcinoma
,
Squamous
Cell
/ epidemiology. Melanoma / epidemiology.
Skin
Neoplasms / epidemiology. Ultraviolet Rays / adverse effects
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17033224.001).
[ISSN]
0385-0684
[Journal-full-title]
Gan to kagaku ryoho. Cancer & chemotherapy
[ISO-abbreviation]
Gan To Kagaku Ryoho
[Language]
jpn
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Japan
36.
Kaae J, Boyd HA, Hansen AV, Wulf HC, Wohlfahrt J, Melbye M:
Photosensitizing medication use and risk of skin cancer.
Cancer Epidemiol Biomarkers Prev
; 2010 Nov;19(11):2942-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Photosensitizing medication use and risk
of skin
cancer.
Whether use of these medications affects
skin
cancer risk, however, is unclear.
METHODS: Using a cohort of all Danish residents ≥15 years old in 1995 to 2006 (n = 4,761,749) and information from Danish national registers, we examined associations between use of photosensitizing medications and risk
of basal cell carcinoma
, cutaneous
malignant
melanoma, Merkel
cell carcinoma
,
and squamous
cell carcinoma
.
RESULTS: Users of only 2 of 19 medications for long-term use (methyldopa and furosemide) had both a ≥20% increased risk
of skin
cancer (compared with nonusers) and an increase in risk with increasing duration of use; these effects were limited to
basal cell carcinoma
and squamous
cell carcinoma
, respectively.
In contrast, 8 of 10 medications for short-term use were associated with both a ≥20% increased risk
of skin
cancer and an increase in risk with increasing use for at least one of the four cancers.
CONCLUSION: We found little evidence of an increased risk
of skin
cancer among users of photosensitizing medications for long-term daily use, but could not rule out the possibility that users of some photosensitizing medications for short-term use may have an increased risk
of skin
cancer.
Our study examined the effect of a wide range of photosensitizing medications on
skin
cancer risk and suggests that future work should focus on photosensitizing medications for short-term use.
[MeSH-major]
Photosensitivity Disorders / chemically induced. Prescription Drugs / adverse effects.
Skin
Neoplasms / epidemiology.
Skin
Neoplasms / etiology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
©2010 AACR.
(PMID = 20861398.001).
[ISSN]
1538-7755
[Journal-full-title]
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
[ISO-abbreviation]
Cancer Epidemiol. Biomarkers Prev.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Prescription Drugs
37.
Al-Arashi MY, Salomatina E, Yaroslavsky AN:
Multimodal confocal microscopy for diagnosing nonmelanoma skin cancers.
Lasers Surg Med
; 2007 Oct;39(9):696-705
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Multimodal confocal microscopy for diagnosing nonmelanoma
skin
cancers.
BACKGROUND AND SIGNIFICANCE: The standard diagnostic procedure for
skin
cancers is invasive biopsy followed by histopathological evaluation.
In this study, the suitability of dye-enhanced multimodal confocal microscopy for the detection of nonmelanoma
skin
cancers was evaluated.
MATERIALS AND METHODS: For the experiments we used fresh
tumor
material stained using 0.2 mg/ml or 0.05 mg/ml aqueous solutions of methylene blue (MB) or toluidine blue (TB), respectively.
Reflectance, fluorescence, and fluorescence polarization images
of skin
specimens stained with MB and TB were excited by 656 nm and 633 nm light, respectively.
In total we imaged, analyzed, and compared to histology at least 10 samples of each
tumor
-type including nodular
basal cell carcinoma
(
BCC
), infiltrative
basal cell carcinoma
,
and squamous
cell carcinoma
(SCC).
RESULTS AND CONCLUSION: The morphological features and appearance
of skin
structures in the fluorescence images correlate well with corresponding histology for all investigated
tumor
-types.
Our results indicate the feasibility of using multimodal confocal microscopy as real-time tool for detecting
skin
pathology.
[MeSH-major]
Microscopy, Confocal.
Skin
Neoplasms / pathology
[MeSH-minor]
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Squamous
Cell
/ pathology. Coloring Agents.
Diagnosis
, Differential. Equipment Design. Humans. In Vitro Techniques. Methylene Blue. Staining and Labeling. Tolonium Chloride
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
METHYLENE BLUE
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
2007 Wiley-Liss, Inc
(PMID = 17960751.001).
[ISSN]
0196-8092
[Journal-full-title]
Lasers in surgery and medicine
[ISO-abbreviation]
Lasers Surg Med
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride; T42P99266K / Methylene Blue
38.
Ezzedine K, Latreille J, Kesse-Guyot E, Galan P, Hercberg S, Guinot C, Malvy D:
Incidence of skin cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation.
Eur J Cancer
; 2010 Dec;46(18):3316-22
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Incidence
of skin
cancers during 5-year follow-up after stopping antioxidant vitamins and mineral supplementation.
CONTEXT: In the SU.VI.MAX study, antioxidant supplementation for 7.5 years was found to increase
skin
cancer risk in women but not in men.
OBJECTIVE: To investigate the potential residual or delayed effect of antioxidant supplementation on
skin
cancer incidence after a 5-year post-intervention follow-up.
DESIGN, SETTING AND PARTICIPANTS: Assessment
of skin
cancer including melanoma and non-melanoma during the post-intervention follow-up (September 2002-August 2007).
MAIN OUTCOME MEASURES: Total
skin
cancer incidence, including melanoma,
squamous
cell carcinoma
and
basal cell carcinoma
.
Six
squamous
cell
carcinomas
were found in women and 15 in men (10 and 25, respectively, for the total period).
Finally, 40
basal cell
carcinomas
appeared in women and 36 in men (98 and 94, respectively, for the total period).
No delayed effects, either on melanoma or non-melanoma
skin
cancers, were observed for either gender.
CONCLUSIONS: The risk
of skin
cancers associated with antioxidant intake declines following interruption of supplementation.
This supports a causative role for antioxidants in the evolution
of skin
cancers.
[MeSH-major]
Antioxidants / adverse effects.
Carcinoma
,
Basal Cell
/ epidemiology.
Carcinoma
,
Squamous
Cell
/ epidemiology. Melanoma / epidemiology.
Skin
Neoplasms / epidemiology. Vitamins / adverse effects
MedlinePlus Health Information.
consumer health - Antioxidants
.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
ClinicalTrials.gov.
clinical trials - ClinicalTrials.gov
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Ltd. All rights reserved.
(PMID = 20605091.001).
[ISSN]
1879-0852
[Journal-full-title]
European journal of cancer (Oxford, England : 1990)
[ISO-abbreviation]
Eur. J. Cancer
[Language]
eng
[Databank-accession-numbers]
ClinicalTrials.gov/ NCT00272428
[Publication-type]
Journal Article; Randomized Controlled Trial
[Publication-country]
England
[Chemical-registry-number]
0 / Antioxidants; 0 / Vitamins
39.
Benbenisty KM, Andea A, Metcalf J, Cook J:
Atypical cellular neurothekeoma treated with Mohs micrographic surgery.
Dermatol Surg
; 2006 Apr;32(4):582-7; discussion 587
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Atypical cellular neurothekeoma is a rare
neoplasm
generally regarded as a benign
tumor
with locally aggressive behavior.
Recurrence is common with inadequate excision, but metastatic
disease
has yet to be reported.
RESULTS: The
neoplasm
was extirpated in a three-stage, five section Mohs surgery procedure.
CONCLUSION: Mohs micrographic surgery is unsurpassed in its efficacy in treating a wide variety of nonmelanoma
skin
cancers.
Although most commonly used to address
basal
and squamous
cell carcinoma
, it has also been reported as a successful treatment for melanoma
and a
wide variety of cutaneous malignancies.
Debate in the literature is ongoing regarding the true histogenesis of this rare
tumor
.
Because of this
tumor
's local destructive behavior and propensity to recur with inadequate resection, we recommend Moths micrographic surgery for the treatment of cellular neurothekeomas.
MedlinePlus Health Information.
consumer health - Nasal Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Dermatol Surg. 2008 Mar;34(3):428
[
18248473.001
]
(PMID = 16681671.001).
[ISSN]
1076-0512
[Journal-full-title]
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
[ISO-abbreviation]
Dermatol Surg
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
21
40.
Honeycutt KA, Waikel RL, Koster MI, Wang XJ, Roop DR:
The effect of c-myc on stem cell fate influences skin tumor phenotype.
Mol Carcinog
; 2010 Apr;49(4):315-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The effect of c-myc on stem
cell
fate influences
skin
tumor
phenotype.
Nonmelanoma
skin
cancers (NMSCs) consist of a variety of
tumor
types including
basal cell carcinoma
,
squamous
cell carcinoma
, a variety of hair follicle tumors, and sebaceous gland tumors.
Our goal in the current study was to determine if alterations in the commitment of multipotent stem cells to different
cell
fates would influence
tumor
phenotype.
[MeSH-major]
Proto-Oncogene Proteins c-myc / genetics.
Skin
Neoplasms / genetics.
Skin
Neoplasms / pathology. Stem Cells / pathology
[MeSH-minor]
9,10-Dimethyl-1,2-benzanthracene / toxicity. Adenocarcinoma, Sebaceous / pathology. Animals. Carcinogens / toxicity.
Cell
Differentiation / genetics.
Cell
Lineage / genetics. Crosses, Genetic. Female. Heterozygote. Male. Mice. Mice, Inbred ICR. Mice, Inbred Strains. Mice, Transgenic. Multipotent Stem Cells / pathology. Papilloma / pathology. Phenotype. Sebaceous Gland Neoplasms / pathology. Tetradecanoylphorbol Acetate / pharmacology. Transgenes
MedlinePlus Health Information.
consumer health - Skin Cancer
.
MedlinePlus Health Information.
consumer health - Stem Cells
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
12-O-TETRADECANOYLPHORBOL-13-ACETATE
.
Hazardous Substances Data Bank.
7,12-DIMETHYLBENZ(A)ANTHRACENE
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20146250.001).
[ISSN]
1098-2744
[Journal-full-title]
Molecular carcinogenesis
[ISO-abbreviation]
Mol. Carcinog.
[Language]
eng
[Grant]
United States / NIAMS NIH HHS / AR / AR47898; United States / NCI NIH HHS / CA / CA09197; United States / NCI NIH HHS / CA / CA105491; United States / NCI NIH HHS / CA / CA52607; United States / NCI NIH HHS / CA / CA79998
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Carcinogens; 0 / Proto-Oncogene Proteins c-myc; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; NI40JAQ945 / Tetradecanoylphorbol Acetate
41.
Watkins J:
Dermatology and the community nurse: actinic (solar) keratosis.
Br J Community Nurs
; 2010 Jan;15(1):6, 8, 10-1
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
They are then able to check other sun-exposed areas such as the face, ears, scalp, back and limbs to discover any other lesions or more serious problems
of basal cell carcinoma
,
squamous
cell carcinoma
or
malignant
melanoma the would require referral, sometimes urgently, to a dermatologist for full assessment and treatment.
[MeSH-major]
Keratosis / nursing.
Skin
Neoplasms / nursing. Sunlight / adverse effects
[MeSH-minor]
Community Health Nursing.
Diagnosis
, Differential. Humans. Nursing
Diagnosis
. Protective Clothing. Risk Factors. Sunscreening Agents
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20216512.001).
[ISSN]
1462-4753
[Journal-full-title]
British journal of community nursing
[ISO-abbreviation]
Br J Community Nurs
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Chemical-registry-number]
0 / Sunscreening Agents
[Number-of-references]
13
42.
Dawe RS:
Treatment options for non-melanoma skin cancer.
G Ital Dermatol Venereol
; 2009 Aug;144(4):453-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Treatment options for non-melanoma
skin
cancer.
Non melanoma
skin
cancers (
basal cell carcinoma
and squamous
cell carcinoma
) are becoming more common.
[MeSH-major]
Carcinoma
,
Basal Cell
/ therapy.
Carcinoma
,
Squamous
Cell
/ therapy.
Skin
Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19755949.001).
[ISSN]
0392-0488
[Journal-full-title]
Giornale italiano di dermatologia e venereologia : organo ufficiale, Società italiana di dermatologia e sifilografia
[ISO-abbreviation]
G Ital Dermatol Venereol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Italy
[Number-of-references]
38
43.
Ross AH, Kennedy CT, Collins C, Harrad RA:
The use of imiquimod in the treatment of periocular tumours.
Orbit
; 2010 Apr;29(2):83-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Two patients were diagnosed with
basal cell carcinoma of
the eyelid, one patient with actinic keratosis, one with intraepidermal
squamous
cell carcinoma
(Bowen's
disease
) and one patient had concomitant
squamous
cell carcinoma
and intraepidermal
squamous
cell carcinoma
.
In our experience, it is a safe and effective treatment for periocular lesions, including actinic keratosis, intraepidermal
squamous
cell carcinoma
,
basal cell carcinoma
and squamous
cell carcinoma
.
To our knowledge, this is the first published description of the successful use of 5% Imiquimod in treating moderately differentiated
squamous
cell carcinoma
of the eyelid.
[MeSH-major]
Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Eyelid Neoplasms / drug therapy. Keratosis, Actinic / drug therapy.
Skin
Neoplasms / drug therapy
[MeSH-minor]
Administration, Topical. Aged. Bowen's
Disease
/ drug therapy. Bowen's
Disease
/ pathology.
Carcinoma
,
Basal Cell
/ drug therapy.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Squamous
Cell
/ drug therapy.
Carcinoma
,
Squamous
Cell
/ pathology. Female. Humans. Male. Middle Aged. Ophthalmic Solutions. Retrospective Studies. Treatment Outcome
MedlinePlus Health Information.
consumer health - Cancer Chemotherapy
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
Imiquimod
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20394545.001).
[ISSN]
1744-5108
[Journal-full-title]
Orbit (Amsterdam, Netherlands)
[ISO-abbreviation]
Orbit
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
England
[Chemical-registry-number]
0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Ophthalmic Solutions; 99011-02-6 / imiquimod
44.
Wilkins K, Dolev JC, Turner R, LeBoit PE, Berger TG, Maurer TA:
Approach to the treatment of cutaneous malignancy in HIV-infected patients.
Dermatol Ther
; 2005 Jan-Feb;18(1):77-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Patients infected with human immunodeficiency virus (HIV) have an increased risk of developing
skin
cancers.
This article will review and discuss management issues for the following malignancies: lymphomas,
malignant
melanoma,
basal cell carcinoma
,
squamous
cell carcinoma
, and Kaposi's sarcoma.
[MeSH-major]
HIV Infections / complications.
Skin
Neoplasms /
diagnosis
.
Skin
Neoplasms / therapy
[MeSH-minor]
Carcinoma
,
Basal Cell
/ complications.
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Basal Cell
/ therapy.
Carcinoma
,
Squamous
Cell
/ complications.
Carcinoma
,
Squamous
Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/ therapy. Humans. Lymphoma / complications. Lymphoma /
diagnosis
. Lymphoma / therapy. Melanoma / complications. Melanoma /
diagnosis
. Melanoma / therapy. Sarcoma, Kaposi / complications. Sarcoma, Kaposi /
diagnosis
. Sarcoma, Kaposi / therapy
Genetic Alliance.
consumer health - HIV
.
MedlinePlus Health Information.
consumer health - HIV/AIDS
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15842615.001).
[ISSN]
1396-0296
[Journal-full-title]
Dermatologic therapy
[ISO-abbreviation]
Dermatol Ther
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Denmark
[Number-of-references]
148
45.
Beljaards RC, Kirtschig G, Boorsma DM:
Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma.
Dermatol Surg
; 2008 Nov;34(11):1577-9
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Expression of neural
cell
adhesion molecule (CD56) in
basal
and squamous
cell carcinoma
.
[MeSH-major]
Antigens, CD56 / biosynthesis.
Carcinoma
,
Basal Cell
/ metabolism.
Carcinoma
,
Squamous
Cell
/ metabolism
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18798745.001).
[ISSN]
1524-4725
[Journal-full-title]
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
[ISO-abbreviation]
Dermatol Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD56
46.
Dotto J, Pelosi G, Rosai J:
Expression of p63 in thymomas and normal thymus.
Am J Clin Pathol
; 2007 Mar;127(3):415-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
The DeltaN-p63 isoforms of p63, which are believed to behave as oncogenes, are expressed in
squamous
cell carcinoma
,
basal cell carcinoma
, and transitional
cell carcinoma
.
We studied 66 cases of thymoma (1 type A, 8 type AB, 12 type B1, 19 type B2, 12 type B3, and 14 type C/thymic
carcinoma
) and 10 specimens of normal human thymus arranged in tissue microarrays.
All thymomas (including thymic
carcinomas
) were positive for p63 regardless of type.
[MeSH-major]
DNA-Binding Proteins / biosynthesis. Thymoma / metabolism. Thymus Gland / chemistry. Thymus Neoplasms / metabolism. Trans-Activators / biosynthesis.
Tumor
Suppressor Proteins / biosynthesis
MedlinePlus Health Information.
consumer health - Thymus Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17276940.001).
[ISSN]
0002-9173
[Journal-full-title]
American journal of clinical pathology
[ISO-abbreviation]
Am. J. Clin. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / DNA-Binding Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins
47.
Szeimies RM, Morton CA, Sidoroff A, Braathen LR:
Photodynamic therapy for non-melanoma skin cancer.
Acta Derm Venereol
; 2005;85(6):483-90
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Photodynamic therapy for non-melanoma
skin
cancer.
Photodynamic therapy is a treatment modality that has been shown to be effective mainly for the dermato-oncologic conditions: actinic keratosis, Bowen's
disease
, in situ
squamous
cell carcinoma
and
basal cell carcinoma
.
For actinic keratosis and
basal cell carcinoma
, methyl aminolevulinate-photodynamic therapy is already approved in Europe, Australia and New Zealand, and is now also approved for actinic keratosis in the US.
[MeSH-major]
Photochemotherapy.
Skin
Neoplasms / drug therapy
[MeSH-minor]
Bowen's
Disease
/ drug therapy.
Carcinoma
,
Basal Cell
/ drug therapy.
Carcinoma
,
Squamous
Cell
/ drug therapy. Humans. Photosensitizing Agents
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16396794.001).
[ISSN]
0001-5555
[Journal-full-title]
Acta dermato-venereologica
[ISO-abbreviation]
Acta Derm. Venereol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
Norway
[Chemical-registry-number]
0 / Photosensitizing Agents
[Number-of-references]
51
48.
Altan-Yaycioglu R, Canan H, Sizmaz S, Bal N, Pelit A, Akova YA:
Nasolacrimal duct obstruction: clinicopathologic analysis of 205 cases.
Orbit
; 2010 Oct;29(5):254-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Only one patient had the
diagnosis
of chronic leukemia, others had no preexisting history of systemic
disease
.
Three patients had abnormal pathology: Lymphoproliferative
disease
in the patient with chronic leukemia, granulomatous inflammation,
and basosquamous
cell carcinoma
.
Even though rare,
malignant
or systemic
disease
in patients with neither specific history nor clinical or radiological
finding
might be observed in these cases.
Thus, we recommend taking biopsy if any suspicion of
abnormality
of the lacrimal sac exists.
[MeSH-major]
Lacrimal Duct Obstruction /
diagnosis
. Nasolacrimal Duct / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Biopsy. Child. Dacryocystorhinostomy. Female. Humans. Lacrimal Apparatus Diseases /
diagnosis
. Male. Middle Aged. Prospective Studies. Young Adult
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20704489.001).
[ISSN]
1744-5108
[Journal-full-title]
Orbit (Amsterdam, Netherlands)
[ISO-abbreviation]
Orbit
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
England
49.
Payette MJ, Whalen J, Grant-Kels JM:
Nutrition and nonmelanoma skin cancers.
Clin Dermatol
; 2010 Nov-Dec;28(6):650-62
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nutrition and nonmelanoma
skin
cancers.
The incidence of nonmelanoma
skin
cancer is increasing every year.
Basal cell carcinoma
and squamous
cell carcinoma
are the two major types of nonmelanoma
skin
cancer.
Among other factors, understanding the potential role of nutrients in the development, progression, and treatment of nonmelanoma
skin
cancer is critical.
This contribution provides a review of the nutrients that have been more extensively investigated in the literature with regard to nonmelanoma
skin
cancer, including dietary fats, retinol, carotenoids, vitamin C, vitamin D, vitamin E, selenium, copper, iron, zinc, green tea, and black tea.
[MeSH-major]
Carcinoma
,
Basal Cell
.
Carcinoma
,
Squamous
Cell
. Diet. Micronutrients / administration & dosage.
Skin
Neoplasms
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Hazardous Substances Data Bank.
Green tea
.
Hazardous Substances Data Bank.
Sodium ascorbate
.
Hazardous Substances Data Bank.
L-Ascorbic Acid
.
Hazardous Substances Data Bank.
VITAMIN A
.
Hazardous Substances Data Bank.
IRON, ELEMENTAL
.
Hazardous Substances Data Bank.
COPPER, ELEMENTAL
.
Hazardous Substances Data Bank.
ZINC, ELEMENTAL
.
Hazardous Substances Data Bank.
SELENIUM, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright © 2010 Elsevier Inc. All rights reserved.
(PMID = 21034989.001).
[ISSN]
1879-1131
[Journal-full-title]
Clinics in dermatology
[ISO-abbreviation]
Clin. Dermatol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Dietary Fats; 0 / Micronutrients; 0 / Tea; 11103-57-4 / Vitamin A; 1406-16-2 / Vitamin D; 1406-18-4 / Vitamin E; 36-88-4 / Carotenoids; 789U1901C5 / Copper; E1UOL152H7 / Iron; H6241UJ22B / Selenium; J41CSQ7QDS / Zinc; PQ6CK8PD0R / Ascorbic Acid
50.
Stollery N:
Basal and squamous cell carcinoma.
Practitioner
; 2006 Dec;250(1689):46, 48-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Basal
and squamous
cell carcinoma
.
[MeSH-major]
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/
diagnosis
. Psoriasis /
diagnosis
.
Skin
Neoplasms /
diagnosis
[MeSH-minor]
Diagnosis
, Differential. Eyelid Neoplasms /
diagnosis
. Humans
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Psoriasis
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17283757.001).
[ISSN]
0032-6518
[Journal-full-title]
The Practitioner
[ISO-abbreviation]
Practitioner
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
England
[Number-of-references]
10
51.
Thomson P, Palamaras I, Hill V, Robles W, Stevens H:
Patients are happy to be informed of their final non-melanoma skin cancer results by post.
Dermatol Online J
; 2010;16(1):5
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Patients are happy to be informed of their final non-melanoma
skin
cancer results by post.
During the past year, because of increasing pressure to see more patients, we have started to write to our patients informing them in a letter of their final
skin
cancer histology results following surgery for non-melanoma
skin
cancers:
basal cell carcinoma
and squamous
cell carcinoma
only.
A questionnaire-based study was carried out to assess whether patients were happy to receive information concerning their non-melanoma
skin
cancer
diagnosis
in a carefully worded letter.
One-hundred fifty patients were involved with
a diagnosis
of "completely excised non-melanoma
skin
cancer (NMSC)" that had previously received their final
diagnosis
by post.
Eighty-seven percent felt that they had been given the cancer
diagnosis
in an appropriate manner; 90 percent reported that they had understood the explanation about their
skin
cancer.
In addition, 81 percent stated that they had been sufficiently involved in the discussion about their
skin
cancer and its treatment.
[MeSH-major]
Carcinoma
,
Basal Cell
/ psychology.
Carcinoma
,
Squamous
Cell
/ psychology. Communication. Patient Acceptance of Health Care. Patient Satisfaction. Patients / psychology. Postal Service.
Skin
Neoplasms / psychology. Truth Disclosure
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20137747.001).
[ISSN]
1087-2108
[Journal-full-title]
Dermatology online journal
[ISO-abbreviation]
Dermatol. Online J.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
52.
Bhoumik A, Fichtman B, Derossi C, Breitwieser W, Kluger HM, Davis S, Subtil A, Meltzer P, Krajewski S, Jones N, Ronai Z:
Suppressor role of activating transcription factor 2 (ATF2) in skin cancer.
Proc Natl Acad Sci U S A
; 2008 Feb 5;105(5):1674-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Suppressor role of activating transcription factor 2 (ATF2) in
skin
cancer.
Crossing the conditionally expressed ATF2 mutant with K14-Cre mice (K14.ATF2(f/f)) resulted in selective expression of mutant ATF2 within the
basal
layer of the epidermis.
When subjected to a two-stage
skin
carcinogenesis protocol [7,12-dimethylbenz[a]anthracene/phorbol 12-tetradecanoate 13-acetate (DMBA/TPA)], K14.ATF2(f/f) mice showed significant increases in both the incidence and prevalence of papilloma development compared with the WT ATF2 mice.
Significantly, a reduction of nuclear ATF2 and increased beta-catenin expression were seen in samples of
squamous and
basal cell carcinoma
, as opposed to normal
skin
.
Our data reveal that loss of ATF2 transcriptional activity serves to promote
skin
tumor
formation, thereby indicating a suppressor activity of ATF2 in
skin
tumor
formation.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
Hazardous Substances Data Bank.
12-O-TETRADECANOYLPHORBOL-13-ACETATE
.
Hazardous Substances Data Bank.
7,12-DIMETHYLBENZ(A)ANTHRACENE
.
KOMP Repository.
gene/protein/disease-specific - KOMP Repository
(subscription/membership/fee required).
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Cancer Res. 2004 Nov 15;64(22):8222-30
[
15548688.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9827-32
[
10449779.001
]
[Cites]
Mol Cell Biol. 2007 Mar;27(5):1730-44
[
17189429.001
]
[Cites]
Genes Dev. 2007 Mar 1;21(5):562-77
[
17344417.001
]
[Cites]
Cancer Res. 2007 Mar 15;67(6):2430-8
[
17363560.001
]
[Cites]
Mol Cell Biol. 2000 Jul;20(13):4814-25
[
10848607.001
]
[Cites]
Oncogene. 2000 Aug 17;19(35):4011-21
[
10962557.001
]
[Cites]
Clin Cancer Res. 2001 Feb;7(2):331-42
[
11234888.001
]
[Cites]
Cancer Res. 2001 May 15;61(10):3908-12
[
11358804.001
]
[Cites]
Oncogene. 2001 Apr 30;20(19):2453-64
[
11402340.001
]
[Cites]
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10863-8
[
11517342.001
]
[Cites]
Oncogene. 2002 Jul 18;21(31):4728-38
[
12101411.001
]
[Cites]
J Clin Invest. 2002 Sep;110(5):643-50
[
12208865.001
]
[Cites]
Cell. 2002 Sep 20;110(6):751-62
[
12297048.001
]
[Cites]
Nat Genet. 2003 Mar;33(3):416-21
[
12590261.001
]
[Cites]
Dev Cell. 2003 Jun;4(6):879-89
[
12791272.001
]
[Cites]
Cancer Res. 2003 Dec 1;63(23):8103-7
[
14678960.001
]
[Cites]
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4222-7
[
15010535.001
]
[Cites]
Nature. 1986 Oct 30-Nov 5;323(6091):822-4
[
2430189.001
]
[Cites]
Oncogene. 1990 Mar;5(3):295-302
[
2138276.001
]
[Cites]
Carcinogenesis. 1993 Feb;14(2):319-21
[
8435875.001
]
[Cites]
Oncogene. 1993 May;8(5):1127-33
[
8479737.001
]
[Cites]
Mol Cell Biol. 1993 Sep;13(9):5479-89
[
8355695.001
]
[Cites]
J Biol Chem. 1993 Oct 5;268(28):21225-31
[
8407959.001
]
[Cites]
Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):609-13
[
8290571.001
]
[Cites]
Cancer Res. 1994 Mar 1;54(5):1178-89
[
8118803.001
]
[Cites]
Cancer Res. 1994 Apr 1;54(7 Suppl):1882s-1885s
[
8137304.001
]
[Cites]
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10613-8
[
17556541.001
]
[Cites]
J Biol Chem. 2007 Oct 26;282(43):31504-16
[
17716970.001
]
[Cites]
Science. 1995 Jan 20;267(5196):389-93
[
7824938.001
]
[Cites]
Exp Cell Res. 1995 Feb;216(2):422-30
[
7843287.001
]
[Cites]
Carcinogenesis. 1995 Apr;16(4):749-56
[
7728951.001
]
[Cites]
EMBO J. 1995 Apr 18;14(8):1798-811
[
7737130.001
]
[Cites]
Cancer Res. 1996 Feb 1;56(3):483-9
[
8564958.001
]
[Cites]
Mol Cell Biol. 1996 Oct;16(10):5232-44
[
8816436.001
]
[Cites]
Carcinogenesis. 1996 Dec;17(12):2551-7
[
9006088.001
]
[Cites]
Genes Dev. 1998 Jan 15;12(2):233-45
[
9436983.001
]
[Cites]
Genes Dev. 1998 Aug 15;12(16):2469-74
[
9716400.001
]
[Cites]
Science. 1998 Sep 4;281(5382):1509-12
[
9727977.001
]
[Cites]
Mol Cell Biol. 1998 Dec;18(12):7020-9
[
9819389.001
]
[Cites]
Nature. 1999 Apr 8;398(6727):518-22
[
10206645.001
]
[Cites]
Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7
[
10318916.001
]
[Cites]
J Biol Chem. 1999 Jun 18;274(25):17813-9
[
10364225.001
]
[Cites]
Mol Cell. 2005 May 27;18(5):577-87
[
15916964.001
]
(PMID = 18227516.001).
[ISSN]
1091-6490
[Journal-full-title]
Proceedings of the National Academy of Sciences of the United States of America
[ISO-abbreviation]
Proc. Natl. Acad. Sci. U.S.A.
[Language]
ENG
[Databank-accession-numbers]
GEO/ GSE9328
[Grant]
United States / NCI NIH HHS / CA / R01 CA099961; United States / NCI NIH HHS / CA / CA099961
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
United States
[Chemical-registry-number]
0 / Activating Transcription Factor 2; 0 / Carcinogens; 0 / Notch1 protein, mouse; 0 / Presenilin-1; 0 / Proto-Oncogene Proteins c-myb; 0 / Receptor, Notch1; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 136601-57-5 / Cyclin D1; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 9007-49-2 / DNA; NI40JAQ945 / Tetradecanoylphorbol Acetate
[Other-IDs]
NLM/ PMC2234203
53.
Liutkeviciūte-Navickiene J, Mordas A, Simkute S, Bloznelyte-Plesniene L:
[Fluorescence diagnostics of skin tumors using 5-aminolevulinic acid and its methyl ester].
Medicina (Kaunas)
; 2009;45(12):937-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Fluorescence diagnostics
of skin
tumors using 5-aminolevulinic acid and its methyl ester].
OBJECTIVE: The incidence of
malignant
skin
tumors is rapidly increasing.
Early
diagnosis
, determining the margins of the
tumor
, is extremely important to achieve good treatment results.
We investigated fluorescence of protoporphyrin IX in
skin
carcinomas
.
The study aimed to compare the effectiveness of topical 5-aminolevulinic acid and methyl-aminolevulinate in determining the exact margins
of skin
tumors.
MATERIALS AND METHODS: Fluorescence measurements were performed in 126 patients with
malignant
, premalignant, and benign
skin
lesions for detection of the margins of
squamous
cell carcinoma
and
basal cell carcinoma
.
5-Aminolevulinic acid or its methyl ester was applied to the
skin
lesion for 2-4 h, and the data of evaluated protoporphyrin IX fluorescence were correlated with the data of morphological tissue examination.
RESULTS:
Malignant
tissue shows a specific red fluorescence when illuminated with blue-violet light, whereas no fluorescence was observed in normal
skin
.
A sensitivity of 95.4%
and a
specificity of 88.6% as well as positive and negative predictive values of 86.1% and 96.3%, respectively, were obtained.
CONCLUSIONS: Fluorescence diagnostics can be used for complete visualization of
malignant
skin
lesions after topical application of 5-aminolevulinic acid or methyl aminolevulinate.
It has been shown to be highly effective in the diagnostics of
malignant
superficial
skin
lesion.
[MeSH-major]
Aminolevulinic Acid / analogs & derivatives.
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/
diagnosis
. Fluorescence. Head and Neck Neoplasms /
diagnosis
. Photosensitizing Agents. Precancerous Conditions /
diagnosis
. Protoporphyrins.
Skin
Neoplasms /
diagnosis
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Esters. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Sensitivity and Specificity.
Skin
/ pathology
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20173396.001).
[ISSN]
1648-9144
[Journal-full-title]
Medicina (Kaunas, Lithuania)
[ISO-abbreviation]
Medicina (Kaunas)
[Language]
lit
[Publication-type]
Comparative Study; English Abstract; Journal Article
[Publication-country]
Lithuania
[Chemical-registry-number]
0 / Esters; 0 / Photosensitizing Agents; 0 / Protoporphyrins; 0 / methyl 5-aminolevulinate; 553-12-8 / protoporphyrin IX; 88755TAZ87 / Aminolevulinic Acid
54.
Srikanth V, Fryer J, Venn A, Blizzard L, Newman L, Cooley H, Albion T, Jones G:
The association between non-melanoma skin cancer and osteoporotic fractures--a population-based record linkage study.
Osteoporos Int
; 2007 May;18(5):687-92
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
The association between non-melanoma
skin
cancer and osteoporotic fractures--a population-based record linkage study.
We studied the association between osteoporotic fractures and prior non-melanoma
skin
cancer (NMSC, a biomarker for cumulative sun exposure).
We aimed to study the association between non-melanoma
skin
cancer (NMSC), a marker of cumulative sun exposure, and osteoporotic fractures in an older cohort.
This effect was significant for most fracture subtypes except pelvic and wrist fractures and observed for both NMSC subtypes,
squamous
cell carcinoma
and
basal cell carcinoma
.
Achieving a balance between adequate lifetime sun exposure and protection against its adverse effects (such as fractures and
skin
cancer) may require assessment of individual risks.
[MeSH-major]
Fractures, Bone / etiology. Medical Record Linkage. Osteoporosis / complications.
Skin
Neoplasms / complications
MedlinePlus Health Information.
consumer health - Fractures
.
MedlinePlus Health Information.
consumer health - Osteoporosis
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Lancet. 2005 May 7-13;365(9471):1621-8
[
15885294.001
]
[Cites]
Am J Epidemiol. 1990 Feb;131(2):373-5
[
2296988.001
]
[Cites]
J Epidemiol Community Health. 2004 Feb;58(2):142-4
[
14729897.001
]
[Cites]
Osteoporos Int. 2005 Jun;16(6):636-41
[
15448989.001
]
[Cites]
Am J Clin Nutr. 1995 Mar;61(3 Suppl):638S-645S
[
7879731.001
]
[Cites]
Public Health Nutr. 2001 Apr;4(2B):547-59
[
11683549.001
]
[Cites]
Am J Clin Nutr. 1990 Jun;51(6):1075-81
[
2349922.001
]
[Cites]
Osteoporos Int. 2001;12(2):124-30
[
11303712.001
]
[Cites]
J Bone Miner Res. 1995 Nov;10(11):1802-15
[
8592959.001
]
[Cites]
Osteoporos Int. 2005 Nov;16(11):1425-31
[
15744449.001
]
[Cites]
Value Health. 2003 Sep-Oct;6(5):574-83
[
14627064.001
]
[Cites]
Cancer Causes Control. 1997 May;8(3):271-83
[
9498892.001
]
[Cites]
J Invest Dermatol. 2003 Jun;120(6):1087-93
[
12787139.001
]
[Cites]
Aust N Z J Med. 2000 Apr;30(2):209-14
[
10833112.001
]
[Cites]
J Clin Endocrinol Metab. 1999 May;84(5):1562-6
[
10323380.001
]
[Cites]
Bone Miner. 1994 May;25(2):83-92
[
8086854.001
]
[Cites]
N Engl J Med. 1992 Dec 3;327(23 ):1637-42
[
1331788.001
]
[Cites]
BMJ. 2005 Apr 30;330(7498):1003
[
15860827.001
]
[Cites]
Australas J Dermatol. 1997 Jun;38 Suppl 1:S1-6
[
10994463.001
]
[Cites]
J Am Coll Nutr. 2003 Apr;22(2):142-6
[
12672710.001
]
[Cites]
Eur J Clin Nutr. 2004 Aug;58(8):1095-109
[
15054436.001
]
[Cites]
Eur J Clin Nutr. 1999 Oct;53(10):824-9
[
10556991.001
]
[Cites]
Osteoporos Int. 2005 Mar;16 Suppl 2:S3-7
[
15365697.001
]
[Cites]
Am J Clin Nutr. 2004 Dec;80(6):1645-9
[
15585781.001
]
[Cites]
Osteoporos Int. 1999;9(1):45-54
[
10367029.001
]
[Cites]
Am J Epidemiol. 2002 Apr 1;155(7):614-21
[
11914188.001
]
[Cites]
BMJ. 2003 Aug 9;327(7410):316
[
12907484.001
]
[Cites]
Am J Clin Nutr. 1987 Dec;46(6):1005-10
[
3687818.001
]
(PMID = 17211531.001).
[ISSN]
0937-941X
[Journal-full-title]
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
[ISO-abbreviation]
Osteoporos Int
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
England
55.
Fekecs T, Kádár Z, Battyáni Z, Kalmár-Nagy K, Szakály P, Horváth OP, Wéber G, Ferencz A:
Incidence of nonmelanoma skin cancer after human organ transplantation: single-center experience in Hungary.
Transplant Proc
; 2010 Jul-Aug;42(6):2333-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Incidence of nonmelanoma
skin
cancer after human organ transplantation: single-center experience in Hungary.
There is increasing evidence that nonmelanoma
skin
cancers (NMSCs) are the most frequently observed tumors in transplant recipients.
All patients underwent a full
skin
examination for NMSC, and completed a standardized questionnaire.
Histologic analysis verified 13
basal cell
carcinomas and
3
squamous
cell
carcinomas
(ratio, 4:1).
These data indicate the relevance
of skin
cancer surveillance in transplant recipients.
Our results correspond to international statistics except for the ratio
of basal cell carcinoma
to
squamous
cell carcinoma
.
[MeSH-major]
Organ Transplantation / adverse effects.
Skin
Neoplasms / epidemiology
[MeSH-minor]
Carcinoma
,
Basal Cell
/ epidemiology.
Carcinoma
,
Squamous
Cell
/ epidemiology. Female. Follow-Up Studies. Humans. Hungary / epidemiology. Kidney Transplantation / adverse effects. Male. Middle Aged. Pancreas Transplantation / adverse effects.
Skin
/ pathology. Surveys and Questionnaires. Time Factors
Genetic Alliance.
consumer health - Transplantation
.
MedlinePlus Health Information.
consumer health - Organ Transplantation
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2010 Elsevier Inc. All rights reserved.
(PMID = 20692474.001).
[ISSN]
1873-2623
[Journal-full-title]
Transplantation proceedings
[ISO-abbreviation]
Transplant. Proc.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
56.
Marcet S:
Atypical fibroxanthoma/malignant fibrous histiocytoma.
Dermatol Ther
; 2008 Nov-Dec;21(6):424-7
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Atypical fibroxanthoma/
malignant
fibrous histiocytoma.
Atypical fibroxanthoma (AFX) is an unusual spindle
cell
tumor
occurring on actinically damaged
skin of
the head and neck.
Clinically, it is often confused with
basal cell carcinoma
,
squamous
cell carcinoma
, or even melanoma.
Although initially thought to be
a diagnosis
of exclusion histologically, newer immunostains have helped in the identification of AFX.
[MeSH-major]
Head and Neck Neoplasms / pathology. Histiocytoma,
Malignant
Fibrous / pathology.
Skin
Neoplasms / pathology
[MeSH-minor]
Humans. Mohs Surgery.
Neoplasm
Recurrence, Local
Genetic Alliance.
consumer health - Malignant fibrous histiocytoma
.
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19076618.001).
[ISSN]
1529-8019
[Journal-full-title]
Dermatologic therapy
[ISO-abbreviation]
Dermatol Ther
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Denmark
57.
Johansen P, Berg K, Selbo PK, Hofbauer GF:
[Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment of skin cancer].
Praxis (Bern 1994)
; 2010 Nov 17;99(23):1423-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Photochemical internalisation (PCI): a further development of photodynamic therapy for the treatment
of skin
cancer].
[Transliterated title]
Photochemische Internalisierung (PCI): eine Weiterentwicklung
der
photodynamischen Therapie zur Behandlung von Hautkrebs.
Recently, several new and non-invasive methods have been introduced for the treatment
of skin
cancers.
Topical creams using the immune modulator imiquimod or the COX inhibitor diclofenac (with hyaluronic acid) are now registered for use against neoplasms such as
basal
or
squamous
cell carcinoma
.
A refined version of PDT, namely photochemical internalisation, is currently subject to a first clinical trial in patients with osteosarcoma,
squamous
cell carcinoma
, head and neck cancer as well as adenocarcinoma of the breast.
[MeSH-major]
Carcinoma
,
Basal Cell
/ drug therapy.
Carcinoma
,
Squamous
Cell
/ drug therapy. Melanoma / drug therapy. Photochemotherapy / methods.
Skin
Neoplasms / drug therapy
[MeSH-minor]
Animals. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Cytosol / drug effects. Endocytosis. Endosomes / drug effects. Humans. Melanoma, Experimental / drug therapy. Mice.
Neoplasm
Transplantation
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 21082595.001).
[ISSN]
1661-8157
[Journal-full-title]
Praxis
[ISO-abbreviation]
Praxis (Bern 1994)
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Switzerland
[Chemical-registry-number]
0 / Antineoplastic Agents
58.
Szeimies RM, Karrer S, Bäcker H:
[Therapeutic options for epithelial skin tumors. Actinic keratoses, Bowen disease, squamous cell carcinoma, and basal cell carcinoma].
Hautarzt
; 2005 May;56(5):430-40
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Therapeutic options for epithelial
skin
tumors. Actinic keratoses, Bowen
disease
,
squamous
cell carcinoma
, and
basal cell carcinoma
].
[Transliterated title]
Therapieoptionen bei epithelialen Hauttumoren Aktinische Keratosen, Morbus Bowen, spinozelluläres
Karzinom
und Basalzellkarzinom.
There has been worldwide a significant rise in the incidence of epithelial
skin
tumors and their precursors in the past years with an increased number of younger patients affected.
In the following article different therapeutic approaches for actinic keratoses, Bowen's
disease
,
basal cell carcinoma
and squamous
cell carcinoma
are presented and analysed.
[MeSH-major]
Risk Assessment / methods.
Skin
Neoplasms /
diagnosis
.
Skin
Neoplasms / therapy
[MeSH-minor]
Antineoplastic Agents / administration & dosage. Bowen's
Disease
/
diagnosis
. Bowen's
Disease
/ therapy.
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Basal Cell
/ therapy.
Carcinoma
,
Squamous
Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/ therapy. Cryotherapy / methods. Curettage / methods. Humans. Keratosis /
diagnosis
. Keratosis / therapy. Practice Guidelines as Topic. Practice Patterns, Physicians'. Risk Factors
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Strahlenther Onkol. 2001 May;177(5):240-6
[
11398609.001
]
[Cites]
Br J Dermatol. 2001 Mar;144(3):567-74
[
11260016.001
]
[Cites]
Int J Dermatol. 2001 Nov;40(11):709-13
[
11737438.001
]
[Cites]
J Am Acad Dermatol. 2001 Mar;44(3):462-70
[
11209116.001
]
[Cites]
J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):414-8
[
10459115.001
]
[Cites]
Dermatologica. 1979;158(5):368-72
[
437226.001
]
[Cites]
Int J Dermatol. 2004 Sep;43(9):687-92
[
15357755.001
]
[Cites]
J Am Acad Dermatol. 2004 May;50(5):722-33
[
15097956.001
]
[Cites]
Clin Exp Dermatol. 1999 Jul;24(4):338-9
[
10457144.001
]
[Cites]
J Dermatol Surg Oncol. 1989 Apr;15(4):424-31
[
2925988.001
]
[Cites]
J Am Acad Dermatol. 2002 Aug;47(2):258-62
[
12140473.001
]
[Cites]
J Am Acad Dermatol. 1982 Nov;7(5):631-2
[
7142470.001
]
[Cites]
J Drugs Dermatol. 2004 Jul-Aug;3(4):401-7
[
15303784.001
]
[Cites]
Dermatol Surg. 2004 Sep;30(9):1214-8
[
15355363.001
]
[Cites]
Br J Dermatol. 1999 Oct;141(4):633-41
[
10583109.001
]
[Cites]
J Eur Acad Dermatol Venereol. 2003 Mar;17(2):167-70
[
12705745.001
]
[Cites]
Dermatol Surg. 2000 Aug;26(8):759-64
[
10940063.001
]
[Cites]
Br J Dermatol. 2000 Apr;142(4):752-7
[
10792227.001
]
[Cites]
Br J Dermatol. 2003 Nov;149 Suppl 66:43-9
[
14616349.001
]
[Cites]
Br J Dermatol. 2004 Jul;151(1):148-56
[
15270884.001
]
[Cites]
Int J Cancer. 1999 May 17;81(4):555-9
[
10225444.001
]
[Cites]
Arch Dermatol. 2002 Nov;138(11):1498-502
[
12437457.001
]
[Cites]
Dermatol Surg. 2004 Apr;30(4 Pt 1):517-20
[
15056141.001
]
[Cites]
Eur J Dermatol. 2002 Nov-Dec;12(6):558-61
[
12459527.001
]
[Cites]
J Am Acad Dermatol. 1998 Mar;38(3):438-42
[
9520026.001
]
[Cites]
Australas J Dermatol. 2000 Feb;41(1):19-30
[
10715896.001
]
[Cites]
J Am Acad Dermatol. 2004 Oct;51(4):547-55
[
15389189.001
]
[Cites]
Clin Dermatol. 2001 May-Jun;19(3):328-38
[
11479045.001
]
[Cites]
Arch Dermatol. 2004 Oct;140(10 ):1284-5
[
15492200.001
]
[Cites]
J Dermatolog Treat. 2003 Jun;14(2):99-106
[
12775317.001
]
[Cites]
Br J Dermatol. 2004 Jul;151(1):141-7
[
15270883.001
]
[Cites]
Br J Cancer. 1997;76(1):100-6
[
9218740.001
]
[Cites]
Br J Dermatol. 2001 Apr;144(4):832-40
[
11298545.001
]
[Cites]
Arch Dermatol. 2004 Oct;140(10 ):1286-7
[
15492202.001
]
[Cites]
Br J Dermatol. 2003 Mar;148(3):539-43
[
12653747.001
]
[Cites]
J Am Acad Dermatol. 1997 Jan;36(1):72-7
[
8996264.001
]
[Cites]
Dermatol Surg. 2003 Nov;29(11):1150-3; discussion 1153
[
14641346.001
]
[Cites]
Dermatol Surg. 2001 Feb;27(2):143-6
[
11207687.001
]
[Cites]
J Am Acad Dermatol. 2003 Sep;49(3):483-6
[
12963913.001
]
[Cites]
Lancet. 2004 Nov 13-19;364(9447):1766-72
[
15541449.001
]
[Cites]
Br J Dermatol. 1996 Nov;135(5):766-71
[
8977678.001
]
[Cites]
J Dermatol Surg Oncol. 1991 Sep;17(9):720-6
[
1820764.001
]
[Cites]
Clin Radiol. 1986 Jan;37(1):33-4
[
3514075.001
]
[Cites]
J Am Acad Dermatol. 2004 May;50(5):714-21
[
15097955.001
]
[Cites]
Clin Ther. 2002 Jun;24(6):990-1000
[
12117087.001
]
[Cites]
Lasers Surg Med. 2004;34(2):114-9
[
15004822.001
]
(PMID = 15815888.001).
[ISSN]
0017-8470
[Journal-full-title]
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
[ISO-abbreviation]
Hautarzt
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antineoplastic Agents
[Number-of-references]
48
59.
Moan J, Porojnicu AC, Dahlback A:
Ultraviolet radiation and malignant melanoma.
Adv Exp Med Biol
; 2008;624:104-16
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Ultraviolet radiation
and malignant
melanoma.
Essential features of the epidemiology and photobiology of cutaneous
malignant
melanoma (CMM) in Norway were studied in comparison with data from countries at lower latitudes.
This hypothesis was supported both by latitude gradients, by time trends and by changing patterns of
tumor
density on different body localizations.
Comparisons
of skin
cancer data from Norway and Australia/New Zealand indicate that
squamous
cell carcinoma
and
basal cell carcinoma
are mainly related to annual solar UVB fluences, while UVA fluences play a larger role for CMM.
[MeSH-major]
Carcinoma
,
Basal Cell
/ epidemiology.
Carcinoma
,
Squamous
Cell
/ epidemiology. Melanoma / epidemiology.
Skin
Neoplasms / epidemiology. Ultraviolet Rays / adverse effects
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18348451.001).
[ISSN]
0065-2598
[Journal-full-title]
Advances in experimental medicine and biology
[ISO-abbreviation]
Adv. Exp. Med. Biol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't; Review
[Publication-country]
United States
[Number-of-references]
52
60.
Abdel-Malek ZA, Kadekaro AL, Swope VB:
Stepping up melanocytes to the challenge of UV exposure.
Pigment Cell Melanoma Res
; 2010 Apr;23(2):171-86
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Exposure to solar ultraviolet radiation (UV) is the main etiological factor for
skin
cancer, including melanoma.
Therefore, maintaining genomic stability of melanocytes is crucial for prevention of melanoma, as well as keratinocyte-derived
basal
and squamous
cell carcinoma
.
The response of melanocytes to UV is mediated mainly by a network of paracrine factors that not only activate melanogenesis, but also DNA repair, anti-oxidant, and survival pathways that are pivotal for maintenance of genomic stability and prevention of
malignant
transformation or apoptosis.
Unraveling these mechanisms might lead to strategies to prevent melanoma, as well as non-melanoma
skin
cancer.
[MeSH-major]
DNA Repair / physiology. Genomic Instability. Melanocytes / metabolism. Melanoma / metabolism.
Skin
Neoplasms / metabolism. Ultraviolet Rays
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentIn]
Pigment Cell Melanoma Res. 2011 Apr;24(2):265-7
[
21513010.001
]
(PMID = 20128873.001).
[ISSN]
1755-148X
[Journal-full-title]
Pigment cell & melanoma research
[ISO-abbreviation]
Pigment Cell Melanoma Res
[Language]
eng
[Grant]
United States / NIEHS NIH HHS / ES / P30-ES006096; United States / NCI NIH HHS / CA / R01CA114095; United States / NIEHS NIH HHS / ES / R01ES009110; United States / NIEHS NIH HHS / ES / R01ES017561
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural; Review
[Publication-country]
England
[Number-of-references]
197
61.
Fabbrocini G, Triassi M, Mauriello MC, Torre G, Annunziata MC, De Vita V, Pastore F, D'Arco V, Monfrecola G:
Epidemiology of skin cancer: role of some environmental factors.
Cancers (Basel)
; 2010;2(4):1980-9
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epidemiology
of skin
cancer: role of some environmental factors.
The incidence rate of melanoma and non-melanoma
skin
cancer entities is dramatically increasing worldwide.
Exposure to UVB radiation is known to induce
basal
and squamous
cell skin
cancer in a dose-dependent way and the depletion of stratospheric ozone has implications for increases in biologically damaging solar UVB radiation reaching the earth's surface.
In humans, arsenic is known to cause cancer of the
skin
, as well as cancer of the lung, bladder, liver, and kidney.
SCC and
BCC
(
squamous and
basal cell carcinoma
) have been reported to be associated with ingestion of arsenic alone or in combination with other risk factors.
Higher temperatures accompanying climate change may lead, among many other effects, to increasing incidence
of skin
cancer.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 24281212.001).
[ISSN]
2072-6694
[Journal-full-title]
Cancers
[ISO-abbreviation]
Cancers (Basel)
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Switzerland
[Other-IDs]
NLM/ PMC3840456
62.
Mogensen M, Jemec GB:
Diagnosis of nonmelanoma skin cancer/keratinocyte carcinoma: a review of diagnostic accuracy of nonmelanoma skin cancer diagnostic tests and technologies.
Dermatol Surg
; 2007 Oct;33(10):1158-74
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Diagnosis
of nonmelanoma
skin
cancer/keratinocyte
carcinoma
: a review of diagnostic accuracy of nonmelanoma
skin
cancer diagnostic tests and technologies.
BACKGROUND: Nonmelanoma
skin
cancer (NMSC) is the most prevalent cancer in the light-skinned population.
OBJECTIVE: The scope of this review is to present data on the current state-of-the-art diagnostic methods for keratinocyte
carcinoma
:
basal cell carcinoma
,
squamous
cell carcinoma
, and actinic keratosis.
[MeSH-major]
Skin
Neoplasms /
diagnosis
[MeSH-minor]
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Basal Cell
/ ultrasonography.
Carcinoma
,
Squamous
Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/ pathology.
Carcinoma
,
Squamous
Cell
/ ultrasonography. Dermoscopy. Diagnostic Tests, Routine. Humans. Keratosis /
diagnosis
. Keratosis / pathology. Keratosis / ultrasonography
MedlinePlus Health Information.
consumer health - Skin Cancer
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17903149.001).
[ISSN]
1076-0512
[Journal-full-title]
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
[ISO-abbreviation]
Dermatol Surg
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
United States
[Number-of-references]
128
63.
Mancuso M, Gallo D, Saran A:
Re: Modulation of basal and squamous cell carcinoma by endogenous estrogen in mouse models of skin cancer.
Carcinogenesis
; 2009 Apr;30(4):721
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Re: Modulation
of basal
and squamous
cell carcinoma
by endogenous estrogen in mouse models
of skin
cancer.
[MeSH-major]
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Squamous
Cell
/ pathology.
Disease
Models, Animal. Estrogens / pharmacology.
Skin
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Mouse Genome Informatics (MGI).
Mouse Genome Informatics (MGI)
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[CommentOn]
Carcinogenesis. 2009 Apr;30(4):720
[
19168587.001
]
(PMID = 19168582.001).
[ISSN]
1460-2180
[Journal-full-title]
Carcinogenesis
[ISO-abbreviation]
Carcinogenesis
[Language]
eng
[Publication-type]
Comment; Letter
[Publication-country]
England
[Chemical-registry-number]
0 / Estrogens
64.
Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, Abeni D, Tessari GP, Feltkamp MC, Claudy A, Stockfleth E, Harwood CA, EPI-HPV-UV-CA group:
Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy.
J Invest Dermatol
; 2007 Jul;127(7):1647-56
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Keratotic
skin
lesions and other risk factors are associated with
skin
cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy.
This study examines the association of keratotic
skin
lesions with the development
of skin
cancer in 915 solid organ-transplant recipients in five European countries.
In a hospital-based case-control study, cases with
squamous
- and
basal
-
cell carcinoma
were compared with controls without
skin
cancer.
Questionnaires, scrutiny of medical charts, and
skin
examination were delivered according to a standardized protocol.
Keratotic
skin
lesions and viral warts were counted on different body sites.
Keratotic
skin
lesions were strongly associated with an increased risk of
squamous
-
cell carcinoma
, with adjusted odds ratios of 4.1 (2.4;7.0) and 12.1 (6.1;24) for 1-49 and 50 and more keratotic
skin
lesions compared with no lesions, respectively.
Keratotic
skin
lesions were also associated with
basal
-
cell carcinoma
with adjusted odds ratios of 2.9 (1.7;4.9) and 4.0 (1.7;9.2) for 1-49 and 50 and more lesions, respectively.
Lighter
skin
types and painful sunburns were also significantly associated with an increased risk of
squamous
- and
basal
-
cell carcinoma
.
Keratotic
skin
lesions are strongly associated with
skin
cancer and are, thus, an important clinical criterion for identifying those organ-transplant recipients at an increased risk
of skin
cancers who should be offered more intensive
skin
surveillance.
[MeSH-major]
Carcinoma
,
Basal Cell
/ epidemiology.
Carcinoma
,
Squamous
Cell
/ epidemiology. Keratosis / epidemiology. Keratosis / pathology.
Skin
Neoplasms / etiology. Transplantation / adverse effects
[MeSH-minor]
Adult. Aged. Case-Control Studies. Europe / epidemiology. Female. Humans. Life Style. Male. Middle Aged. Papillomavirus Infections / epidemiology. Risk Factors. Sex Characteristics.
Skin
Pigmentation. Sunlight / adverse effects
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Crit Rev Oncol Hematol. 2005 Oct;56(1):87-99
[
15979889.001
]
[Cites]
J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307
[
10642700.001
]
[Cites]
Transplantation. 2000 Jan 15;69(1):44-9
[
10653378.001
]
[Cites]
J Clin Microbiol. 2000 Jun;38(6):2087-96
[
10834958.001
]
[Cites]
J Med Virol. 2000 Jul;61(3):289-97
[
10861635.001
]
[Cites]
Am J Kidney Dis. 2000 Jul;36(1):167-76
[
10873887.001
]
[Cites]
Br J Dermatol. 2000 Sep;143(3):513-9
[
10971322.001
]
[Cites]
Genes Dev. 2000 Dec 1;14(23):3065-73
[
11114894.001
]
[Cites]
Transplantation. 2000 Nov 27;70(10):1479-84
[
11118094.001
]
[Cites]
J Clin Oncol. 2001 Jan 1;19(1):231-8
[
11134217.001
]
[Cites]
J Photochem Photobiol B. 2001 Oct;63(1-3):8-18
[
11684447.001
]
[Cites]
J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20
[
12077575.001
]
[Cites]
EMBO J. 2002 Sep 2;21(17):4741-8
[
12198176.001
]
[Cites]
Br J Dermatol. 2002 Nov;147(5):950-6
[
12410706.001
]
[Cites]
N Engl J Med. 2003 Apr 24;348(17):1681-91
[
12711744.001
]
[Cites]
Acta Otolaryngol. 2005 Sep;125(9):991-8
[
16193590.001
]
[Cites]
Acta Derm Venereol. 2003;83(3):189-93
[
12816154.001
]
[Cites]
Arch Dermatol. 2003 Jul;139(7):890-4
[
12873884.001
]
[Cites]
Br J Cancer. 2003 Oct 6;89(7):1221-7
[
14520450.001
]
[Cites]
Arch Dermatol Res. 2003 Dec;295(7):273-9
[
14618345.001
]
[Cites]
J Invest Dermatol. 2003 Dec;121(6):1531-5
[
14675206.001
]
[Cites]
Cancer Epidemiol Biomarkers Prev. 2003 Dec;12(12):1540-3
[
14693751.001
]
[Cites]
N Engl J Med. 2004 Jun 24;350(26):2639-42
[
15215478.001
]
[Cites]
Science. 2005 Sep 16;309(5742):1871-4
[
16166520.001
]
[Cites]
Cancer Res. 2003 May 15;63(10):2695-700
[
12750299.001
]
[Cites]
J Natl Cancer Inst. 2006 Mar 15;98(6):389-95
[
16537831.001
]
[Cites]
Br J Dermatol. 2006 Mar;154(3):498-504
[
16445782.001
]
[Cites]
Arch Dermatol. 2004 Sep;140(9):1079-85
[
15381547.001
]
[Cites]
J Invest Dermatol. 2005 Jul;125(1):93-7
[
15982308.001
]
[Cites]
J Clin Microbiol. 1999 Nov;37(11):3545-55
[
10523550.001
]
[Cites]
Transplantation. 1996 Mar 15;61(5):715-21
[
8607173.001
]
[Cites]
J Invest Dermatol. 1995 Sep;105(3):367-71
[
7665914.001
]
[Cites]
Br J Dermatol. 1993 Sep;129(3):242-9
[
8286220.001
]
[Cites]
N Engl J Med. 1991 Sep 19;325(12):843-8
[
1875968.001
]
[Cites]
Acta Derm Venereol. 1990;70(6):491-4
[
1981421.001
]
[Cites]
Transplantation. 1990 Mar;49(3):506-9
[
2316011.001
]
[Cites]
Q J Med. 1987 Jul;64(243):609-16
[
3313494.001
]
[Cites]
Lancet. 1984 Mar 31;1(8379):702-5
[
6143041.001
]
(PMID = 17380113.001).
[ISSN]
1523-1747
[Journal-full-title]
The Journal of investigative dermatology
[ISO-abbreviation]
J. Invest. Dermatol.
[Language]
eng
[Grant]
United Kingdom / Cancer Research UK / / A6695
[Publication-type]
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2478722; NLM/ UKMS1916
65.
Wagoner J, Keehn C, Morgan MB:
CD-10 immunostaining differentiates superficial basal cell carcinoma from cutaneous squamous cell carcinoma.
Am J Dermatopathol
; 2007 Dec;29(6):555-8
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
CD-10 immunostaining differentiates superficial
basal cell carcinoma
from cutaneous
squamous
cell carcinoma
.
Basal cell carcinoma
and squamous
cell carcinoma
are common entities in clinical practice.
We sought to determine if the CD10 immunostain could have diagnostic utility in distinguishing between early superficial
basal cell carcinoma
(
BCC
)
and squamous
cell carcinoma
(SCC).
CD10 was negative in the
tumor
cells in 13 out of 13 superficially invasive SCCs and SCC in situ.
These findings support the utility of CD10 as a marker for early
BCC
, especially when SCC cannot be excluded clinically or by conventional stains.
Furthermore, these results implicate CD10 in the pathogenesis
of BCC
.
[MeSH-major]
Biomarkers,
Tumor
/ analysis.
Carcinoma
in Situ /
diagnosis
.
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/
diagnosis
. Neprilysin / analysis.
Skin
Neoplasms /
diagnosis
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18032951.001).
[ISSN]
1533-0311
[Journal-full-title]
The American Journal of dermatopathology
[ISO-abbreviation]
Am J Dermatopathol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; EC 3.4.24.11 / Neprilysin
66.
Leiter U, Garbe C:
[Skin cancer in organ transplant patients. Epidemiology and management].
Hautarzt
; 2010 Mar;61(3):207-13
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[
Skin
cancer in organ transplant patients. Epidemiology and management].
Skin
cancer is the most common cancer, representing 40-50% of post transplant malignancies.
In the first 10 years post transplantation, some 15%-40% of patients develop
skin
cancer, primarily
squamous
cell carcinoma
and
basal cell carcinoma
, but also melanoma, Merkel
cell carcinoma
and virally-induced Kaposi sarcoma.
The management
of skin
cancer includes secondary prophylaxis and address attention to areas of widespread actinic damage, usually with topical agents.
In high risk
skin
cancer or metastatic
disease a
substantial reduction in immunosuppression to switching to mTOR inhibitors appears to substantially improve the prognosis.
The management of the individual
tumor
types is discussed; in general it follows the current guidelines.
[MeSH-major]
Antineoplastic Agents / administration & dosage. Immunosuppressive Agents / administration & dosage. Organ Transplantation / statistics & numerical data. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control.
Skin
Neoplasms / epidemiology.
Skin
Neoplasms / prevention & control
MedlinePlus Health Information.
consumer health - After Surgery
.
MedlinePlus Health Information.
consumer health - Organ Transplantation
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Melanoma Res. 2008 Apr;18(2):152-60
[
18337653.001
]
[Cites]
J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S15-6
[
18801136.001
]
[Cites]
Am J Transplant. 2008 Sep;8(9):1891-900
[
18786232.001
]
[Cites]
Curr Opin Oncol. 2009 May;21(3):232-7
[
19370807.001
]
[Cites]
Transplantation. 1999 Dec 15;68(11):1717-21
[
10609948.001
]
[Cites]
J Am Acad Dermatol. 2000 Feb;42(2 Pt 1):307
[
10642700.001
]
[Cites]
Br J Dermatol. 2000 Sep;143(3):513-9
[
10971322.001
]
[Cites]
J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S2-4
[
18801139.001
]
[Cites]
ScientificWorldJournal. 2008 Sep 21;8:909-19
[
18836658.001
]
[Cites]
Br J Dermatol. 2007 May;156 Suppl 3:40-2
[
17488405.001
]
[Cites]
J Am Acad Dermatol. 2005 Nov;53(5):783-90
[
16243126.001
]
[Cites]
Am J Transplant. 2006 Sep;6(9):2164-8
[
16780549.001
]
[Cites]
Transplantation. 2009 Aug 27;88(4):597-8
[
19696647.001
]
[Cites]
Cancer. 2007 Jul 1;110(1):1-12
[
17520670.001
]
[Cites]
Dermatol Surg. 2009 Oct;35(10):1567-72
[
19681993.001
]
[Cites]
Am J Transplant. 2008 Nov;8(11):2192-8
[
18782290.001
]
[Cites]
Dermatol Surg. 2002 Feb;28(2):113-7; discussion 117
[
11860419.001
]
[Cites]
J Invest Dermatol. 2006 Mar;126(3):569-74
[
16374480.001
]
[Cites]
Transplantation. 2006 Dec 27;82(12):1792-3
[
17198278.001
]
[Cites]
Br J Dermatol. 2008 Jul;159(1):35-48
[
18593385.001
]
[Cites]
N Engl J Med. 2003 Apr 24;348(17):1681-91
[
12711744.001
]
[Cites]
Am J Transplant. 2004 Jun;4(6):905-13
[
15147424.001
]
[Cites]
J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S19-24
[
18801138.001
]
[Cites]
J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S9-S14
[
18801142.001
]
[Cites]
J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S5-8
[
18801141.001
]
[Cites]
Transplantation. 1990 Mar;49(3):506-9
[
2316011.001
]
[Cites]
Nat Clin Pract Oncol. 2008 Sep;5(9):510-1
[
18679393.001
]
[Cites]
J Am Acad Dermatol. 2008 Sep;59(3):405-17
[
18556089.001
]
[Cites]
Transplant Proc. 1988 Jun;20(3 Suppl 3):885-92
[
3388524.001
]
[Cites]
Melanoma Res. 2008 Feb;18(1):61-7
[
18227710.001
]
[Cites]
Swiss Med Wkly. 2009 Jul 25;139(29-30):407-15
[
19680830.001
]
[Cites]
Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50
[
15061849.001
]
[Cites]
J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20
[
12077575.001
]
[Cites]
Transplantation. 1997 Sep 15;64(5):669-73
[
9311700.001
]
[Cites]
J Clin Microbiol. 2001 Feb;39(2):506-8
[
11158097.001
]
[Cites]
Br J Dermatol. 2006 Aug;155(2):451-4
[
16882188.001
]
[Cites]
J Clin Oncol. 2006 Jun 10;24(17):2659-65
[
16763280.001
]
[Cites]
Transplantation. 2004 Feb 27;77(4):574-9
[
15084938.001
]
[Cites]
Br J Dermatol. 2007 Dec;157 Suppl 2:25-31
[
18067628.001
]
[Cites]
Dermatol Surg. 2004 Apr;30(4 Pt 2):622-7
[
15061846.001
]
[Cites]
Transplantation. 1996 Mar 15;61(5):715-21
[
8607173.001
]
[Cites]
N Engl J Med. 2006 Feb 9;354(6):567-78
[
16467544.001
]
[Cites]
Clin Oncol (R Coll Radiol). 2007 Jun;19(5):365-6
[
17379490.001
]
[Cites]
Br J Dermatol. 2007 Dec;157(6):1183-8
[
17916206.001
]
[Cites]
Arch Dermatol. 2001 Apr;137(4):459-63
[
11295926.001
]
(PMID = 20145902.001).
[ISSN]
1432-1173
[Journal-full-title]
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
[ISO-abbreviation]
Hautarzt
[Language]
ger
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Germany
[Chemical-registry-number]
0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
67.
Kummoona R:
Periorbital and orbital malignancies: methods of management and reconstruction in Iraq.
J Craniofac Surg
; 2007 Nov;18(6):1370-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Tumor
types were
squamous
cell carcinoma
,
basal cell carcinoma
, conjunctival
squamous
cell carcinoma
, retinoblastoma, fibrosarcoma, and ectopic
mixed tumor
in two, one, two, one, one, and one patients, respectively, in addition to eight patients with jaw lymphoma involving the orbit, out of 24 patients reported by us.
Surgery consisted of complete excision of orbital content (exenteration) with or without partial orbitectomy in four patients and wide excision of the
tumor
in four patients.
Reconstruction of the defect was accomplished using various local
skin
flaps and temporalis muscle flap was used for augmenting the orbit in the four exenterated patients.
There is no single best method for reconstruction of the periorbital and orbital defects left after
tumor
resection, and different flaps applied for reconstruction had given satisfactory results related to the type and complexity of the deformity.
[MeSH-minor]
Adolescent. Adult. Aged.
Carcinoma
,
Squamous
Cell
/ radiotherapy.
Carcinoma
,
Squamous
Cell
/ surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Eye Enucleation. Female. Humans. Infant. Iraq. Lymphoma / chemistry. Lymphoma / surgery. Male. Middle Aged. Radiotherapy, Adjuvant.
Skin
Transplantation
MedlinePlus Health Information.
consumer health - Plastic and Cosmetic Surgery
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17993883.001).
[ISSN]
1049-2275
[Journal-full-title]
The Journal of craniofacial surgery
[ISO-abbreviation]
J Craniofac Surg
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
68.
Rodríguez-Domínguez FJ, Hernández-Gil J, Segarra Fenoll JD, Hernández-Gil A:
[Facial mutilant basosquamous carcinoma].
An Otorrinolaringol Ibero Am
; 2007;34(6):549-55
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Facial mutilant
basosquamous
carcinoma
].
[Transliterated title]
Carcinoma
basoescamoso
mutilante en región facial.
Basosquamous
carcinoma
is a rare epithelial
malignant neoplasm
with clinical and biological features of both
basal
and squamous
cell carcinoma
.
This
neoplasm
has been characterized for years as a variant
of basal cell carcinoma
, although now it is widely accepted as a clinical entity.
The most important features of
basosquamous
carcinoma
are its great local aggressiveness, high frequency of recurrences and its metastatic potential.
[MeSH-major]
Carcinoma
,
Basosquamous
/ pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods
[MeSH-minor]
Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged.
Neoplasm
Invasiveness.
Neoplasm
Staging
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Palliative Care
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18293774.001).
[ISSN]
0303-8874
[Journal-full-title]
Anales otorrinolaringológicos ibero-americanos
[ISO-abbreviation]
An Otorrinolaringol Ibero Am
[Language]
spa
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Spain
[Chemical-registry-number]
0 / Anti-Bacterial Agents
69.
Tichý M, Ditrichová D, Brychtová S, Tichá V, Urbánek J:
Double skin tumors with an atypical clinical picture.
Acta Dermatovenerol Alp Pannonica Adriat
; 2007 Jun;16(2):63-6
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Double
skin
tumors with an atypical clinical picture.
The authors present a rare case of double
skin
tumors: acral lentiginous melanoma and
metatypical carcinoma
.
The
skin
biopsies showed advanced acral lentiginous melanoma on the sole and
metatypical carcinoma
of the lower leg.
Soon after the
diagnosis
was made, the melanoma generalized.
The article discusses the differential
diagnosis
of both leg ulcerations, correct diagnostic procedures, and characteristic features of both tumors that are important questions for general practitioners, dermatologists, and surgeons.
[MeSH-major]
Carcinoma
/
diagnosis
. Leg Ulcer / etiology. Melanoma /
diagnosis
. Neoplasms, Multiple Primary /
diagnosis
.
Skin
Neoplasms /
diagnosis
[MeSH-minor]
Aged.
Diagnosis
, Differential. Foot Ulcer / etiology. Humans. Male
MedlinePlus Health Information.
consumer health - Leg Injuries and Disorders
.
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17992460.001).
[ISSN]
1318-4458
[Journal-full-title]
Acta dermatovenerologica Alpina, Pannonica, et Adriatica
[ISO-abbreviation]
Acta Dermatovenerol Alp Pannonica Adriat
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Slovenia
70.
Kolm I, Hofbauer G, Braun RP:
[Early diagnosis of skin cancer].
Ther Umsch
; 2010 Sep;67(9):439-46
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Early
diagnosis
of skin
cancer].
The
skin
is the most affected organ by cancer.
The incidence rates
of skin
cancer are steadily increasing, both for melanoma and non-melanoma
skin
cancers (
squamous
cell carcinoma
,
basal cell carcinoma
).
Over 90 % of the death cases from
skin
cancers attribute to melanoma.
In the last years a number of new non invasive techniques for the early
diagnosis
of melanoma have been developed which are superior to the naked eye examination.
In this overview article we present some non-invasive diagnostic techniques like total body photography, digital dermoscopy and confocal microscopy which in addition to dermoscopy assist the dermatologist in differentiating nevi from early melanomas.Non-melanoma
skin
cancer can be prevented by accurate sun protection.
Early
squamous
cell
carcinomas and
basal cell
carcinomas
can be treated either invasively or non-invasively with excellent prognosis.
[MeSH-major]
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Basal Cell
/ prevention & control.
Carcinoma
,
Squamous
Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/ prevention & control. Melanoma /
diagnosis
. Melanoma / prevention & control. Precancerous Conditions /
diagnosis
. Precancerous Conditions / prevention & control.
Skin
Neoplasms /
diagnosis
.
Skin
Neoplasms / prevention & control
[MeSH-minor]
Dermoscopy. Early
Diagnosis
. Humans. Microscopy, Confocal. Photography. Risk Factors.
Skin
/ pathology
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20806172.001).
[ISSN]
0040-5930
[Journal-full-title]
Therapeutische Umschau. Revue thérapeutique
[ISO-abbreviation]
Ther Umsch
[Language]
ger
[Publication-type]
English Abstract; Journal Article; Review
[Publication-country]
Switzerland
71.
Dixon A, Rosengren H, Connelly T, Dixon J:
Education in skin cancer management--assessing knowledge and safety.
Aust Fam Physician
; 2009 Jul;38(7):557-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Education in
skin
cancer management--assessing knowledge and safety.
BACKGROUND: General practitioners manage the majority
of skin
cancers in Australia.
There are a range of training opportunities for, and certifications in,
skin
cancer management.
METHOD: Between 15 June and 25 June 2008, an online examination was placed on the Australasian College
of Skin
Cancer Medicine website.
Thirty questions were asked pertaining to the management of a hypothetical case study including melanoma,
basal cell carcinoma
and squamous
cell carcinoma
.
Two days of training may not make doctors sufficiently safe in
skin
cancer management; it appeared to improved knowledge, but not to a point where unsafe practice was eliminated.
[MeSH-major]
Family Practice / education.
Skin
Neoplasms /
diagnosis
.
Skin
Neoplasms / therapy
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19575076.001).
[ISSN]
0300-8495
[Journal-full-title]
Australian family physician
[ISO-abbreviation]
Aust Fam Physician
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Australia
72.
Hoang MP, Dresser KA, Kapur P, High WA, Mahalingam M:
Microcystic adnexal carcinoma: an immunohistochemical reappraisal.
Mod Pathol
; 2008 Feb;21(2):178-85
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Microcystic adnexal
carcinoma
: an immunohistochemical reappraisal.
Even though immunohistochemical comparisons of microcystic adnexal
carcinoma
vs infiltrative
basal cell carcinoma
and desmoplastic trichoepithelioma exist, they are mostly restricted to the use of a single stain.
In addition, a comparison with
squamous
cell carcinoma
has not been reported previously.
In this study, we compare the expression of cytokeratin (CK) 15, CK7, CK20, CK903, carcinoembryonic antigen (CEA), CD10, CD15 and BerEP4 in 13 microcystic adnexal
carcinoma
, eight desmoplastic trichoepithelioma, 10 infiltrative
basal cell carcinoma
, and eight
squamous
cell carcinoma
of which five exhibited ductal differentiation.
We found that the majority of microcystic adnexal
carcinoma
(92%) and desmoplastic trichoepithelioma (100%) cases expressed CK15 while the infiltrative
basal cell carcinoma
and squamous
cell carcinoma
cases were all negative.
Forty percent of infiltrative
basal cell carcinoma
expressed CK7; while only two microcystic adnexal
carcinoma
cases (15%) and one
squamous
cell carcinoma
with ductal differentiation (12%) expressed CK7 in the remaining three
tumor
categories.
While the neoplastic cells were negative, luminal staining of ductal structures was noted for CK7, CD15 and CEA in some of the microcystic adnexal
carcinoma
, desmoplastic trichoepithelioma
and squamous
cell carcinoma
with ductal differentiation cases.
Sixty percent of infiltrative
basal cell carcinoma
, 31% of microcystic adnexal
carcinoma
, and 25% of
squamous
cell carcinoma
express CD10.
BerEP4 expression was noted in 38% of microcystic adnexal
carcinoma
, 57% of desmoplastic trichoepithelioma, 100% of infiltrative
basal cell carcinoma
, and 38% of
squamous
cell carcinoma
.
In conclusion, we found CK15 to be a useful marker in distinguishing microcystic adnexal
carcinoma
from infiltrative
basal cell carcinoma
and squamous
cell carcinoma
with ductal differentiation.
Our experience indicates that microcystic adnexal
carcinoma
and desmoplastic trichoepithelioma have a similar immunohistochemical profile that is, CK15+ and BerEP4+/-; thus, additional studies are needed to separate these two entities.
[MeSH-major]
Biomarkers,
Tumor
/ analysis.
Carcinoma
,
Skin
Appendage / chemistry. Head and Neck Neoplasms / chemistry. Immunohistochemistry / methods.
Skin
Neoplasms / chemistry
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over.
Carcinoma
,
Basal Cell
/ chemistry.
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/ chemistry.
Carcinoma
,
Squamous
Cell
/
diagnosis
.
Diagnosis
, Differential. Female. Humans. Keratin-15 / analysis. Male. Middle Aged
Genetic Alliance.
consumer health - Microcystic adnexal carcinoma
.
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18065959.001).
[ISSN]
0893-3952
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Keratin-15; 0 / human epithelial antigen-125
73.
Skroza N, Panetta C, Schwartz RA, Balzani A, Rota C, Buccheri EM, Alfano C, Innocenzi D:
Giant meta-typical carcinoma: an unusual tumor.
Acta Dermatovenerol Croat
; 2006;14(1):46-51
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Giant meta-typical
carcinoma
: an unusual
tumor
.
Meta-typical
carcinoma
(MTC) or
basosquamous
carcinoma
is a remarkable malignancy with features of both
basal
and squamous
cell carcinoma
.
It is typically located on the back and face, often with clinical features
of basal cell carcinoma
but tending to be more aggressive with enhanced prospects of lymph node or distant metastases.
Our report describes a huge neglected MTC of the back of ten-year duration, a giant ulcero-vegetative
tumor
measuring 20 x 25 cm.
Histologic examination of specimens from the margins and periphery revealed aspects of both
basal
and squamous
cell carcinoma
, while the ulcerated center showed sclerotic tissue without
tumor
.
This may have been related to an intense inflammatory host response with elimination of neoplastic tissue and consequent local sclerosis evident in the central
tumor
-free portion.
This central
tumor
regression is to our knowledge a unique
finding
in MTC.
[MeSH-major]
Carcinoma
,
Squamous
Cell
/ pathology.
Skin
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16603102.001).
[ISSN]
1330-027X
[Journal-full-title]
Acta dermatovenerologica Croatica : ADC
[ISO-abbreviation]
Acta Dermatovenerol Croat
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
Croatia
74.
Hönigsmann H, Diepgen TL:
[UV-induced skin cancers].
J Dtsch Dermatol Ges
; 2005 Sep;3 Suppl 2:S26-31
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[UV-induced
skin
cancers].
In this review the epidemiology and pathogenetic aspects of UV-induced
malignant
skin
tumours (
basal cell carcinoma
,
squamous
cell carcinoma
and melanoma) are discussed with regard to current literature.
Whereas present knowledge, in particular, gained from experimental data, permits substantial conclusions about the development of
squamous
cell carcinoma
, the situation for
basal cell carcinoma
and melanoma does not appear to be unequivocally clear.
[MeSH-major]
Carcinoma
,
Basal Cell
/ etiology.
Carcinoma
,
Squamous
Cell
/ etiology. Melanoma / etiology. Neoplasms, Radiation-Induced / etiology.
Skin
Neoplasms / etiology. Ultraviolet Rays / adverse effects
[MeSH-minor]
Adolescent. Age Factors. Child. DNA Damage. DNA Repair. Humans. Risk Factors.
Skin
/ pathology. Sunburn / complications
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16117740.001).
[ISSN]
1610-0379
[Journal-full-title]
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
[ISO-abbreviation]
J Dtsch Dermatol Ges
[Language]
ger
[Publication-type]
Comparative Study; English Abstract; Journal Article; Review
[Publication-country]
Germany
[Number-of-references]
37
75.
Lehnerdt G, Manz D, Jahnke K, Schmitz KJ:
[Cutaneous basosquamous cell carcinoma].
HNO
; 2008 Mar;56(3):306-11
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Cutaneous
basosquamous
cell carcinoma
].
[Transliterated title]
Basosquamöses
Karzinom der Haut
.
BACKGROUND:
Basosquamous
carcinoma
(BSC) is a rare malignancy with specific histopathological features of both
basal cell
(
BCC
)
and squamous
cell carcinoma
(SCC).
Therefore, the histological
diagnosis
is challenging.
In the case of the
carcinoma
on the forehead, a local excision was performed.
CONCLUSIONS: The histological
diagnosis
of BSC is confirmed by the use of EMA and BerEP4 immunohistological staining.
Clinically, BSC is a rare, aggressive
skin
tumor
.
Despite the histological similarity to
basal cell carcinoma
, BSC has an imminent risk of metastasizing.
[MeSH-major]
Carcinoma
,
Basosquamous
/ pathology.
Carcinoma
,
Basosquamous
/ surgery. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures / methods.
Skin
Neoplasms / pathology.
Skin
Neoplasms / surgery
[MeSH-minor]
Aged. Aged, 80 and over.
Diagnosis
, Differential. Female. Humans. Male. Middle Aged. Treatment Outcome
MedlinePlus Health Information.
consumer health - Head and Neck Cancer
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Dermatol Online J. 2006 Oct 31;12(6):9
[
17083889.001
]
[Cites]
Clin Exp Dermatol. 2003 Jan;28(1):96-7
[
12558644.001
]
[Cites]
Laryngorhinootologie. 2005 Jul;84(7):482-6
[
16010628.001
]
[Cites]
Arch Pathol Lab Med. 2006 Jan;130(1):45-51
[
16390237.001
]
[Cites]
Br J Cancer. 1951 Jun;5(2):195-212
[
14869589.001
]
[Cites]
Histopathology. 2000 Sep;37(3):218-23
[
10971697.001
]
[Cites]
Arch Pathol. 1973 May;95(5):293-7
[
4694069.001
]
[Cites]
Dermatol Online J. 2006 Sep 08;12(5):7
[
16962022.001
]
[Cites]
Dermatol Surg. 2003 Aug;29(8):830-2; discussion 833
[
12859383.001
]
[Cites]
Cancer. 2000 Mar 15;88(6):1365-9
[
10717618.001
]
[Cites]
Tumori. 2002 Jan-Feb;88(1):48-52
[
12004850.001
]
[Cites]
HNO. 2002 Apr;50(4):370-8; quiz 378-9
[
12063698.001
]
[Cites]
HNO. 1988 Feb;36(2):84-7
[
3360629.001
]
[Cites]
Dermatol Surg. 1997 Mar;23(3):181-4
[
9145960.001
]
[Cites]
Int J Radiat Oncol Biol Phys. 2000 May 1;47(2):451-9
[
10802373.001
]
[Cites]
HNO. 2004 Jun;52(6):518-24
[
15257397.001
]
[Cites]
HNO. 2001 Apr;49(4):283-8
[
11382109.001
]
(PMID = 17464493.001).
[ISSN]
1433-0458
[Journal-full-title]
HNO
[ISO-abbreviation]
HNO
[Language]
ger
[Publication-type]
Clinical Trial; English Abstract; Journal Article
[Publication-country]
Germany
76.
McKnight CA, Wise AG, Maes RK, Howe C, Rector A, Van Ranst M, Kiupel M:
Papillomavirus-associated basosquamous carcinoma in an Egyptian fruit bat (Rousettus aegyptiacus).
J Zoo Wildl Med
; 2006 Jun;37(2):193-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Papillomavirus-associated
basosquamous
carcinoma
in an Egyptian fruit bat (Rousettus aegyptiacus).
Six additional variably sized, raised, smooth to cauliflower-like
skin
masses were observed randomly distributed throughout the left wing membranes.
Four masses were removed and diagnosed microscopically as
basosquamous carcinomas
and papillomas.
Additional masses, removed 6 mo and 1 yr later, showed bony invasion
and squamous
differentiation.
Polymerase chain reaction done on DNA extracts from formalin-fixed, paraffin-embedded
tumor
tissue amplified a 450 base-pair segment analogous to the L1 region of human papillomavirus types 96 and 5.
To our knowledge, this is the first report of papillomavirus-associated
carcinoma
in a chiropteran species.
[MeSH-major]
Carcinoma
,
Squamous
Cell
/ veterinary. Chiroptera / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary.
Skin
Neoplasms / veterinary
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 17312801.001).
[ISSN]
1042-7260
[Journal-full-title]
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
[ISO-abbreviation]
J. Zoo Wildl. Med.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
77.
Tarallo M, Cigna E, Frati R, Delfino S, Innocenzi D, Fama U, Corbianco A, Scuderi N:
Metatypical basal cell carcinoma: a clinical review.
J Exp Clin Cancer Res
; 2008;27:65
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Metatypical basal cell carcinoma
: a clinical review.
BACKGROUND:
Metatypical cell carcinoma
can be considered as a new entity
of skin
cancer, being an intermediate typology between
basal cell
carcinomas and squamous
cell
carcinomas
.
The behaviour of the
metatypical cell carcinoma
lies between these two varieties
of skin
cancer.
It is difficult to perform a differential
diagnosis
based on morphological and clinical features - therefore it is only possible by accurate histology.
METHODS: The authors have retrospectively analysed clinical records of 240 patients who were affected by
metatypical skin
cancer and who were treated by surgery, radiotherapy and chemotherapy.
CONCLUSION: In this manuscript, the authors have emphasised the importance of conducting a differential
diagnosis
, and the importance of the specific treatment for
metatypical skin
cancer, even though more clinical studies and long-term follow-ups are required before establishing specific guidelines.
[MeSH-major]
Carcinoma
,
Basal Cell
/ pathology.
Skin
Neoplasms / pathology
MedlinePlus Health Information.
consumer health - Skin Cancer
.
The Weizmann Institute of Science GeneCards and MalaCards databases.
gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Am Acad Dermatol. 2001 Feb;44(2):224-30
[
11174379.001
]
[Cites]
Plast Reconstr Surg. 2001 Apr 1;107(4):942-7
[
11252086.001
]
[Cites]
Plast Reconstr Surg. 2002 Apr 1;109(4):1466-7
[
11965016.001
]
[Cites]
Br J Dermatol. 2002 Apr;146 Suppl 61:1-6
[
11966724.001
]
[Cites]
Virchows Arch. 2002 Dec;441(6):551-8
[
12461611.001
]
[Cites]
Otolaryngol Head Neck Surg. 2003 May;128(5):663-73
[
12748559.001
]
[Cites]
Dermatol Surg. 2003 Jul;29(7):700-11
[
12828693.001
]
[Cites]
Dermatol Surg. 2003 Aug;29(8):830-2; discussion 833
[
12859383.001
]
[Cites]
J Craniomaxillofac Surg. 2004 Feb;32(1):16-8
[
14729044.001
]
[Cites]
Dermatol Surg. 2004 Feb;30(2 Pt 2):248-52
[
14871217.001
]
[Cites]
Br J Ophthalmol. 2004 Mar;88(3):358-60
[
14977769.001
]
[Cites]
Acta Derm Venereol. 2004;84(1):44-7
[
15040477.001
]
[Cites]
Arch Facial Plast Surg. 2004 May-Jun;6(3):158-61
[
15148122.001
]
[Cites]
Br J Oral Maxillofac Surg. 2004 Aug;42(4):311-4
[
15225948.001
]
[Cites]
Arch Dermatol. 1965 Dec;92(6):635-7
[
5846318.001
]
[Cites]
Br J Dermatol. 1973 Jul;89(1):37-43
[
4788317.001
]
[Cites]
Ophthalmologica. 1983;187(1):51-8
[
6877760.001
]
[Cites]
Arkh Patol. 1983;45(6):35-9
[
6625927.001
]
[Cites]
J Am Acad Dermatol. 1984 Oct;11(4 Pt 1):557-62
[
6490979.001
]
[Cites]
Dermatologica. 1985;171(1):21-6
[
2411609.001
]
[Cites]
Arch Dermatol. 1987 Mar;123(3):340-4
[
3813602.001
]
[Cites]
J Dermatol Surg Oncol. 1987 May;13(5):556-7
[
3571694.001
]
[Cites]
J Dermatol Surg Oncol. 1988 Jun;14(6):600-2
[
3372843.001
]
[Cites]
Dermatol Clin. 1988 Jul;6(3):397-405
[
3048822.001
]
[Cites]
Mod Pathol. 1991 May;4(3):325-30
[
2068058.001
]
[Cites]
J Am Acad Dermatol. 1992 Jan;26(1):1-26
[
1732313.001
]
[Cites]
Pathol Res Pract. 1991 Dec;187(8):978-85
[
1792194.001
]
[Cites]
J Am Acad Dermatol. 1992 Jun;26(6):976-90
[
1607418.001
]
[Cites]
J Am Acad Dermatol. 1992 Aug;27(2 Pt 1):241-8
[
1430364.001
]
[Cites]
J Invest Dermatol. 1994 Jun;102(6):6S-9S
[
8006441.001
]
[Cites]
Cancer. 1995 Jan 15;75(2 Suppl):667-73
[
7804993.001
]
[Cites]
Arkh Patol. 1994 Jul-Aug;56(4):35-8
[
7848103.001
]
[Cites]
Ann Chir Plast Esthet. 1994 Apr;39(2):176-83
[
7872634.001
]
[Cites]
Am J Surg. 1995 Nov;170(5):446-50
[
7485729.001
]
[Cites]
Laryngoscope. 1996 Feb;106(2 Pt 1):156-8
[
8583845.001
]
[Cites]
Am J Dermatopathol. 1996 Feb;18(1):35-42
[
8721589.001
]
[Cites]
Neurosurgery. 1997 Jul;41(1):279-81; discussion 281-2
[
9218319.001
]
[Cites]
J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):430-7
[
9308559.001
]
[Cites]
Clin Plast Surg. 1997 Oct;24(4):627-36
[
9342506.001
]
[Cites]
Clin Plast Surg. 1997 Oct;24(4):673-86
[
9342510.001
]
[Cites]
J Cutan Pathol. 1998 Mar;25(3):153-9
[
9550314.001
]
[Cites]
Br J Plast Surg. 1999 Jan;52(1):24-8
[
10343586.001
]
[Cites]
Lancet. 2004 Nov 13-19;364(9447):1766-72
[
15541449.001
]
[Cites]
Semin Cutan Med Surg. 2004 Sep;23(3):167-73
[
15584682.001
]
[Cites]
Cancer. 2005 Jul 1;104(1):170-5
[
15929123.001
]
[Cites]
Br J Plast Surg. 2005 Sep;58(6):795-805
[
16086990.001
]
[Cites]
J Am Acad Dermatol. 2005 Sep;53(3):464-8
[
16112354.001
]
[Cites]
J Plast Reconstr Aesthet Surg. 2007;60(1):41-7
[
17126265.001
]
[Cites]
Eur J Dermatol. 2000 Jun;10(4):315-6
[
10939863.001
]
[Cites]
Br J Oral Maxillofac Surg. 2000 Oct;38(5):477-9
[
11010777.001
]
[Cites]
J Natl Compr Canc Netw. 2004 Jan;2(1):2
[
19777690.001
]
(PMID = 18992138.001).
[ISSN]
1756-9966
[Journal-full-title]
Journal of experimental & clinical cancer research : CR
[ISO-abbreviation]
J. Exp. Clin. Cancer Res.
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
Italy
[Number-of-references]
55
[Other-IDs]
NLM/ PMC2585560
78.
Schouten HW, Knippels MC, Franken RJ:
[Maggots in the wound, debridement, disinfection and wound healing].
Ned Tijdschr Geneeskd
; 2009;153:A624
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Transliterated title]
Vliegenmaden in
de
wond: débridement, desinfectie en wondgenezing.
An 87-year-old man had a longstanding untreated large
basosquamous
carcinoma
on his right ear.
A striking
finding
was that the smell of the wound had disappeared and that the wound was much cleaner, with a reddish aspect and less necrosis.
[MeSH-minor]
Aged, 80 and over. Animals.
Carcinoma
,
Basosquamous
/ complications.
Carcinoma
,
Basosquamous
/ parasitology.
Carcinoma
,
Basosquamous
/ surgery. Ear Neoplasms / complications. Ear Neoplasms / parasitology. Ear Neoplasms / surgery. Humans. Larva. Male. Treatment Outcome
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19900320.001).
[ISSN]
1876-8784
[Journal-full-title]
Nederlands tijdschrift voor geneeskunde
[ISO-abbreviation]
Ned Tijdschr Geneeskd
[Language]
dut
[Publication-type]
Case Reports; English Abstract; Journal Article
[Publication-country]
Netherlands
79.
Akyol M, Ozçelik S:
Non-acne dermatologic indications for systemic isotretinoin.
Am J Clin Dermatol
; 2005;6(3):175-84
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Diseases such as psoriasis, pityriasis rubra pilaris, condylomata acuminata,
skin
cancers, rosacea, hidradenitis suppurativa, granuloma annulare, lupus erythematosus and lichen planus have been shown to respond to the immunomodulatory, anti-inflammatory and antitumor activities of the drug.
Isotretinoin also helps prevent
skin
cancers such as
basal cell carcinoma
or
squamous
cell carcinoma
.
A combination of systemic isotretinoin and interferon-alpha-2a may provide a more potent effect than isotretinoin alone in the prevention and treatment
of skin
cancers.Systemic isotretinoin may be considered as an alternative drug in some dermatologic diseases unresponsive to conventional treatment modalities.
[MeSH-major]
Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Dermatologic Agents / therapeutic use. Isotretinoin / therapeutic use.
Skin
Diseases / drug therapy
[MeSH-minor]
Acne Vulgaris / drug therapy. Anti-Bacterial Agents / therapeutic use. Condylomata Acuminata / drug therapy. Drug Therapy, Combination. Granuloma Annulare / drug therapy. Hidradenitis Suppurativa / drug therapy. Humans. Keratolytic Agents / therapeutic use. Lichen Planus / drug therapy. Lupus Erythematosus, Systemic / drug therapy. Pityriasis Rubra Pilaris / drug therapy. Psoriasis / drug therapy. Rosacea / drug therapy. Sebaceous Glands / drug effects.
Skin
Neoplasms / drug therapy
MedlinePlus Health Information.
consumer health - Skin Conditions
.
Hazardous Substances Data Bank.
13-CIS-RETINOIC ACID
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15943494.001).
[ISSN]
1175-0561
[Journal-full-title]
American journal of clinical dermatology
[ISO-abbreviation]
Am J Clin Dermatol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
New Zealand
[Chemical-registry-number]
0 / Anti-Bacterial Agents; 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents; 0 / Keratolytic Agents; EH28UP18IF / Isotretinoin
[Number-of-references]
133
80.
Ishihara K, Saida T, Otsuka F, Yamazaki N, Prognosis and Statistical Investigation Committee of the Japanese Skin Cancer Society:
Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update.
Int J Clin Oncol
; 2008 Feb;13(1):33-41
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Statistical profiles of
malignant
melanoma and other
skin
cancers in Japan: 2007 update.
BACKGROUND: In the previous report of the Prognosis and Statistical Investigation Committee of the Japanese
Skin
Cancer Society, we tabulated data on patients with
malignant
melanoma who had been registered at major medical institutions (22 institutions on average) in Japan over 5-year periods from 1987 to 1991 (group A) and from 1992 to 1996 (group B).
In the present study, patients registered from 1997 to 2001 (group C) were investigated and the data were compared with findings obtained by the subsequent follow-up of groups
A and
B.
Because the International Union Against Cancer (UICC) TNM and stage classifications for
malignant
melanoma were changed substantially in 2002, analyses in the present investigation were performed according to the new classifications.
In addition, the numbers of patients with various kinds
of skin
malignancies, including not only
malignant
melanoma but also
basal cell carcinoma
,
squamous
cell carcinoma
, mycosis fungoides, actinic keratosis, Bowen's
disease
, and Paget's
disease
, registered at approximately 100 medical institutions in Japan from 1987 to 2001, were also investigated and data were tabulated.
RESULTS: The nationwide survey of Japanese patients with
malignant
skin
tumors from 1987 to 2001 showed that the most prevalent
skin
tumor
was
basal cell carcinoma
, which increased year by year, followed by
squamous
cell carcinoma
, and then by
malignant
melanoma.
The following results were obtained from the data for melanoma patients registered at major institutions from 1987 to 2001. (1) The overall 10-year survival rates for melanoma patients in each chronological group were ranked as: group C > B > A, although only the difference between groups
C and
A was statistically significant. (2) The male-to-female ratio ranged from 1: 0.97 to 1: 1.14, and the survival rate of female patients was higher than that of male patients (the 140-month survival rate was 70.6% in females and 60% in males). (3) Assessment of the age distribution showed that the number of patients increased rapidly from ages 40-49 years and reached a peak at around 60 years in all three groups. (4) The sole of the foot was the most common site of melanoma in both males and females, while melanomas on the lower limbs were also prevalent in females. (5) Acral lentiginous melanoma (ALM) was the most common type in all three groups, accounting for nearly 50% of the patients in each group.
The prognosis of NM was the worst, while that of SSM was the most favorable. (6) The proportion of stage I patients was larger in group C than in groups
A and
B, but no significant difference among the groups was observed in the proportions of stage II, III, and IV patients.
For patients in stage IV, the survival rate in group C was slightly lower than that in group A or B. (7) In group C, the overall survival rates for substages III A, B,
and C
were ranked as III A > III B > III C. (8) The overall survival rates for stage IV M1a, M1b, and M1c were ranked as M1a > M1b > M1c.
CONCLUSION: In Japan, the number of patients with
malignant
skin
tumors has increased year by year.
The prognosis of patients with advanced
malignant
melanoma remains extremely poor, but that of patients in stage III has shown an improvement.
[MeSH-major]
Melanoma / epidemiology.
Skin
Neoplasms / epidemiology
MedlinePlus Health Information.
consumer health - Melanoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Int J Epidemiol. 1995 Oct;24(5):897-907
[
8557445.001
]
[Cites]
Int J Clin Oncol. 2003 Jun;8(3):139-50
[
12851837.001
]
[Cites]
Int J Clin Oncol. 2001 Jun;6(3):109-16
[
11706778.001
]
[Cites]
Cancer. 2000 Mar 15;88(6):1484-91
[
10717634.001
]
[Cites]
J Clin Oncol. 2001 Aug 15;19(16):3635-48
[
11504745.001
]
[Cites]
Harefuah. 1995 Jun 15;128(12):745-51, 824
[
7557679.001
]
(PMID = 18307017.001).
[ISSN]
1341-9625
[Journal-full-title]
International journal of clinical oncology
[ISO-abbreviation]
Int. J. Clin. Oncol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Japan
81.
Malejczyk M, Józwiak J, Jablonska S, Pfister H, Majewski S, Malejczyk J:
Circulating soluble tumour necrosis factor receptors in patients with epidermodysplasia verruciformis as compared to patients with cutaneous tumours in the general population.
Oncol Rep
; 2005 Jan;13(1):151-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Soluble tumour necrosis factor receptors type I and II (sTNF-RI and II) were evaluated in sera from patients with epidermodysplasia verruciformis and patients with cutaneous warts, actinic keratoses,
squamous
cell
carcinomas
or
basal cell
carcinomas
by specific enzyme-linked immunobiological assays.
The levels of sTNF-RI were significantly increased in patients with multiple actinic keratoses,
squamous
cell carcinoma
and
basal cell carcinoma
.
[MeSH-major]
Epidermodysplasia Verruciformis /
diagnosis
. Receptors,
Tumor
Necrosis Factor, Type I / blood. Receptors,
Tumor
Necrosis Factor, Type II / blood
[MeSH-minor]
Adult. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged.
Skin
Neoplasms /
diagnosis
.
Skin
Neoplasms / metabolism
Genetic Alliance.
consumer health - Epidermodysplasia Verruciformis
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15583817.001).
[ISSN]
1021-335X
[Journal-full-title]
Oncology reports
[ISO-abbreviation]
Oncol. Rep.
[Language]
eng
[Publication-type]
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Greece
[Chemical-registry-number]
0 / Receptors, Tumor Necrosis Factor, Type I; 0 / Receptors, Tumor Necrosis Factor, Type II
82.
Sengupta SR, Das NK, Datta PK:
Pathogenesis, clinical features and pathology of chronic arsenicosis.
Indian J Dermatol Venereol Leprol
; 2008 Nov-Dec;74(6):559-70
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
Arsenicosis is a multisystem
disorder
, with virtually no system spared from its vicious claw; though its predominant manifestations are linked to cutaneous involvement.
Cutaneous effects take the form of pigmentary changes, hyperkeratosis, and
skin
cancers (Bowen's
disease
,
squamous
cell carcinoma
, and
basal cell
epithelioma).
Peripheral vascular
disease
(blackfoot
disease
), hypertension, ischemic heart
disease
, noncirrhotic portal hypertension, hepatomegaly, peripheral neuropathy, respiratory and renal involvement, bad obstetrical outcome, hematological disturbances, and diabetes mellitus are among the other clinical features linked to arsenic toxicity.
Understandably the detoxification/bio-inactivation process is not a complete defense against the vicious metalloid, and it can cause chromosomal aberration, impairment of DNA repair process, alteration in the activity of
tumor
suppressor gene, etc., leading to genotoxicity and carcinogenicity.
Increased expression of cytokeratins, keratin-16 (marker for hyperproliferation) and keratin-8 and -18 (marker for less differentiated epithelial cells), can be related to the histopathological findings of hyperkeratosis and dysplastic cells in the arsenicosis
skin
lesion.
[MeSH-major]
Arsenic Poisoning / epidemiology. Arsenic Poisoning / pathology.
Skin
Diseases / epidemiology.
Skin
Diseases / pathology
[MeSH-minor]
Animals. Arsenic / adverse effects. Chronic
Disease
. Environmental Exposure / adverse effects. Humans. Water Pollutants / adverse effects. World Health Organization
MedlinePlus Health Information.
consumer health - Arsenic
.
MedlinePlus Health Information.
consumer health - Skin Conditions
.
Hazardous Substances Data Bank.
ARSENIC, ELEMENTAL
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19171978.001).
[ISSN]
0973-3922
[Journal-full-title]
Indian journal of dermatology, venereology and leprology
[ISO-abbreviation]
Indian J Dermatol Venereol Leprol
[Language]
eng
[Publication-type]
Journal Article; Review
[Publication-country]
India
[Chemical-registry-number]
0 / Water Pollutants; N712M78A8G / Arsenic
[Number-of-references]
115
83.
Rollison DE, Pawlita M, Giuliano AR, Iannacone MR, Sondak VK, Messina JL, Cruse CW, Fenske NA, Glass LF, Kienstra M, Michael KM, Waterboer T, Gheit T, Tommasino M:
Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma skin cancers.
Int J Cancer
; 2008 Nov 15;123(10):2337-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Measures of cutaneous human papillomavirus infection in normal tissues as biomarkers of HPV in corresponding nonmelanoma
skin
cancers.
Cutaneous human papillomavirus (HPV) may be associated with the development of nonmelanoma
skin
cancer (NMSC), as suggested by reports of HPV DNA in NMSC tumors.
NMSC
tumor
tissue was obtained from 20 patients with pathology-confirmed
basal
or
squamous
cell carcinoma
of the
skin
, in addition to several normal tissues, including eyebrow hairs, normal
skin
swabs obtained using multiple techniques, normal
skin
punch and shave biopsies, and serum for antibody measurement.
Using HPV DNA in
tumor
tissues as a gold standard, sensitivity and specificity were calculated for each measure of HPV infection in normal tissues. beta-Papillomavirus DNA was observed in
tumor
tissues in 60% of patients.
The normal
skin
punch biopsy demonstrated optimal sensitivity (75%) and specificity (75%).
[MeSH-major]
Biomarkers / metabolism. Papillomavirus Infections / virology.
Skin
Diseases, Viral / virology.
Skin
Neoplasms / virology
[MeSH-minor]
Betapapillomavirus / isolation & purification.
Carcinoma
,
Basal Cell
/ metabolism.
Carcinoma
,
Basal Cell
/ virology.
Carcinoma
,
Squamous
Cell
/ metabolism.
Carcinoma
,
Squamous
Cell
/ virology. Enzyme-Linked Immunosorbent Assay. Humans. Risk Factors
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
(c) 2008 Wiley-Liss, Inc.
(PMID = 18729188.001).
[ISSN]
1097-0215
[Journal-full-title]
International journal of cancer
[ISO-abbreviation]
Int. J. Cancer
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers
84.
Heneghan MK, Hazan C, Halpern AC, Oliveria SA:
Skin cancer coverage in a national newspaper: a teachable moment.
J Cancer Educ
; 2007;22(2):99-104
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Skin
cancer coverage in a national newspaper: a teachable moment.
BACKGROUND: The objectives of this study were to (1) identify the number of published articles related to
skin
cancer in The New York Times newspaper from 1980-2004;.
(2) assess the content of the articles related to
skin
cancer, and (3) examine the trends in media coverage
of skin
cancer over time.
METHODS: We performed a content analysis on articles related to
skin
cancer appearing in The New York Times during January 1, 1980, through December 31, 2004, using the ProQuest online content repository database and key words
skin
cancer.
We conducted an advanced focus search of all "
skin
cancer" articles using key words "melanoma," "
squamous
cell carcinoma
," "
basal cell carcinoma
," "sunscreen," "tanning," "sunbathing," and "tanning salon".
RESULTS: We identified 874 published articles relating to
skin
cancer.
Coverage of other major subjects included sunscreen (11%), tanning (9%),
basal cell carcinoma
(7%),
squamous
cell carcinoma
(3%), sunbathing (2%), and tanning salon (2%).
The remaining 37% of articles contained some mention
of skin
cancer, but
skin
cancer was not the main topic nor were any of the focus terms.
Over the 25-year period we examined, there was a slight upward trend in the number
of skin
-cancer-related articles, although we observed year-to-year variation.
CONCLUSIONS: Understanding how the print media portrays
skin
cancer issues provides valuable feedback for federal agencies and cancer organizations and may ultimately help promote
skin
cancer prevention and education.
[MeSH-major]
Bibliometrics. Health Education. Journalism, Medical. Newspapers as Topic.
Skin
Neoplasms / prevention & control
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Health Commun. 2000 Apr-Jun;5(2):117-34
[
11010345.001
]
[Cites]
Breast Cancer Res Treat. 2000 Jul;62(1):71-9
[
10989987.001
]
[Cites]
Am J Public Health. 1989 Nov;79(11):1551-2
[
2683815.001
]
[Cites]
AIDS Educ Prev. 1992 Winter;4(4):295-307
[
1472415.001
]
[Cites]
Adolescence. 1996 Summer;31(122):253-64
[
8726887.001
]
[Cites]
J Am Acad Dermatol. 1986 Apr;14(4):676-9
[
3958278.001
]
[Cites]
J Commun. 1975 Summer;25(3):171-3
[
1184780.001
]
[Cites]
J Am Acad Dermatol. 1997 Aug;37(2 Pt 1):179-86
[
9270501.001
]
[Cites]
Arch Dermatol. 2005 Apr;141(4):491-6
[
15837868.001
]
[Cites]
Addiction. 1997 Jun;92 Suppl 2:S189-99
[
9231444.001
]
[Cites]
Prev Med. 2005 Aug;41(2):511-20
[
15917047.001
]
[Cites]
Clin Exp Dermatol. 1993 Sep;18(5):396-400
[
8252756.001
]
[Cites]
Am J Prev Med. 2004 Jul;27(1):57-65
[
15212776.001
]
[Cites]
Health Educ Q. 1996 Aug;23(3):346-64
[
8841819.001
]
[Cites]
Public Health Rep. 1982 Mar-Apr;97(2):113-5
[
7063590.001
]
[Cites]
J Womens Health Gend Based Med. 2000 Jun;9(5):471-5
[
10883937.001
]
[Cites]
J Am Acad Dermatol. 1996 Jun;34(6):971-8
[
8647990.001
]
[Cites]
Prev Med. 1992 Sep;21(5):654-69
[
1438112.001
]
[Cites]
Arch Intern Med. 1989 Jan;149(1):140-4
[
2912403.001
]
[Cites]
N Engl J Med. 1991 Oct 17;325(16):1180-3
[
1891034.001
]
[Cites]
J Am Diet Assoc. 1977 Nov;71(5):505-9
[
615901.001
]
[Cites]
Am J Public Health. 1992 Oct;82(10):1374-6
[
1415863.001
]
[Cites]
J Community Health. 1992 Jun;17(3):153-65
[
1512306.001
]
[Cites]
J Clin Epidemiol. 1993 Sep;46(9):987-1001
[
8263584.001
]
[Cites]
Eval Rev. 1996 Aug;20(4):404-23
[
10183257.001
]
[Cites]
Arch Intern Med. 2003 Jul 14;163(13):1601-5
[
12860585.001
]
[Cites]
Lancet. 1996 Jun 8;347(9015):1600-3
[
8667872.001
]
[Cites]
J Pediatr Psychol. 1994 Feb;19(1):3-17; discussion 19-26
[
8151494.001
]
[Cites]
Tob Control. 2003 Sep;12 Suppl 2:ii75-81
[
12878777.001
]
[Cites]
J Am Acad Dermatol. 1999 Jul;41(1):81-99
[
10411417.001
]
[Cites]
CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
[
17237035.001
]
[Cites]
N Engl J Med. 1998 Jul 9;339(2):87-92
[
9654540.001
]
[Cites]
JAMA. 1998 Mar 11;279(10):762-6
[
9508152.001
]
(PMID = 17605623.001).
[ISSN]
0885-8195
[Journal-full-title]
Journal of cancer education : the official journal of the American Association for Cancer Education
[ISO-abbreviation]
J Cancer Educ
[Language]
eng
[Grant]
United States / NCI NIH HHS / CA / K07 CA94002
[Publication-type]
Journal Article; Research Support, N.I.H., Extramural
[Publication-country]
England
85.
Kim GK, Del Rosso JQ, Bellew S:
Skin cancer in asians: part 1: nonmelanoma skin cancer.
J Clin Aesthet Dermatol
; 2009 Aug;2(8):39-42
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Skin
cancer in asians: part 1: nonmelanoma
skin
cancer.
Since the 1960s,
basal cell carcinoma
and squamous
cell carcinoma
among the Caucasian population have increased 3 to 8 percent annually.
Although Asians display relative protection from
basal cell carcinoma
and squamous
cell carcinoma
, incidence rates of these nonmelanoma
skin
cancers have been increasing over the past three decades.
With changing demographics
and a
steady rise in the minority population in the United States, there is an increased need for further studies of cutaneous malignancies within Asian and other ethnic populations.
This article reviews nonmelanoma
skin
cancers in the Asian population with an insight into contributing factors, such as
skin
type, occupation, cultural practices, and genetic components.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
Photochem Photobiol. 2008 Jan-Feb;84(1):63-6
[
18173702.001
]
[Cites]
Science. 1991 Jul 5;253(5015):49-53
[
1905840.001
]
[Cites]
J Am Acad Dermatol. 2006 Nov;55(5):741-60; quiz 761-4
[
17052479.001
]
[Cites]
Photochem Photobiol Sci. 2006 Feb;5(2):208-14
[
16465307.001
]
[Cites]
Ann Surg. 1965 Feb;161:170-88
[
14260013.001
]
[Cites]
Med Oncol. 1999 Jul;16(2):86-94
[
10456656.001
]
[Cites]
Arch Dermatol. 1999 Jul;135(7):843-4
[
10411160.001
]
[Cites]
J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21
[
2212139.001
]
[Cites]
Arch Dermatol. 1988 Jun;124(6):869-71
[
3377516.001
]
[Cites]
J Dermatol. 1984 Aug;11(4):313-21
[
6392379.001
]
[Cites]
J Dermatol. 1990 Jun;17(6):342-6
[
2384636.001
]
[Cites]
Plast Reconstr Surg. 1978 Sep;62(3):407-14
[
693668.001
]
[Cites]
Ann Dermatol Venereol. 2003 Apr;130(4):413-6
[
12843850.001
]
[Cites]
Br J Dermatol. 2001 Apr;144(4):841-8
[
11298546.001
]
[Cites]
J Epidemiol. 1999 Dec;9(6 Suppl):S14-21
[
10709346.001
]
[Cites]
Arch Dermatol. 1999 Jul;135(7):781-6
[
10411152.001
]
[Cites]
J Dermatol Sci. 1999 Apr;19(3):161-5
[
10215187.001
]
[Cites]
J Dermatol Sci. 1997 Nov;16(1):74-8
[
9438911.001
]
[Cites]
J Dermatol Sci. 1997 Sep;15(3):183-7
[
9302646.001
]
[Cites]
Photodermatol Photoimmunol Photomed. 1996 Feb;12(1):22-6
[
8884895.001
]
[Cites]
J Trauma. 1997 Jan;42(1):104-7
[
9003266.001
]
[Cites]
Am J Dermatopathol. 2006 Dec;28(6):472-7
[
17122490.001
]
[Cites]
J Surg Oncol. 1996 Feb;61(2):124-30
[
8606543.001
]
[Cites]
Dermatol Surg. 1996 Mar;22(3):217-26
[
8599733.001
]
[Cites]
Dermatol Clin. 1995 Jul;13(3):583-94
[
7554506.001
]
[Cites]
J Invest Dermatol. 1994 Apr;102(4):440-4
[
8151121.001
]
[Cites]
Recent Results Cancer Res. 1995;139:263-73
[
7597297.001
]
[Cites]
Int J Cancer. 1993 Apr 1;53(6):886-91
[
8473047.001
]
[Cites]
Am J Epidemiol. 1996 Dec 1;144(11):1034-40
[
8942434.001
]
(PMID = 20729955.001).
[ISSN]
1941-2789
[Journal-full-title]
The Journal of clinical and aesthetic dermatology
[ISO-abbreviation]
J Clin Aesthet Dermatol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Other-IDs]
NLM/ PMC2923966
86.
Kimball KJ, Straughn JM, Conner MG, Kirby TO:
Recurrent basosquamous cell carcinoma of the vulva.
Gynecol Oncol
; 2006 Aug;102(2):400-2
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Recurrent
basosquamous
cell carcinoma
of the vulva.
BACKGROUND:
Basosquamous
cell carcinoma
(BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
CONCLUSION: BSC is a rare
disorder
of the vulva.
The metastatic potential of this
tumor
is not fully understood, but likely is intermediate between
squamous
cell carcinoma
and
basal cell carcinoma
.
[MeSH-major]
Carcinoma
,
Basosquamous
/ pathology.
Carcinoma
,
Basosquamous
/ surgery.
Neoplasm
Recurrence, Local / pathology.
Neoplasm
Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Vulvar Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16624392.001).
[ISSN]
0090-8258
[Journal-full-title]
Gynecologic oncology
[ISO-abbreviation]
Gynecol. Oncol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article
[Publication-country]
United States
87.
Snarskaia ES, Molochkov VA, Frank GA, Zavalishina LA:
[Matrix metalloproteinases and their tissue inhibitors in basal cell and metatypical cancer of the skin].
Arkh Patol
; 2005 May-Jun;67(3):14-6
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Matrix metalloproteinases and their tissue inhibitors in
basal cell
and
metatypical
cancer of the
skin
].
10 cases of ulcerative-nodular
basal cell carcinoma
and 10 cases
of metatypical carcinoma of
the
skin
were studied immunohistochemically for immunoexpression of matrix metalloproteinases (MMP-1, MMP-9) and their endogenic tissue inhibitors (TIMP-1, TIMP-2) in combination with PCNA, p53
tumor
complexes.
[MeSH-major]
Carcinoma
,
Basal Cell
/
diagnosis
. Matrix Metalloproteinase 1 / analysis. Matrix Metalloproteinase 9 / analysis.
Skin
Neoplasms /
diagnosis
. Tissue Inhibitor of Metalloproteinases / analysis
[MeSH-minor]
Diagnosis
, Differential. Humans. Proliferating
Cell
Nuclear Antigen / analysis. Tissue Inhibitor of Metalloproteinase-1 / analysis. Tissue Inhibitor of Metalloproteinase-2 / analysis.
Tumor
Suppressor Protein p53 / analysis
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16075605.001).
[ISSN]
0004-1955
[Journal-full-title]
Arkhiv patologii
[ISO-abbreviation]
Arkh. Patol.
[Language]
rus
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Russia (Federation)
[Chemical-registry-number]
0 / Proliferating Cell Nuclear Antigen; 0 / Tissue Inhibitor of Metalloproteinase-1; 0 / Tissue Inhibitor of Metalloproteinases; 0 / Tumor Suppressor Protein p53; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.7 / Matrix Metalloproteinase 1
88.
Hernández-Martín A, Arias-Palomo D, Barahona E, Hidalgo C, Muñoz C, García-Higuera I:
[Analysis of surgical treatment for nonmelanoma skin cancer performed by dermatologists in a public hospital: clinical-pathological correlation, use of hospital resources, and waiting list time from diagnosis].
Actas Dermosifiliogr
; 2007 Dec;98(10):694-701
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
[Analysis of surgical treatment for nonmelanoma
skin
cancer performed by dermatologists in a public hospital: clinical-pathological correlation, use of hospital resources, and waiting list time from
diagnosis
].
[Transliterated title]
Análisis del tratamiento quirúrgico del cáncer cutáneo no melanoma cuando es realizado por dermatólogos en un hospital público: correlación anatomoclínica, empleo
de
recursos hospitalarios y tiempo
de
espera desde el diagnóstico.
BACKGROUND: Nonmelanoma
skin
cancer is the most common form of cancer in humans.
No studies have been published addressing differences in the management of surgical treatment for nonmelanoma
skin
cancer according to the specialties involved.
OBJECTIVES: To assess the preoperative diagnostic accuracy and the use of health care resources when surgical treatment of nonmelanoma
skin
cancer is done by dermatologists belonging to the Spanish national health service.
METHODS: A prospective observational study was carried out over a period of 36 months using data corresponding to all patients diagnosed with nonmelanoma
skin
cancer and treated surgically in the Dermatology Department of Complejo Hospitalario
de
Burgos, Spain.
Data were analyzed for clinical-pathological correlation, complexity of the intervention, use of health care resources, and time elapsed between clinical
diagnosis and
surgery.
RESULTS: The study included 448 patients and 521
skin
lesions suspected to be nonmelanoma
skin
cancer (
basal cell carcinoma
or
squamous
cell carcinoma
).
Diagnosis
was exclusively clinical in 487 tumors
and a
clinical-pathological correlation of 84.39% was observed.
In 349 patients (77.90%) the procedure was performed on an outpatient
basis
, 73 (16.29%) required a short stay in the surgical day care unit, and 26 (5.80%) required hospital admission.
The mean (SD) delay from clinical
diagnosis
to surgery was 68.44 (42.22) days, with a median delay of 60 days.
CONCLUSIONS: Dermatology specialists are highly qualified to diagnose
malignant
skin
tumors and accurately identify those patients requiring surgery.
[MeSH-major]
Skin
Neoplasms / pathology.
Skin
Neoplasms / surgery
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[ErratumIn]
Actas Dermosifiliogr. 2008 Mar;99(2):170
(PMID = 18035027.001).
[ISSN]
0001-7310
[Journal-full-title]
Actas dermo-sifiliográficas
[ISO-abbreviation]
Actas Dermosifiliogr
[Language]
spa
[Publication-type]
English Abstract; Journal Article
[Publication-country]
Spain
89.
Abdulla FR, Kerns MJ, Mutasim DF:
Amelanotic lentigo maligna: a report of three cases and review of the literature.
J Am Acad Dermatol
; 2010 May;62(5):857-60
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
BACKGROUND: Amelanotic lentigo maligna is not clinically suspected and is often mistaken for a
basal cell carcinoma
,
squamous
cell carcinoma
, or dermatitis.
CONCLUSION: A high degree of clinical and histologic suspicion is required to make the
diagnosis
of this clinically nondescript
neoplasm
.
[MeSH-major]
Hutchinson's Melanotic Freckle / pathology.
Skin
Neoplasms / pathology
[MeSH-minor]
Carcinoma
,
Basal Cell
/
diagnosis
.
Diagnosis
, Differential. Female. Forearm. Humans. Keratosis, Actinic /
diagnosis
. Male. Middle Aged. Neck
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Copyright]
Copyright 2009 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.
(PMID = 19766347.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Review
[Publication-country]
United States
[Number-of-references]
11
90.
Bailey JS, Goldwasser MS:
Surgical management of facial skin cancer.
Oral Maxillofac Surg Clin North Am
; 2005 May;17(2):205-33, vi
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Surgical management of facial
skin
cancer.
Surgical excision is the gold standard for management of cutaneous
basal cell carcinoma
or
squamous
cell carcinoma
.
Surgical management of nonmelanotic facial
skin
cancer requires preoperative planning and an in-depth understanding of reconstructive techniques, including primary closure,
skin
grafting, and local tissue flaps.
The decision regarding the method of treatment of nonmelanotic
skin
cancer is highly individualized and depends on patient age, cancer size, histologic subtype, and site.
In this article we discuss the principles and techniques of surgical excision and reconstruction of site-specific facial
skin
cancers.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18088778.001).
[ISSN]
1042-3699
[Journal-full-title]
Oral and maxillofacial surgery clinics of North America
[ISO-abbreviation]
Oral Maxillofac Surg Clin North Am
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
91.
Gass JK, Chan SK, Rytina E, Greenberg DC, Burrows NP:
Multiple primary malignancies in patients with Merkel cell carcinoma.
J Eur Acad Dermatol Venereol
; 2010 May;24(5):601-3
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Multiple primary malignancies in patients with Merkel
cell carcinoma
.
BACKGROUND: Merkel
cell carcinoma
(MCC) is a rare
malignant
cutaneous tumour, the incidence of which is increasing.
OBJECTIVES: We report the rate and nature of multiple malignancies in patients with MCC treated over a 10 year period in Addenbrooke's Hospital in Cambridge, United Kingdom, as well as the temporal relationship of these additional malignancies to the
diagnosis
of MCC.
RESULTS: The 27 patients had an approximately equal sex incidence with a median age at
diagnosis
of 79 years.
Seventy percent (n=19) of patients had a second primary
malignant
tumour; and 7 of these patients had two or more tumours in addition to the MCC.
Eighteen patients had additional cutaneous malignancies: melanoma,
squamous
cell carcinoma
and
basal cell carcinoma
, and 8 patients presented non-cutaneous malignancy including colorectal, haematological and breast tumours.
Of the 28 additional tumours in our patients, half were diagnosed prior to presentation of MCC, 32% within 6 months of
diagnosis
, and 18% between 6 months and 3 years after
diagnosis
.
CONCLUSIONS: Our figures reflect a higher incidence of multiple malignancies in those with Merkel
cell
tumour than has previously been reported.
[MeSH-major]
Carcinoma
, Merkel
Cell
/ complications. Neoplasms, Multiple Primary / complications.
Skin
Neoplasms / complications
MedlinePlus Health Information.
consumer health - Skin Cancer
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 19900177.001).
[ISSN]
1468-3083
[Journal-full-title]
Journal of the European Academy of Dermatology and Venereology : JEADV
[ISO-abbreviation]
J Eur Acad Dermatol Venereol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
Netherlands
92.
Rector A, Mostmans S, Van Doorslaer K, McKnight CA, Maes RK, Wise AG, Kiupel M, Van Ranst M:
Genetic characterization of the first chiropteran papillomavirus, isolated from a basosquamous carcinoma in an Egyptian fruit bat: the Rousettus aegyptiacus papillomavirus type 1.
Vet Microbiol
; 2006 Oct 31;117(2-4):267-75
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Genetic characterization of the first chiropteran papillomavirus, isolated from
a basosquamous
carcinoma
in an Egyptian fruit bat: the Rousettus aegyptiacus papillomavirus type 1.
The complete genomic DNA of a novel papillomavirus (PV) was isolated from
a basosquamous
carcinoma
on the wing of an Egyptian fruit bat (Rousettus aegyptiacus).
[MeSH-major]
Carcinoma
,
Basosquamous
/ veterinary. Chiroptera / virology. Papillomaviridae / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / veterinary.
Skin
Neoplasms / veterinary
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16854536.001).
[ISSN]
0378-1135
[Journal-full-title]
Veterinary microbiology
[ISO-abbreviation]
Vet. Microbiol.
[Language]
eng
[Publication-type]
Case Reports; Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Netherlands
[Chemical-registry-number]
0 / DNA Transposable Elements; 0 / DNA, Viral
93.
Agero AL, Busam KJ, Benvenuto-Andrade C, Scope A, Gill M, Marghoob AA, González S, Halpern AC:
Reflectance confocal microscopy of pigmented basal cell carcinoma.
J Am Acad Dermatol
; 2006 Apr;54(4):638-43
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Reflectance confocal microscopy of pigmented
basal cell carcinoma
.
BACKGROUND: Reflectance confocal microscopy (RCM) is a high-resolution imaging tool for in vivo noninvasive evaluation
of skin
lesions.
OBJECTIVE: We sought to describe the relevant RCM features for pigmented
basal cell carcinoma
(
BCC
).
METHODS: Pigmented
skin
lesions with a differential
diagnosis
of pigmented
BCC
were imaged using dermoscopy and RCM, followed by excision for histologic analysis.
RESULTS: RCM demonstrated aggregations of tightly packed cells with palisading, forming cordlike structures and nodules with irregular borders and variable brightness; these represented nests of pigmented basaloid
tumor
cells on histopathology, and blue-gray ovoid areas on dermoscopy.
These
tumor
nests were associated with bright dendritic structures, identified histologically as either melanocytes or Langerhans cells, together with numerous bright oval to stellate-shaped structures with indistinct borders representing melanophages, and with highly refractile granules of melanin.
LIMITATIONS: The pigmented BCCs imaged in this study were predominantly nodular; a different set or additional criteria may be necessary for detection of infiltrative and
metatypical
BCCs.
CONCLUSION: RCM may permit in vivo
diagnosis
of pigmented
BCC
.
[MeSH-major]
Carcinoma
,
Basal Cell
/ pathology.
Skin
Neoplasms / pathology
[MeSH-minor]
Aged. Aged, 80 and over.
Diagnosis
, Differential. Female. Humans. Male. Melanoma /
diagnosis
. Melanoma / pathology. Microscopy, Confocal. Middle Aged
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
The Lens.
Cited by Patents in
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 16546585.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
94.
Ostler DA, Prieto VG, Reed JA, Deavers MT, Lazar AJ, Ivan D:
Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear cell histology: an immunohistochemical study of 117 cases.
Mod Pathol
; 2010 Apr;23(4):567-73
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Adipophilin expression in sebaceous tumors and other cutaneous lesions with clear
cell
histology: an immunohistochemical study of 117 cases.
This study examines adipophilin expression in various sebaceous lesions and other cutaneous tumors with a clear
cell
histology that may mimic sebaceous differentiation.
A total of 117 cutaneous clear
cell
lesions including 16 sebaceous adenomas, 25 sebaceous
carcinomas
, 8
basal cell
carcinomas
, 12
squamous
cell
carcinomas
, 6 xanthomas, 10 xanthelasmas, 10 xanthogranulomas, 4 balloon
cell
nevi, 5 trichilemmomas, 8 clear
cell
hidradenomas, and 13 metastatic renal
cell
carcinomas
were examined using immunohistochemistry for the expression of adipophilin.
Adipophilin was expressed in 16 of 16 (100%) sebaceous adenomas, 23 of 25 (92%) sebaceous
carcinomas
, 10 of 10 (100%) xanthelasmas, 9 of 10 (90%) xanthogranulomas, 6 of 6 (100%) xanthomas, and 9 of 13 (62.5%) metastatic renal
cell
carcinomas
.
Adipophilin expression was not seen in any of the other lesions with clear
cell
histology,
basal cell
carcinomas
, or
squamous
cell
carcinomas
, including cases that had focal clear
cell
differentiation.
Adipophilin can be valuable in an immunohistochemical panel when evaluating cutaneous lesions with clear
cell
histology as it identifies intracytoplasmic lipid vesicles in sebaceous and xanthomatous lesions.
In periocular lesions, it is effective in helping to exclude
basal cell carcinoma
and squamous
cell carcinoma
when sebaceous
carcinoma
is under consideration.
Adipophilin expression is not as useful for the differential
diagnosis
that includes metastatic renal
cell carcinoma
, a rare but important, diagnostic differential.
[MeSH-major]
Biomarkers,
Tumor
/ analysis. Peptides / metabolism. Sebaceous Gland Neoplasms / metabolism. Sebaceous Gland Neoplasms / pathology.
Skin
Neoplasms / metabolism.
Skin
Neoplasms / pathology
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Membrane Proteins. Middle Aged. Neoplasms, Adnexal and
Skin
Appendage / metabolism. Neoplasms, Adnexal and
Skin
Appendage / pathology. Young Adult
MedlinePlus Health Information.
consumer health - Skin Cancer
.
COS Scholar Universe.
author profiles
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 20118912.001).
[ISSN]
1530-0285
[Journal-full-title]
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
[ISO-abbreviation]
Mod. Pathol.
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Biomarkers, Tumor; 0 / Membrane Proteins; 0 / Peptides; 0 / perilipin 2
95.
Panda S:
Nonmelanoma skin cancer in India: current scenario.
Indian J Dermatol
; 2010 Oct;55(4):373-8
[Fulltext service]
Download
fulltext PDF
of
this article and others
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Nonmelanoma
skin
cancer in India: current scenario.
Incidence
of skin
cancers has been increasing since the last few decades worldwide.
Nonmelanoma
skin
cancer (NMSC) is the commonest variety of cutaneous malignancy.
Conventional wisdom has it that the incidence of all varieties
of skin
cancers is lower among Indians due to the protective effects of melanin.
Reports of quite a few atypical cases lead us to hypothesize that factors other than ultraviolet radiation may be important in the occurrences of these cancers, particularly in the
skin
types prevalent in India.
The descriptive epidemiology and clinical characteristics of
squamous and
basal cell carcinoma
in India, including their variants, are discussed here along with hypotheses on their etiopathogenesis.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
[Cites]
J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):138-50
[
10863242.001
]
[Cites]
Arch Dermatol. 2000 Jun;136(6):800
[
10871955.001
]
[Cites]
Australas J Dermatol. 1997 Jun;38 Suppl 1:S31-5
[
10994469.001
]
[Cites]
Cancer. 1975 Mar;35(3):600-5
[
1111931.001
]
[Cites]
J Am Acad Dermatol. 2001 Mar;44(3):462-70
[
11209116.001
]
[Cites]
J Am Acad Dermatol. 2001 Mar;44(3):497-9
[
11209121.001
]
[Cites]
Hautarzt. 2002 Feb;53(2):118-20
[
11963191.001
]
[Cites]
Am J Dermatopathol. 2002 Apr;24(2):144-8
[
11979075.001
]
[Cites]
N Engl J Med. 1992 Dec 3;327(23):1649-62
[
1435901.001
]
[Cites]
Cancer. 1992 Jul 1;70(1):104-8
[
1606530.001
]
[Cites]
J Am Acad Dermatol. 1992 Jun;26(6):976-90
[
1607418.001
]
[Cites]
Ann Univ Mariae Curie Sklodowska Med. 2004;59(2):498-502
[
16146137.001
]
[Cites]
Indian J Dermatol Venereol Leprol. 2005 Nov-Dec;71(6):414-6
[
16394484.001
]
[Cites]
Indian J Dermatol Venereol Leprol. 2005 Nov-Dec;71(6):430-1
[
16394491.001
]
[Cites]
Indian J Dermatol Venereol Leprol. 2007 Mar-Apr;73(2):127-8
[
17456927.001
]
[Cites]
Arch Dermatol Res. 2008 Apr;300 Suppl 1:S43-50
[
17985102.001
]
[Cites]
Int J Dermatol. 2008 Jan;47(1):59-60
[
18173605.001
]
[Cites]
Indian J Dermatol Venereol Leprol. 2008 Nov-Dec;74(6):662-4
[
19172004.001
]
[Cites]
CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36
[
1984806.001
]
[Cites]
Indian J Dermatol. 2008;53(3):137-9
[
19882013.001
]
[Cites]
Indian J Dermatol. 2008;53(3):140-1
[
19882014.001
]
[Cites]
Indian J Dermatol. 2008;53(4):192-4
[
19882033.001
]
[Cites]
J Am Acad Dermatol. 1991 Jan;24(1):1-13
[
1999506.001
]
[Cites]
Indian J Dermatol. 2009;54(1):46-8
[
20049269.001
]
[Cites]
Indian J Dermatol. 2009;54(2):196-9
[
20101326.001
]
[Cites]
Indian J Dermatol. 2009;54(4):342-6
[
20101335.001
]
[Cites]
Indian J Dermatol. 2010 Oct;55(4):363-6
[
21430891.001
]
[Cites]
Indian J Dermatol. 2009 Jul;54(3):247-50
[
20161856.001
]
[Cites]
Indian J Dermatol. 2009 Jul;54(3):225-8
[
20161851.001
]
[Cites]
Indian J Dermatol. 2010 Oct;55(4):387-9
[
21430898.001
]
[Cites]
Indian J Dermatol. 2009 Jul;54(3):283-6
[
20161865.001
]
[Cites]
Indian J Dermatol. 2010 Apr-Jun;55(2):178-80
[
20606890.001
]
[Cites]
Indian J Dermatol. 2010 Apr-Jun;55(2):201-4
[
20606900.001
]
[Cites]
Indian J Dermatol Venereol Leprol. 2010 Jul-Aug;76(4):420-2
[
20657132.001
]
[Cites]
J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):413-21
[
2212139.001
]
[Cites]
J Am Acad Dermatol. 1990 Dec;23(6 Pt 1):1118-26
[
2273112.001
]
[Cites]
N Engl J Med. 1989 Dec 7;321(23):1577-83
[
2511446.001
]
[Cites]
Histopathology. 1989 Feb;14(2):129-39
[
2540085.001
]
[Cites]
J Am Acad Dermatol. 1988 Feb;18(2 Pt 1):292-8
[
3346413.001
]
[Cites]
Arch Dermatol. 1988 Aug;124(8):1244-5
[
3401029.001
]
[Cites]
Cancer. 1987 Jul 1;60(1):118-20
[
3581025.001
]
[Cites]
Cancer. 1974 Oct;34(4):1333-8
[
4422100.001
]
[Cites]
Ann Surg. 1973 Jan;177(1):1-7
[
4682500.001
]
[Cites]
J Surg Oncol. 1973 May;5(5):431-63
[
4752463.001
]
[Cites]
Arch Dermatol. 1971 Aug;104(2):124-7
[
5093166.001
]
[Cites]
J Am Acad Dermatol. 1980 Feb;2(2):155-60
[
6245113.001
]
[Cites]
J Am Acad Dermatol. 1983 Oct;9(4):487-502
[
6355213.001
]
[Cites]
Am J Dermatopathol. 1984 Apr;6(2):187-93
[
6375422.001
]
[Cites]
Cancer Invest. 1983;1(2):119-26
[
6667401.001
]
[Cites]
Cancer. 1983 Jul 1;52(1):173-5
[
6850540.001
]
[Cites]
Cancer. 1982 Jan 15;49(2):350-3
[
7053833.001
]
[Cites]
Cancer. 1981 Mar 15;47(6):1436-8
[
7226069.001
]
[Cites]
J Am Acad Dermatol. 1981 Nov;5(5):535-43
[
7298919.001
]
[Cites]
Clin Plast Surg. 1980 Jul;7(3):301-11
[
7438701.001
]
[Cites]
Arch Dermatol. 1998 Mar;134(3):333-7
[
9580120.001
]
[Cites]
JAMA. 1977 Aug 8;238(6):513
[
327111.001
]
(PMID = 21430894.001).
[ISSN]
1998-3611
[Journal-full-title]
Indian journal of dermatology
[ISO-abbreviation]
Indian J Dermatol
[Language]
eng
[Publication-type]
Journal Article
[Publication-country]
India
[Other-IDs]
NLM/ PMC3051301
[Keywords]
NOTNLM ; Squamous cell carcinoma / basal cell carcinoma / nonmelanoma skin cancer
96.
Leibovitch I, Huilgol SC, Selva D, Lun K, Richards S, Paver R:
Microcystic adnexal carcinoma: treatment with Mohs micrographic surgery.
J Am Acad Dermatol
; 2005 Feb;52(2):295-300
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Microcystic adnexal
carcinoma
: treatment with Mohs micrographic surgery.
BACKGROUND: Microcystic adnexal
carcinoma
(MAC) is reported to have a high rate of recurrence with standard wide local excision.
METHODS: This prospective, multi-center case series included all patients in Australia treated with MMS for MAC, who were monitored by the
Skin
and Cancer Foundation between 1993 and 2002.
In 31.8% of cases it was a recurrent
tumor
.
In 32.5% of cases the
tumor
was initially misdiagnosed as
basal cell carcinoma
or
squamous
cell carcinoma
.
[MeSH-major]
Carcinoma
,
Skin
Appendage / surgery. Mohs Surgery.
Skin
Neoplasms / surgery
[MeSH-minor]
Adolescent. Adult. Aged. Aged, 80 and over. Australia / epidemiology.
Carcinoma
,
Basal Cell
/
diagnosis
.
Carcinoma
,
Squamous
Cell
/
diagnosis
. Child. Databases, Factual. Diagnostic Errors. Female. Follow-Up Studies. Head and Neck Neoplasms /
diagnosis
. Head and Neck Neoplasms / epidemiology. Head and Neck Neoplasms / surgery. Humans. Male. Middle Aged.
Neoplasm
Invasiveness.
Neoplasm
Recurrence, Local. Prospective Studies. Retrospective Studies. Treatment Outcome
Genetic Alliance.
consumer health - Microcystic adnexal carcinoma
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
Faculty of 1000.
commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine.
(subscription/membership/fee required).
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 15692477.001).
[ISSN]
1097-6787
[Journal-full-title]
Journal of the American Academy of Dermatology
[ISO-abbreviation]
J. Am. Acad. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Multicenter Study; Review
[Publication-country]
United States
[Number-of-references]
24
97.
Son KD, Kim TJ, Lee YS, Park GS, Han KT, Lim JS, Kang CS:
Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in squamous cell carcinoma and basal cell carcinoma of the skin.
J Surg Oncol
; 2008 Jun 1;97(7):615-20
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Comparative analysis of immunohistochemical markers with invasiveness and histologic differentiation in
squamous
cell carcinoma
and
basal cell carcinoma of
the
skin
.
BACKGROUND: This study evaluates several
tumor
-related markers to examine the expression pattern of markers according to the invasiveness and histopathologic differentiation of
squamous
cell carcinoma
and
basal cell carcinoma
.
METHODS: Ninety-four cases of
squamous
cell carcinoma
and 108 cases
of basal cell carcinoma
using tissue array in order to determine correlations between the expression of Ki-67, p53, EGFR, CD44v6, MMP-1 and MMP-3, invasiveness and histologic differentiation.
RESULTS: The depth of invasion showed a correlation with CD44v6 expression of
tumor
cell
in both
squamous
cell carcinoma
and
basal cell carcinoma
(P = 0.009, P = 0.036, respectively) and with the MMP-1 expression of stromal
cell
in
squamous
cell carcinoma
(P = 0.010).
The differentiation of
squamous
cell carcinoma
was correlated with Ki-67 index.
The loss of palisading arrangement in
basal cell carcinoma
was correlated with the MMP-1 expression of stromal cells (P = 0.045).
CONCLUSIONS: CD44v6 and MMP-1, expressed in
tumor
cells and stromal cells respectively, are significant markers associated with the invasiveness of tumors in
squamous
cell carcinoma
and
basal cell carcinoma of
the
skin
and that it will be helpful to evaluate the invasiveness by measuring the expression of these markers.
[MeSH-major]
Biomarkers,
Tumor
/ biosynthesis.
Carcinoma
,
Basal Cell
/ pathology.
Carcinoma
,
Squamous
Cell
/ pathology.
Skin
Neoplasms / pathology
[MeSH-minor]
Adult. Aged. Aged, 80 and over. Antigens, CD44 / biosynthesis. Female. Genes, erbB-1. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Male. Matrix Metalloproteinase 1 / biosynthesis. Matrix Metalloproteinase 3 / biosynthesis. Middle Aged.
Neoplasm
Invasiveness.
Tumor
Suppressor Protein p53 / biosynthesis
Genetic Alliance.
consumer health - Carcinoma, Squamous Cell
.
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18404670.001).
[ISSN]
0022-4790
[Journal-full-title]
Journal of surgical oncology
[ISO-abbreviation]
J Surg Oncol
[Language]
eng
[Publication-type]
Comparative Study; Journal Article
[Publication-country]
United States
[Chemical-registry-number]
0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 3.4.24.17 / Matrix Metalloproteinase 3; EC 3.4.24.7 / Matrix Metalloproteinase 1
98.
Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, Meunier L:
Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
Exp Dermatol
; 2008 Nov;17(11):908-15
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Decreased expression of thymidine phosphorylase/platelet-derived endothelial
cell
growth factor in
basal cell
carcinomas
.
Thymidine phosphorylase (TP)/platelet-derived endothelial
cell
growth factor is associated with
tumor
angiogenesis.
We evaluated the TP mRNA and protein expression in
basal cell
carcinomas
(
BCC
) and in various
skin
tumors including numerous
BCC
histological simulants.
Immunohistochemistry was performed on 99 paraffin sections of formalin-fixed
skin
tumors using monoclonal antibodies (mAb) against TP.
TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM)
BCC
tumor
cells.
TP immunostaining was negative in all
BCC
variants and in most of the benign trichogeneic tumors studied.
By contrast, TP was constantly immunodetected in actinic keratosis (AK),
squamous
cell
carcinomas
(SCC), syringomatous
carcinomas
(SC),
basosquamous carcinomas
(BSC) and melanomas.
TP mRNA levels were low and statistically not different in wBCC and normal
skin
but were strongly downregulated in LCM-
BCC
as compared with LCM-normal epidermis.
We concluded that (i) anti-TP mAb is an useful marker to differentiate
BCC
from AK, SCC, BSC and SC but not from trichoblastic tumors, (ii) the lack of TP protein expression in
BCC
tumoral cells is linked to transcriptional regulatory mechanisms, (iii) the low TP mRNA levels in whole
BCC
may be related to the low intra-tumoral microvessel density, the slow growth and the very low metastatic potential of these tumors.
[MeSH-major]
Carcinoma
,
Basal Cell
/ pathology.
Skin
Neoplasms / pathology. Thymidine Phosphorylase / genetics
[MeSH-minor]
Carcinoma
,
Basosquamous
/ genetics.
Carcinoma
,
Basosquamous
/ metabolism.
Carcinoma
,
Basosquamous
/ pathology.
Carcinoma
,
Squamous
Cell
/ genetics.
Carcinoma
,
Squamous
Cell
/ metabolism.
Carcinoma
,
Squamous
Cell
/ pathology. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratosis, Actinic / genetics. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTC Antibody Characterization Program.
NCI CPTC Antibody Characterization Program
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMID = 18341568.001).
[ISSN]
1600-0625
[Journal-full-title]
Experimental dermatology
[ISO-abbreviation]
Exp. Dermatol.
[Language]
eng
[Publication-type]
Journal Article; Research Support, Non-U.S. Gov't
[Publication-country]
Denmark
[Chemical-registry-number]
0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
99.
Massari LP, Kastelan M, Gruber F:
Epidermal malignant tumors: pathogenesis, influence of UV light and apoptosis.
Coll Antropol
; 2007 Jan;31 Suppl 1:83-5
[Fulltext service]
Get downloadable
fulltext PDFs
of
articles closely matching to this article
, as many as you want.
[Source]
The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
[Title]
Epidermal
malignant
tumors: pathogenesis, influence of UV light and apoptosis.
Basal cell carcinoma
and squamous
cell carcinoma
, collectively termed non-melanoma
skin
cancers are the most common
malignant
tumors in humans.
Basal cell carcinoma
grows slowly and metastatic spread is very rare.
Squamous
cell carcinoma
is characterized by infiltrative, destructive growth and metastasis.
Long-term exposure
of skin
to UV light has a great impact on development of these epidermal malignancies.
The major role in development
of skin
cancer is given to proapoptotic p53 molecule or
tumor
suppressor gene which mutation due to UV exposure leads to resistance of DNA-damaged
cell
to apoptosis.
Other proapoptotic molecules such as Fas ligand (FasL)
and tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) are strongly expressed in
basal cell carcinoma
and squamous
cell carcinoma
that could be explained by the ability of
tumor
to escape the attack of immune system.
[MeSH-major]
Apoptosis.
Carcinoma
,
Basal Cell
/ physiopathology.
Carcinoma
,
Squamous
Cell
/ physiopathology. Neoplasms, Radiation-Induced / physiopathology.
Skin
Neoplasms / physiopathology. Ultraviolet Rays / adverse effects
MedlinePlus Health Information.
consumer health - Skin Cancer
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
NCI CPTAC Assay Portal.
NCI CPTAC Assay Portal
.
[Email]
Email this result item
Email the results to the following email address:
[X] Close
(PMI